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STUDIES ON THE VIRULENCE MECHANISMS OF CLOSTRIDIUM
SORDELLII
CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Clostridium
The genus Clostridium is comprised of over 60 species of Gram-positive,
anaerobic, spore-forming bacilli that normally reside in the soil.  This genus has
been studied in a variety of microbiological arenas, some of which have resulted
in the development of these organisms as beneficial industrial and medical tools.
Both Clostridium acetobutylicum and Clostridium beijerinckii have been utilized
for many years as an efficient means of producing solvents, such as acetone and
butanol, through fermentation processes (103, 123).  C l o s t r i d i u m
hydroxybenzoicum and Clostridium bifermentans have been utilized as promising
bioremediation agents in the degradation of certain chlorinated hydrocarbons (85,
126).  In addition to these industrial applications, the clostridia have recently been
used as reagents in specific areas of medicine.  In particular, Clostridium novyi
has been studied as a therapy for certain tumors.  This initial research has shown
that non-toxigenic forms of C. novyi, injected into mice, colonize the low-oxygen
2
regions of tumors, suggesting this organism could be used as a potential
therapeutic reagent in cancer research (47, 48).  Apart from these examples of
beneficial clostridial uses, the members of the Clostridium genus have become
most infamous for the ability of some species to cause a variety of life-threatening
diseases.
Clostridial Disease in Humans
In order to cause disease in the host, the pathogenic clostridia produce and
utilize an impressive array of virulence factors, including hemolysins,
phospholipases, glycosyltransferases, neurotoxins, and neuraminidases that aid
the bacterium in establishing infection and causing disease.  To date, Clostridium,
as a genus, produce the largest number of toxins among bacterial pathogens (72).
While many of these virulence determinants have been functionally and
structurally characterized, their contribution to disease is not fully understood.
However, due to this versatility in virulence factor production, the clostridia have
become one of the most clinically significant groups of pathogenic bacteria.
Clostridial diseases have been studied for many years, with gas gangrene
being one of the most serious, traumatic wound infections observed in the clinical
setting (135).  However, disease caused by the clostridia is not restricted to
traumatic gas gangrene.  Several additional disease syndromes have been
attributed to members of the clostridia including spastic paralysis (Clostridium
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tetani) (51), flaccid paralysis (Clostridium botulinum) (150), atraumatic gangrene
(Clostridium septicum) (72), antibiotic-associated diarrhea and
pseudomembranous colitis (Clostridium difficile) (17), and toxic shock-like
disease (Clostridium sordellii) (113).  The clostridia also often cause disease in
livestock.  As residents of the soil, these organisms gain access to grazing hosts
such as cattle, horses, and sheep.  Once in the host, the clostridia are able to
establish an infection and cause diseases such as blackleg (Clostridium chauvei)
(168), gangrene (Clostridium novyi) (72), and malignant edema (C. sordellii)
(116).
Clostridium sordellii
C. sordellii was originally discovered, in 1923, by Alfred Sordelli in
Argentina (156), who cultured the organism from a wound sustained by a war
injury.  Sordelli initially named this newly identified organism Bacillus oedematis
sporogenes, due to the edema observed at the site of infection.  Following further
characterization of the organism, Hall and Scott renamed the bacterium Bacillus
sordellii in honor of the man who had discovered this pathogenic microbe (70).
Eventually, the organism was renamed C. sordellii following classification as a
member of the Clostridium genus.  For many years following its discovery, C.
sordellii was considered to be the pathogenic form of Clostridium bifermentans,
due to the extensive similarities between these two soil-dwelling microorganisms.
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Through numerous studies, however, it was determined that these two bacteria
were not the same organism based largely on the ability of C. sordellii to produce
a urease, its inability to ferment specific sugars, such as mannose and sorbitol (28,
124, 142) and, more recently, the observed differences in the 16S rRNA-encoding
gene sequences of these two species (177).  These distinctions have permanently
classified C. sordellii as its own species, separate from its closest neighbors.
Like the other members of the clostridia, C. sordellii resides in the soil as
a spore, which is considered the infectious form of the pathogen.  The organism is
a Gram-positive bacillus that measures ~ 3 - 4.5 µM in length and ~ 1 – 1.5 µM in
width (141).  C. sordellii spores are normally terminal to sub-terminal in position,
with some strains producing spore appendages (141).  Following germination, the
organism releases virulence factors that aid in causing disease.
From the time of its discovery until the late 1970s, C. sordellii was widely
regarded as the most probable cause of pseudomembranous colitis (PMC) (98,
140), a severe form of intestinal disease now known to be caused by C. difficile.
This misidentification occurred because early studies utilized C. sordellii
antitoxin to neutralize the toxic activity in animals with PMC (8, 17, 18, 19).  In
1978, Bartlett et al. reported the seminal finding that the causative agent of PMC
in clindamycin-treated hamsters was C. difficile, with the C. sordellii antitoxin
protective effect due to the homology shared between the toxins produced by the
two organisms (20).  After excluding this organism as the cause of PMC, over the
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next two decades, C. sordellii was rarely reported as a human pathogen.  Indeed,
there were only 14 reported cases of C. sordellii illness in humans from 1978 to
2000 (1, 2, 15, 26, 30, 46, 68, 83, 102, 110, 143, 155, 157, 162).  More recently,
however, C. sordellii has been emerging as a pathogen associated with toxic
shock-like illnesses in humans (34, 95, 113, 151).
C. sordellii is still widely regarded as an important veterinary pathogen.
As mentioned above, the organism resides in the soil, as a spore, which gains
access to a variety of livestock hosts.  In many cases, early definitive symptoms
are not observed due to the rapid onset of disease and sudden death of the animal
(100, 101).  However, there have been a number of reports documenting specific
diseases caused by C. sordellii that suggest the organism predominantly causes
intestinal disease in animals.  In sheep, C. sordellii causes abomasal bloat,
hemorrhaging, ulcers, enteritis, and sudden death (5, 42, 100, 116, 139, 170), and
in cattle, it has been reported to cause diarrhea and enteric lesions (6).  A vaccine
composed of products from seven different clostridial species, including C.
sordellii, is the current immunization regimen used to prevent clostridial disease
in the agricultural setting (163).  However, this crude vaccine is only partially
effective and C. sordellii remains a problem in areas of livestock overcrowding,
such as stockyards.
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C. sordellii-Associated Disease in Humans
Since its discovery, in 1923, C. sordellii has been commonly grouped with
the myonecrotic clostridia, which cause traumatic gangrene in animals and
humans.  As mentioned above, this organism was initially cultured from a war
wound (156), and wound infection has historically been the primary presentation
assumed for this pathogenic bacterium.  However, an extensive investigation of
the literature suggests that C. sordellii has been erroneously grouped with the
myonecrotic clostridia.  In a limited number of cases, necrosis is reported in the
pathology findings; however, these studies are in the minority.  In the more than
35 reports of C. sordellii disease since 1950, only four cases were reported that
described the tissue necrosis that is typical of gangrene (14, 83, 95, 155).
Additionally, many of these studies that reported this organism as a cause of
gangrene also routinely observed the presence of additional myonecrotic
clostridial species, such as C. perfringens, at the site of infection, suggesting a
mixed infection contributed to the gangrenous conditions observed (14, 95, 155).
The most commonly reported form of C. sordellii-associated disease, and
one increasing in number, presents as a toxic shock-like death (24, 34, 110, 113,
143, 151).  In these reports, bacteremia is often reported, with septicemia and
shock resulting within 2 – 4 days following observation of the first symptoms.
The initial symptoms of the disease are normally non-descript and are
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characterized by absence of fever.  A concerning increase in this toxic shock-like
death has been recently reported among postpartum and post-abortion patients
(24, 34, 110, 143, 151).  The first report of this type of postpartum toxic shock-
like death attributable to C. sordellii was in 1989 and described a patient who was
released from the hospital following a successful delivery and then succumbed to
the disease with little warning (110).  Since this report, three more cases of
postpartum toxic shock-like death have been reported (24, 143, 151), indicating a
potential risk for C. sordellii infection in these patients.  While the origin of these
infections was unknown, it was suggested that these patients were already
colonized with a pathogenic strain of the organism, or that contamination
occurred during delivery.
A second area of increasing C. sordellii infections is in post-abortion
patients, particularly following medically induced abortions using RU-486, or
Mifepristone, and Misoprostol.  Since 2002, five cases of this type of C. sordellii
infection have been reported, with each resulting in death of the patient following
a rapid onset of disease (34, 151).  Due to this rise in C. sordellii infections, in a
very specific area of medicine, the Food and Drug Administration has recently
issued a warning regarding the potential for infection with this organism
following administration of the abortion pill, RU-486 (34).  Again, as with the
postpartum disease reports, the mode of infection in these patients is unknown,
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and the effect of the abortion-inducing drugs on C. sordellii growth and virulence
factor production has not been studied.
A third area of increased concern regarding C. sordellii, and the subject of
Chapter III of this dissertation, is the transmission of the pathogen via
musculoskeletal tissue allografts.  In 2001, the Centers for Disease Control and
Prevention (CDC) reported on the death of a patient, due to bacterial infection,
following a routine knee transplant (35).  The ensuing investigation found that
transplant material had been taken from a cadaver donor that was contaminated by
C. sordellii, the same organism cultured from the patient postmortem.  Following
this investigation, two studies in 2003 showed that C. sordellii is a common
contaminant of cadavers that are commonly used for tissue samples in
transplantation procedures (104, 106).  In these studies, Clostridium spp.
accounted for ~ 8% of the total bacterial species cultured from the cadavers, and
C. sordellii made up ~ 40% of the Clostridium.  As noted by Martinez et al. (106),
C. sordellii contamination may occur when resident bacteria disseminate into
tissue as the integrity of the bowel is compromised during the perimortem period
or at death.
As described in Chapter IV of this dissertation, the exceptional stability of
the lethal toxin (TcsL) produced by C. sordellii could pose a serious problem in
this new presentation of the disease due to the fact that many types of tissue used
in transplantation cannot be subjected to rigorous sterilization without damaging
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the tissue.  As a result, non-sterilized tissue could harbor C. sordellii, TcsL, or
both, resulting in a potentially dangerous condition for the transplant recipient.
These new areas of C. sordellii pathogenesis demonstrate how a rarely
encountered pathogen in humans can present itself as an emerging threat given an
appropriate set of conditions.
Treatment of C. sordellii-Associated Disease in Humans
A successful treatment for C. sordellii-associated disease has not been
developed.  C. sordellii infections are normally fatal, despite patients receiving
intense antibiotic treatment.  Common antibiotics, such as penicillin, vancomycin,
clindamycin, and metronidazole, have been employed in reported cases of the
disease (14, 26, 29, 30, 151).  In a 1986 study, Nakamura et al. reported that
several strains of C. sordellii were susceptible to most antibiotics, including
penicillin, clindamycin, vancomycin, and metronidazole (122).  In most cases, a
combination of antibiotics is used; yet, the patient succumbs to the disease in a
very short period of time after initial symptoms are observed.  Difficulties in the
early diagnosis of C. sordellii infections also contribute to its mortality rate in
humans.
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C. sordellii Virulence Factors
C. sordellii, like many of the pathogenic clostridia, produces a variety of
virulence factors that can potentially contribute to disease.  Unlike other
pathogenic clostridia, these virulence determinants have not been well
characterized, and, furthermore, their role in C. sordellii-associated disease is
even less clear.  However, the ability of this pathogen to produce an array of
soluble, proteinaceous virulence determinants likely provides an advantage to the
organism in establishing infection and causing disease.  Among the virulence
factors reportedly produced by this pathogen are lethal toxin (TcsL), hemorrhagic
toxin (TcsH), hemolysin, phospholipase C, and neuraminidase (11, 93).  Of this
panel of proteins, TcsL and TcsH have been studied most extensively, but their
contribution to disease remains unclear.  The hemolysin, phospholipase C, and
neuraminidase have been infrequently reported and their function during infection
is not understood; however, other pathogenic clostridia produce and utilize similar
proteins in order to cause disease, suggesting these proteins could also provide an
advantage for C. sordellii in the host setting.
While their role in disease is not understood, toxoids of TcsL and TcsH
protect against subsequent challenge with C. sordellii spores in the guinea pig
model of infection (10).  Due to these initial studies, and corresponding work
regarding C. difficile TcdB and TcdA, these two toxins are considered the primary
virulence determinants in C. sordellii disease.  These two virulence factors also
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belong to a five-member family of toxins collectively referred to as the large
clostridial toxins (LCTs), and TcsL will be a major focus of this dissertation.
Large Clostridial Toxins
Clostridium difficile Toxins: Mechanism of Action and Role in Disease.
(Daniel E. Voth and Jimmy D. Ballard. 2003.  Clinical Microbiology Reviews.
18:247-263)
C. sordellii produces two toxic proteins, TcsL (131) and TcsH (108), that
belong to the LCT family of bacterial toxins.  This family of virulence
determinants is comprised of five members that are grouped together due to their
similar high molecular weight sizes and enzymatic activities.  The LCT family is
made up of five of the largest toxins discovered to date, ranging from 250 – 308
kDa in size.  As mentioned, C. sordellii produces TcsL (270 kDa) and TcsH (300
kDa), C. difficile produces TcdB (280 kDa) and TcdA (308 kDa), and C. novyi
produces Tcnα (250 kDa).  Each of these proteins consists of a single polypeptide
chain that does not possess a known signal sequence for secretion from its
respective organism.  In addition to their related unique size, each of these toxins
modulate host cell physiology via the glycosyltransferase activity contained in the
N-terminal region of the protein.  Most of the LCT studies regarding genetics and
mechanism of action have been performed using TcdA and TcdB.
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Genetics of the LCTs
The gene encoding TcsL has been sequenced and is comprised of 7095 bp,
in a single open reading frame, which encodes for a 2364 residue protein (69).
The gene sequence of TcsH has not yet been reported.  It is thought that these two
LCTs are encoded on a pathogenicity locus as are the LCTs produced by C.
difficile (71).  This proposed genetic arrangement includes positive and negative
regulators of toxin production (43, 86) and a region encoding a putative holin-like
protein involved in toxin release from the organism (160).  Like TcdA and TcdB
from C. difficile, tcsl is a low G + C content gene.  As with TcdB, the enzymatic
activity of TcsL resides in the first 556 residues at the N-terminal end of the
protein, as discussed in Chapter III.  The C-terminus of the proteins contains
repeat regions that, in the case of TcdA and TcdB, have been termed CROPs
(Combined Repetitive OligoPeptides), which are involved in binding specific cell
surface receptors (172, 173).  These regions are comprised of 21 – 50 residues
repeated throughout the C-terminal region of the toxins.  While TcsL contains
these repeat regions of homology (69), no receptor for the toxin has yet been
identified.
The LCTs produced by C. sordellii demonstrate a high degree of
homology to the other members of the LCT family.  TcsL is most homologous to
TcdB, which explains early observations on the cross-reactivity of antiserum
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raised against crude supernatants of C. sordellii with TcdB (36).  Subsequent
purification of TcsL demonstrated cross-reactivity between TcsL-specific
antiserum and TcdB (131).  The major contrasting regions in these two proteins
are found at the N-termini and are responsible for the difference in intracellular
substrate specificity, with TcdB modifying Rho, Rac, and Cdc42 (25, 91) and
TcsL glucosylating Ras, Rac, Rap, Ral, and Cdc42 (79).  Interestingly, while
TcdB is more cytotoxic to cultured cell in vitro, TcsL possesses an ~ 10-fold
lower LD50 as compared to TcdB (107).  As with TcsL and TcdB, TcdA antiserum
cross-reacts with TcsH and vice versa (108), further demonstrating the close
homology shared between these two proteins, which are considered the
enterotoxins produced by their respective organisms.  The remaining member of
the LCT family, Tcnα , produced by C. novyi, shares the least amount of
homology with the other LCTs, and this may be due to significant phylogenetic
differences between the organisms (81).
Mechanism of Action of the LCTs
As mentioned above, most LCT studies have utilized TcdB from C.
difficile as a representative member of this toxin family, and, thus, TcsL’s
mechanism of action will be discussed, in large part, in the context of TcdB.  The
LCTs utilize a well-defined mechanism of action in order to modulate cell
physiology and, consequently, alter the host environment.  As mentioned above,
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these toxins target the Ras superfamily of small GTPases for modification via
glycosylation.  This irreversible modification inactivates these small regulatory
proteins, leading to disruption of vital signaling pathways in the cell (Fig. 1).
However, in addition to enzymatic modification of targets, there are several steps
in receptor binding and cell entry, which are important for intoxication.
 Cell surface receptors for the LCTs
In order to elicit cytotoxic effects, the LCTs must be internalized into the
host cell, via endocytosis, and require an acidic endosome for access to the
cytosol (54, 75, 114, 137).  Receptor binding is the first essential step in the
process of cell entry.  The receptors for the LCTs are thought to be non-
proteinaceous and, as shown for TcdA, share the disaccharide Galβ1-4GlcNac.
This disaccharide is found on I, X, and Y blood antigens present on a variety of
cells, and these antigens have been shown to act as receptors for TcdA (166).
Various animal species susceptible to TcdA may not necessarily share identical
receptors.  For example, TcdA is reported to bind to Galα1-3Galβ1-4GlcNAc
(96); yet, this receptor does not appear to be present on human cells.
In line with these studies, pretreatment of cells or tissue with galactosidase
reduces binding by TcdA (41, 44, 96, 154).  A possible protein receptor, sucrase-
isomaltase, was found on cells in the ileum of rabbits, but, again, this protein is
not found on cells targeted within the human colon (134).  The receptor for the
Figure 1.  Overview of intracellular modifications by the LCTs.  The LCTs act
intracellularly as glycosyltransferases.  Each toxin modifies and inactivates small
GTPases via transfer of a sugar moiety, using UDP-glucose as a co-substrate.


























remaining LCTs has been more elusive than that for TcdA; however, due to C-
terminal sequence homology, it is thought that the LCTs utilize similar cell
surface proteins for cell entry.  In our experiments, and those of others, TcdB and
TcsL have been shown to intoxicate a broad range of cell types, indicating the
receptor for these toxins, while undefined, is ubiquitous.
Receptor-mediated endocytosis and membrane translocation
The LCTs enter the cell through receptor-mediated endocytosis and
require an acidified endosome for translocation.  Cytotoxic effects of these toxins
can be directly inhibited by a variety of lysosomotropic inhibitors, such as
bafilomycin A and ammonium chloride (54).  Furthermore, conditions that
prevent lysosome fusion with the endosome attenuate TcdB activity (55).
The requirement for low pH appears to be due to important structural
changes which occur in the toxins, leading to exposure of hydrophobic domains
prior to insertion into the target membrane (137, 138).  Indeed, Barth and
colleagues have observed the formation of channels in lipid bilayers by TcdB
through an acid pH-dependent process (16).
Until recently, it was not known as to whether the full toxin translocated to
the cytoplasm or only the enzymatic domain.  However, recent work by Pfeifer
and colleagues showed that, following proteolytic cleavage, only the N-terminal
domain of TcdB exits the endosome and gains access to substrates (130).  While a
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putative membrane insertion/translocation domain, located within the middle of
the protein, has been proposed for the LCTs, this region of the proteins has not
been definitively shown to promote translocation of the N-terminal enzymatic
fragment.
Following translocation into the cytosol of the cell, little is known
regarding trafficking of the LCTs in order for substrate modification to occur.  In
the case of TcsL, however, two recent studies show TcsL localization to cell
membranes (112, 129).  Petit et al. originally showed that TcsL localizes to the
mitochondrial membrane within five minutes of exposure of cells to the toxin
(129).  In contrast, Mesmin et al. demonstrated a phosphatidylserine binding site
in the N-terminal region of TcsL, suggesting the toxin localizes to the inner leaflet
of the plasma membrane following cell entry (112).  The latter finding appears to
be the most likely event to occur for the toxin to access membrane-bound
GTPases for modification.  However, these two findings have yet to be reconciled
and will be discussed further in the context of the results in Chapter V.
Modification of intracellular targets
Following receptor binding and internalization into the target cell cytosol,
the LCTs elicit specific effects that modulate host cell physiology.  Discoveries
from initial studies indicated that cells exposed to TcdB exhibited marked
changes in the organization of their actin cytoskeleton (114, 161, 175).  Following
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these studies on TcdB, TcsL was also found to adversely impact the actin
cytoskeleton in a variety of cell lines (120, 121).  However, TcsL intoxication of
mammalian cells results in completely rounded cells, in contrast to the elongation
observed during a routine TcdB treatment (13, 23).  These adverse effects on the
actin cytoskeleton have since become a hallmark in the intoxication of cells by the
LCTs and are thought to be a prelude to cell death in a variety of cell types.
In line with these early observations, Just and colleagues discovered Rho
from TcdB-treated cell lysates was no longer subject to ADP-ribosylation by C.
botulinum C3 exoenzyme (88).  C3 ADP-ribosylates Asn-41 in Rho (149), yet
TcdB was not found to have a similar activity.  These observations did suggest,
however, that TcdB was somehow altering Rho within the cell.  Other
experiments found that over-expression of Rho protected cells from TcdB-
induced rounding, further implicating this protein as a target for TcdB.  TcdA was
subsequently found to exert a similar effect on Rho (90).  Additionally, expression
of RhoA, -B, and -C in HeLa cells was found to provide protection against TcdB;
however, these same conditions did not afford protection against TcsL, suggesting
that TcsL targeted different GTPases than its closest neighbor toxin (67).
These initial studies allowed investigators to focus on the Rho family of
GTPases as a putative target of the LCTs.  In a seminal report, Just and colleagues
demonstrated the ability of TcdB to glucosylate RhoA via transfer of a sugar
moiety to Thr-37 of the GTPase using UDP-glucose as a co-substrate (91).  In the
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same study, two other GTPases, Rac and Cdc42, were also found to be
glucosylated by TcdB.  Additionally, this group observed the ability of TcdA to
modify RhoA using the same UDP-glucose-dependent mechanism as TcdB (92).
In line with these observations, cells with reduced levels of UDP-glucose are less
sensitive to cytopathic effects (CPE) induced by the LCTs (38).  Following these
initial studies on TcdB, TcsL was likewise found to act as a glucosyltransferase
(25, 82, 89, 132).  In contrast to TcdB, however, TcsL was not capable of
modifying Rho.  Instead, this LCT glucosylates Ras, Rac, Rap, and Ral.  Cdc42 is
additionally glucosylated by TcsL produced by certain strains of C. sordellii.
Further characterization of TcsH also identified the toxin to be a
glucosyltransferase, modifying Rho, Rac, and Cdc42, as in the case of the C.
difficile toxins (63).  Collectively, these studies defined the LCTs as
glucosyltransferases, capable of inactivating small GTPases within the cell.
Small GTPase proteins as targets of the LCTs
The studies highlighted in the previous section clearly defined LCTs as
glucosyltransferases that inactivate small GTPases.  Thus, to appreciate the role of
these proteins in cellular intoxication, it is important to understand GTPase
proteins and their activities.  Small GTPases, such as Rho and Ras, bind and
hydrolyze GTP to GDP, and it is the alternation between the GTP-bound (active)
and GDP-bound (inactive) states that regulates activity.  The exchange of GDP
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for GTP is regulated by guanine exchange factors (GEFs) within the cell (181).
Activated GTPases intrinsically hydrolyze GTP, removing the γ-phosphate group
and returning to the “off” GDP-bound state through a process enhanced by
GTPase activating proteins (GAPs) (61, 62).  Further regulation comes from GDP
dissociation inhibitors (GDIs), which block nucleotide exchange and maintain
GTPases in the GDP-bound form within the cytoplasm, preventing association of
the GTPase with the membrane and interactions with GEFs (60, 77, 115).
Activation of small GTPase signaling is initiated by factors that promote
the dissociation of GDIs from GDP-bound GTPase and release the protein for
localization to the cell membrane.  Thus, in a model of GTPase activation, GDIs
maintain the inactive protein in the cytosol, and, following dissociation from these
inhibitors, the GTPase localizes to the membrane where GEFs enhance
dissociation of GDP.  As GTP is in excess compared to GDP in the cell, GTPases
subsequently bind GTP and become activated, promoting downstream signaling
events.  Due to inherent GTPase activity and the action of GAPs, the protein
subsequently returns to the “off” state, returning to the GDP-bound form.  Each of
the GTPases of importance to these studies, Ras, Rac, Rap, Cdc42, and Ral, share
similar mechanisms of regulation, as described above.
Inactivation of these GTPases can exert a variety of adverse effects on the
intoxicated cell due to the loss of normal GTPase functions.  In the case of TcsL,
Ras, Rap, Ral, and Cdc42 inactivation could potentially inhibit multiple cell
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signaling pathways that are vital components of cell viability.  In the case of Ras,
this versatile GTPase is largely involved in cell proliferation and survival.  The
best-characterized downstream effector of Ras is Raf, and this protein is
responsible for activation of the mitogen-activated protein kinase kinase cascade
that ultimately results in phosphorylation and activation of ERK1 and 2, which
are involved in transcriptional regulation (105).  Ral is involved in cell
transformation processes, likely through its influence on proteins such as Fos
(119), and Ral is also regulated upstream by the Ras signaling pathway.  As with
Ral, Rap is involved in cell transformation and DNA synthesis (9, 180).  In
addition to these signaling GTPases, Rac and Cdc42 are more specifically
involved with lamellipodium and filopodium formation (125).  Lamellipodia and
filopodia are important structural extensions at the leading edge of migrating cells
and are essential to movement and sensing the environment during cell migration.
These results suggest that Rac and Cdc42 could play a major role in TcsL-induced
CPE in intoxicated cells.
Predictably, the inactivation of GTPase proteins by the LCTs could occur
at various steps, including blocking membrane localization, GEF interaction, or
contact with downstream effectors.  The elucidation of the crystal structures of
RhoA/GDP (176) and RhoA/GTPγS (87) have provided the information necessary
for making predictions regarding the effects of glucosylation on these small
GTPases.  The RhoA/GDP structure has been determined to 2.1 Å while the
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RhoA/GTPγS structure has been determined to 2.4 Å.  Upon examination of the
RhoA crystal structure, the impact of glucosylation would appear to prevent Thr-
37 (Thr-35 in Ras, Rac, and Cdc42) from forming a complex at the γ phosphate of
the bound GTP molecule.  In the GTP-bound form of Rho, Thr-37 (Thr-35 in Ras,
Rac, and Cdc42) contributes to Mg2+ interactions through the reactive hydroxyl
group (87), which is also subject to glucosylation.  Examination of the Rho three-
dimensional structure in the GTP-bound form indicates this hydroxyl group is not
readily accessible as it is complexed with Mg2+ and is directed away from the
solvent.  However, in the GDP-bound form, the hydroxyl group of Thr-37 (Thr-35
in Ras, Rac, and Cdc42) aids in the stabilization of a water molecule that
coordinates the Mg2+ ion, but is susceptible to glucosylation.  In fact, the ability of
the LCTs to more easily modify GDP-bound GTPases, as opposed to the GTP-
bound form, has been shown quite convincingly in previous studies (91).
Interestingly, and as discussed further in Chapter IV, Herrmann et al. have shown
that, while GTP blocks glucosylation of Ras by TcsL, glucosylation does not
appear to reduce GTP binding (76).  Based on the structure of GTP-bound Ras, it
is difficult to appreciate how this protein is capable of stably binding GTP without
the contributions from the hydroxyl group of Thr-35 (Thr-37 in Rho).  This may
suggest other, more subtle, yet poorly understood mechanisms are involved in the
process of glucosylating GTPases.  Additional studies suggest that glucosylation
does, however, maintain the GTPase effector loop region in conformation that
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inhibits downstream signaling (66, 171).  While these reports demonstrate
inhibition of downstream signaling, no information is available on the ability of
glucosylated GTPases to maintain interactions with other proteins at the
membrane, a condition that could adversely effect intracellular signaling.  This
possibility will be discussed further in the context of the results in Chapter V.
The Thr-37/Thr-35 residues are highly conserved among small GTPases; yet, only
Rho, Rac, and Cdc42 are targeted by TcdA and TcdB and only Ras, Rap, and Ral
are modified by TcsL.  As shown in Fig. 2, the reason for this substrate specificity
has been shown to be due to residues 24 – 29 in Rho (corresponding residues 22 –
27 in Ras, Rac, and Cdc42) that lie just outside the effector loop region and
comprise part of the transition between the α1-helix and the switch I region (118).
Through the use of Rho/Rac chimeric protein fusions and substitution
mutagenesis, the importance of specific residues within this region has been
defined, and the results indicate the lysine residue at position 27 (25 in Ras, Rac,
and Cdc42) plays a major part in substrate distinction.  Construction of the Rho
mutant K27T allowed for glucosylation of Rho by TcsL, while native Rho is not
targeted by TcsL.  These mutagenesis results have provided a strong basis for the
substrate specificity observed among the LCTs.
Figure 2.  Crystal structure of GDP-bound RhoA.  In the GDP-bound form of
Rho, the Mg2+ ion is coordinated by the β phosphate group of GDP and a water
molecule that interacts with T37 for stabilization.  The OH group of T37 is
glucosylated by the LCTs, consequently inactivating this regulatory protein.  The
region involved in substrate specificity is colored in purple and includes residues












Functional Domains of the LCTs
Based on the known activities for the LCTs, the proteins were predicted to
have enzymatic, translocation, and receptor-binding domains, each serving a
specific function during cellular intoxication (see Fig. 3).  The N-terminal
enzymatic and C-terminal receptor-binding domains are the best-understood
regions of these proteins, while the membrane-inserting, translocation domain
remains undefined.
 Organization of the enzymatic domain
The activities necessary for glucosylation are found within a 546 residue N-
terminal region of TcdB (80) and the 556 residue N-terminal region of TcsL, as
shown in Chapter III.  This region can effectively complete glucosylation of
substrates in vitro but lacks any detectable cytotoxic activity.  Furthermore,
delivery of this enzymatic domain, using surrogate cell entry systems, results in
cytotoxic effects similar to that observed with full-length TcdB (159) and TcsL
(Chapter III).  It is worth noting 546 residues is still as large or larger than most
full-length intracellular bacterial toxins, yet even minor deletions (e.g. 30
residues) from the C-terminal end of this fragment dramatically reduce activity.
Conflicting with these studies, Wagenknecht-Wiesner et al. reduced the
enzymatically active portion of TcdB to residues 1-467, a region that retained the
Figure 3.  Proposed protein domain structure of the LCTs.  Through deletion
mutagenesis, research combined from multiple research groups has given rise to a
three-domain structure of the LCTs.  The glycosyltransferase activity is located at
the N-terminus of the protein and the C-terminus is involved in receptor binding.
Located in the middle domain of the protein is a putative transmembrane segment
that is thought to be involved in membrane translocation.
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Figure 3.












ability to glucosylate Rho, Rac, and Cdc42 in vitro (174).  In contrast, deletions
down to residues 1-500 were shown to be completely devoid of enzymatic activity
(158).
The substrate recognition region of TcdB and TcsL has been narrowed to
residues 364 to 516 by using chimeric hybrids between these two toxins, which
target differing subsets of small GTPases (79).  By swapping this region between
the two toxins, it was possible to change the substrate specificity between TcsL
and TcdB and identify the region important for substrate modification.  In
addition to delineating the region responsible for substrate specificity, Busch and
colleagues found that the glucosyltransferase activity of these LCTs is dependent
on the presence of a DXD motif in the enzymatic domain (32).  Mutations in this
vital motif rendered forms of the toxin deficient in the ability to modify small
GTPases via glucosylation in vitro.  The DXD motif is conserved amongst each of
the LCTs, indicating its importance in this toxin family.  Continuing the
investigation of critical regions involved in LCT-induced glucosylation, Busch, et
al. determined that Trp-102 is involved in UDP-glucose binding, and mutants
lacking this residue were no longer cytotoxic to cells (31).  The combined work of
these groups has provided a strict basis for the regions of the LCTs involved in
substrate specificity and enzymatic activity.
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Receptor-Binding Domain
As mentioned above, LCT receptor-binding studies have been performed
exclusively using TcdA as a representative member of this toxin family.  The C-
terminal, receptor-binding domain of TcdA makes up roughly one-third of the
toxin, and contains up to 38 repeating CROP modules.  However, as noted by
Rupnik et al., the CROP region of TcdA has isolate-specific repeats and deletions,
suggesting this region of the toxin may be derived from multiple duplication and
recombination events within the gene (144).  The CROP sequences vary in length,
up to 50 amino acids in size, but contain a consensus triad (YYF) and an overall
hydrophilic stretch of residues indicative of a solvent-exposed region of the
protein (179).  This high degree of repetition may explain the agglutinating
activity of TcdA.   Furthermore, the CROP regions are similar to other proteins
including those from Streptococcus downei and Streptococcus mutans, which
function as saccahride-binding proteins (178).
The experimental evidence for receptor binding by the C-terminus of
TcdA comes from a series of studies showing the neutralizing capacity of
monoclonal antibodies to this region of the protein (56) and the ability of
recombinant fragments from this region to protect against the toxin.  A fragment
of the C-terminus containing the repeat moieties in TcdA was constructed by
Sauerborn et al. and was shown to block TcdA-induced cytotoxicity in cell culture
by competitive inhibition of receptor binding (145).   The same protein fragment
29
was also found to immunize mice against TcdA.  In recent studies, the entire C-
terminal, receptor-binding domain has been shown to be necessary for both
receptor binding and effective endocytosis of the holotoxin (57).  While not yet
experimentally shown, the C-terminal repeat regions of the remaining LCTs are
thought to act similarly to TcdA.
Influence of LCTs on Cell Physiology
The LCTs have a dramatic influence on mammalian cell physiology,
altering events ranging from cell signaling to ultrastructure maintenance.  In many
cases, cells do not survive intoxication by these toxins, even at relatively low
doses in comparison with other cytotoxins.  Thus, cell death is one of the most
obvious impacts of these toxins on cell physiology.  Early studies demonstrated
the LCT’s broad cell tropism and found TcsL and TcdB to be the more effective
cytotoxins.  In an initial study by Donta et al., the researchers indicated that TcdB
could intoxicate mouse adrenal cells, hamster ovary cells, rat hepatic cells, and
human cervical epithelial cells (50).  Depending on the cell type, TcdB ranged
from 4-fold to 200-fold more cytotoxic than TcdA in these studies.  Subsequent
studies found that mouse teratocarcinoma cells were more sensitive than CHO
cells to TcdA, possibly due to increased levels of TcdA-specific carbohydrate
receptors (165).  Subsequent studies have shown TcsL to be a potent cytotoxin
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similar to TcdB (13, 23), while TcsH has been labeled an enterotoxin that acts in a
similar manner to TcdA (108).
Impact on cell morphology
The first, and most obvious, impact on cell physiology is the loss of
structural integrity, which results from the decline in F-actin in cells exposed to
the LCTs.  Chang et al. were among the first investigators to examine
ultrastructural changes in intoxicated cells and reported alterations in cell surface
projections and rearranged microvilli (37).  Upon closer examination, it was
found that TcdA altered the ultrastructure of CHO cells, and distinct
actinomorphic changes were identified by electron microscopy (53).  TcdA-
intoxicated cells also demonstrate a distinct cell retraction phenotype, and this is
linked to changes in the microfilament system (53).  In the same study,
marginalization of the nucleus was observed, and, again, this was likely a
reflection of changes in the cytoskeleton.  Similar studies have been performed
using TcdB, and the cytopathic effects observed are like those induced by TcdA.
Mechanistically, the loss of structural integrity in TcdA- and TcdB-treated cells is
expected since Rho, Rac, and Cdc42 each regulate structural processes dependent
on actin polymerization.  While the C. difficile toxins induce cell rounding with
elongated filaments, TcsL induces a more complete cell rounding that makes its
cellular effects distinct from those of the other LCTs (13, 23).
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Recent studies indicate cell rounding and cell death are temporally distinct
events (136).  TcdB is capable of inducing cell rounding in less than 2 h, but cell
death, as assayed by a variety of methods, does not occur until almost 24 h
following treatment.  As will be seen in Chapter IV, these observations are similar
for TcsL, with cell rounding occurring 6 – 8 h and cell death occurring at 24 h
post-treatment.  Thus, as these events relate to disease, cytopathic effects may be
more relevant than actual cell death, since cells with considerable loss of actin
cytoskeleton integrity are unlikely to carry out their roles within the host.
Apoptosis accounts for the mechanism of death in cells exposed to the
LCTs.  Initial LCT apoptosis studies by Brito and colleagues showed that TcdA
induced the apoptotic pathway in T84 intestinal cells via caspases-3, -6, -8, -9,
and Bid activation and further demonstrated the disruption of mitochondrial
membrane potential and release of cytochrome c (27).  However, there are both
temporal and spatial reasons to suggest TcdA can induce apoptosis outside of
inactivating GTPases.  Treatment of cells with TcdA results in accumulation of
the toxin at the mitochondria within five minutes following exposure, and this
localization event occurs before detectable glucosylation of Rho proteins (73).
Thus, TcdA may induce apoptosis by disrupting mitochondria, which promotes
pro-apoptotic events.
Following these TcdA studies, TcdB and TcsL were also found to induce
apoptosis as a mechanism of death in intoxicated cells.  HeLa cells intoxicated by
32
TcdB were shown to undergo caspase-3-dependent apoptosis with a concurrent
loss in host cell vimentin (136).  Results in the same study also found TcdB was
able to not only induce caspase-dependent cell death, but was also able to induce
caspase-independent apoptosis specifically due to substrate inactivation.  The
proteome of TcdB-treated cells contains fragments of intermediate filaments that
result from cleavage by caspase-3.  Since intermediate filaments, such as
vimentin, are involved in maintaining the cell’s structural integrity, the loss of
these proteins may also account for changes in cell morphology.
Following this discovery, TcsL was also shown to employ a caspase-
dependent form of cell death (129).  Results from this study indicated TcsL also
induces apoptosis via caspase-3; however, like TcdA, TcsL was shown to rapidly
localize to the mitochondria following incubation with cells.  These results
initially suggest TcsL could also possess a mechanism of cell death separate from
its known GTPase activity.  Together, these results demonstrate some of the
potential effects of GTPase inactivation on the host cell due to intoxication by the





While the number of C. sordellii cases appears to be on the rise in humans,
and the organism continues to present itself as an important veterinary pathogen,
little progress has been reported regarding the mechanisms by which this versatile
microbe establishes human infection and causes disease.  Some progress has been
made in understanding biochemical aspects of the LCTs; however, this research
has largely been performed alongside the C. difficile LCTs.  As such, this
information, while beneficial to understanding toxin enzymatic activities, lends
little to understanding C. sordellii-specific pathogenesis.
Following initial reports of LCT production by C. sordellii, TcsL and
TcsH have been considered to be the primary virulence factors of this pathogen.
This, however, has only been experimentally supported in one report, which
demonstrated protection from C. sordellii following administration of TcsL and
TcsH toxoids to hamsters (10).  Furthermore, the frequency at which strains of C.
sordellii produce these LCTs is unknown.  While the C. sordellii LCTs have been
studied in some detail, the remaining virulence determinants, hemolysin,
phospholipase C, and neuraminidase, have not been characterized, and, therefore,
their contribution to disease is not understood.
34
In light of these gaps in the current understanding of C. sordellii-
associated virulence and disease, the work in this dissertation has been performed
in order to characterize virulence factor production in this anaerobic pathogen,
and these results will be described in Chapter III of this dissertation.  Following
these initial determinations of C. sordellii virulence factor profiles, Chapters IV
and V of this dissertation will describe biochemical studies of TcsL and its impact
on mammalian cell physiology in order to better understand the mechanism by
which this potent cytotoxin induces host cell death.  In total, the work described
herein, and future studies of C. sordellii virulence factors, should, in my opinion,
contribute to this area of pathogenesis through a better understanding of the role
played by the LCTs and accessory virulence factors.
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CHAPTER III
STRAIN CHARACTERIZATION AND ASSESSMENT OF THE
VIRULENCE FACTOR PROFILE OF CLOSTRIDIUM SORDELLII
TcsL and TcsH, which glucosylate small GTP-binding proteins in the
cytosol of mammalian cells, are among the primary virulence factors produced by
C. sordellii (25) and exhibit low a LD50 ranging from 5 – 50 ng/kg in mice (107).
In addition, C. sordellii has been reported to produce a hemolysin, neuraminidase,
and phospholipases (11).  Furthermore, whether clinical C. sordellii isolates
produce one, or combinations, of these virulence factors is currently unknown.
The overall virulence factor profiles of C. sordellii isolates have not been
determined.  Many of the pathogenic clostridia are known to produce a plethora of
virulence factors, with some species (e.g. strains of Clostridium perfringens)
releasing over a dozen different toxins (72).  Yet, various types of C. perfringens
can cause markedly different illnesses, ranging from food poisoning to gas
gangrene, and the specific disease directly correlates with the particular toxins
produced by the type infecting the host (153).  In contrast, other pathogenic
clostridia, such as Clostridium difficile, Clostridium tetani, and Clostridium
botulinum, produce only one or two major exotoxins and are generally associated
with only one disease (72).  A survey of clinical descriptions of diseases caused
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by C. sordellii, suggest this pathogen may be more like C. perfringens, as a
variety of distinct illnesses have been attributed to this organism (14, 153, 155).
In some cases, C. sordellii remains localized to the site of infection, with limited
myonecrosis, and a shock-like death occurs (143, 151), while in other reports, C.
sordellii bacteremia directly correlates with death of the patient (1, 46, 117).  In
cases of postpartum shock, bacteremia can occur, while in other descriptions C.
sordellii could not be detected in the bloodstream (24, 143).  Tissue necrosis also
varies among patients with severe C. sordellii disease, despite similar modes of
infection (14, 29, 155).  Indeed, the different forms C. sordellii disease - shock-
like, localized, systemic, and myonecrotic - do not correlate with the mode of
infection, suggesting that different virotypes may largely contribute to the type of
disease occurring in the infected patient.  Unfortunately, a collective analysis of
the virulence factor profiles of different C. sordellii isolates has not been
performed.
For these reasons, in the current study, we sought to characterize 14 C.
sordellii isolates collected from cadaver-derived tissue transplant material.  The
data described herein suggest strain differences are dictated by the presence, or
absence, of TcsL and a previously undescribed hemolysin, sordellilysin (SDL).
Interestingly, although TcsL has been touted as a major virulence factor, this
exotoxin was found at a relatively low frequency, with only one strain producing
detectable toxin; yet, this strain was substantially more virulent than other
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cadaver-derived isolates.  In contrast, SDL was detected at a higher frequency but
demonstrated an ~ 10-fold higher LD50 compared to TcsL.  Collectively, the
current findings indicate cadaver-derived isolates of C. sordellii differ
substantially in their virulence factor profiles and toxicity, raising the possibility
of a range of clinical outcomes following transplant of tissue contaminated with
this organism.
RESULTS
Characterization of cadaver-derived C. sordellii isolates.  Candidate
isolates of C. sordellii were collected from the ATCC, a laboratory stock
collection, and during the routine screening of prospective donors of tissue for
transplantation.  The strains used in this study, and the source of each strain, are
listed in Table 1.  Although each strain was initially identified as C. sordellii by
biochemical analysis, the close relationship of this organism to Clostridium
bifermentans required further analysis of the genes encoding 16S rRNA in each of
these isolates for definitive confirmation of genus and species.  Each of the C.
sordellii isolates in this study revealed between 98% and 100% homology with
the 16S rRNA-encoding sequence of ATCC strain 9714, which also corresponded
to the GenBank reported sequence (accession number M59105) for the 16S
rRNA-encoding gene of C. sordellii.
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Table 1. Virulence Factor Profiles of C. sordellii Isolates





ATCC9714 ATCC + + + + - + +
UMTB1 Cadaver + - - + + + +
UMTB2 Cadaver + - - + + + +
UMC164 BMAa + + + + - + +
UMC178 BLb & BMA - - - + - + +
UMC193 hemipelvis - - - + - + +
UMC212 BL & BMA - - - + - + +
PS4401 BL & ilium + - - + + + +
PS4404 BL & BMA + - - + + + +
PS4422 hemipelvis - - - + - + +










+ - - + + + +
PS4477 BL, BMA, &ilium - - - + - + +
PS4490 BMA, tibia, &femur - - - + - + + a BMA = Bone Marrow Aspirate
b BL = Blood Culture
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Ribotype analysis of C. sordellii strains.  PCR ribotyping was employed
to determine the relative genotypic similarity between the cadaver-derived
isolates of C. sordellii.  The profile of PCR amplified products ranging in size
from 400 to 800 bp was analyzed to make relative comparisons among the
isolates of C. sordellii, since this size region demonstrated the most variation
between strains.  As shown in Fig. 4, this analysis led to the identification of five
distinct ribotypes.  For reasons that remain unclear, one strain (PS4401) yielded
weaker amplification products than the remaining 14 isolates, despite the addition
of excess primers and template DNA to the standard reaction.  Collectively, these
strains were categorized into the following ribotype groups:  Ribotype I
(ATCC9714), Ribotype II (UMTB2 and UMC178), Ribotype III (UMTB1),
Ribotype IV (UMC164, UMC193, UMC212, PS4423, and PS4475), and
Ribotype V (PS4401, PS4404, PS4422, PS4451, PS4477, and PS4490).
Phenotypic characterization of cadaver-derived isolates of C. sordellii.
In light of the genotypic variation observed among the C. sordellii isolates, each
of the strains was further examined for phenotypic differences including
variations in morphology, antibiotic susceptibility, phospholipase activity, and
presence of neuraminidase activity.  As shown in Fig. 5, when observed using
transmission electron microscopy, all strains used in this study exhibited a similar
rod-shaped morphology.  Each of the rods measured ~ 3 – 6 µM in length and
Figure 4.  PCR ribotyping of C. sordellii isolates.  Oligonucleotide primers
designed to amplify the intergenic region between the 16S and 23S rRNA-
encoding genes were included in PCR reactions for each isolate.  Amplification
products were separated via 2% agarose gel electrophoresis and visualized via
ethidium bromide staining.  Lanes are designated by the strain name of each
isolate in the figure, and ribotype designations are indicated below the gel.  The
profile shown is representative of five experimental repeats of this analysis.
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Figure. 4.
Figure 5.  TEM analysis of C. sordellii isolates.  Mid-log phase cultures of each
isolate were collected and placed on Formvar-coated electron microscopy grids.
Following a 5 min incubation on the grids, each sample was stained with 2%
phosphotungstic acid for 15 sec.  After drying, grids were examined via TEM and
the pictures shown are representative of the cells seen across the grid for each
isolate.  Samples were observed at 4000 – 6000 X magnification and strain




contained sub-terminal endospores, all of which corresponded with the reported
characteristics of C. sordellii (141).
Using the antibiotic disk method for relative comparisons among strains,
each of the C. sordellii isolates were examined for sensitivity/resistance to
cefoxitin, ceftriaxone, gentamicin, erythromycin, clindamycin, vancomycin,
ampicillin, penicillin G, amoxicillin/clavulanic acid, ciprofloxacin, levofloxacin,
and tetracycline.  As shown in Table 2, 11 of the strains showed intermediate
resistance to clindamycin.  Nine of the isolates demonstrated intermediate
resistance to ciprofloxacin and two of the 15 strains showed intermediate
resistance to gentamicin.  Additionally, one isolate, PS4490, demonstrated
resistance to tetracycline relative to the other C. sordellii strains tested.  Since
clindamycin is used as a first line of treatment in anaerobic infections, strain
susceptibility to this antibiotic was further confirmed using the E-test method for
direct minimal inhibitory concentration (MIC) measurements.  Using this method,
the same 11 isolates showed resistance at 4 – 10 µg clindamycin/ml (data not
shown), which is consistent with intermediate resistance when compared to the
known clindamycin susceptibility standards for anaerobic organisms.
For further phenotypic characterization of the C. sordellii isolates,
phospholipase and neuraminidase activities were examined, since these proteins
have been previously described as putative virulence factors produced by C.
sordellii (11).  As shown in Table 1, each of the strains in this study produced
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Table 2. Antimicrobial Resistance of C. sordellii Isolates
(zones of clearing (mm))
Strain GEN CLI TET CIP
ATCC9714 Ia (13) Rb (12) Sc (28) I (16)
UMTB1 S (19) I (18) S (36) S (21)
UMTB2 S (15) R (13) S (31) I (20)
UMC164 I (12) R (10) S (29) I (16)
UMC178 S (23) I (15) S (35) I (17)
UMC193 S (18) R (14) S (40) S (21)
UMC212 S (16) S (20) S (29) I (19)
PS4401 S (16) R (12) S (32) I (20)
PS4404 S (19) I (16) S (36) I (20)
PS4422 S (20) S (29) S (35) I (20)
PS4423 S (18) S (19) S (38) S (21)
PS4451 S (17) R (11) S (33) I (20)
PS4475 S (18) S (23) S (35) S (22)
PS4477 S (19) I (18) S (36) I (19)
PS4490 S (15) R (13) I (16) I (19)
              a I = Intermediate Resistance
             b R = Resistant
              c S = Sensitive
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active neuraminidase, and 14 of the 15 strains demonstrated phospholipase
activity.  Collectively, these data, along with the ribotyping and antibiotic
susceptibility results, suggested both genotypic and phenotypic variability among
these isolates of C. sordellii.
Cytotoxicity of supernatants from C. sordellii isolates.  As shown in
Table 1, initial analysis of 24 h and 48 h culture supernatants from each of the
isolates found 7 of the 15 strains to possess cytotoxic activity when incubated
with cultured HeLa cells.  Cell rounding, indicative of TcsL-like cytopathic
effects (CPE), was only detected upon exposure to supernatants from C. sordellii
ATCC9714 and UMC164, even when the supernatants from other strains were
concentrated 10-100 fold and assayed for activity (Fig. 6C).  The CPE observed
following treatment with supernatant from strains UMTB1, UMTB2, PS4401,
PS4404, and PS4475 were different from morphological changes observed in a
routine TcsL treatment.  Supernatants from these 5 strains caused rapid cell
rounding, blebbing, and lysis within 2 h following treatment (Fig. 6B).  This time-
course of cytolysis contrasted with the effects observed following exposure of the
cells to supernatants from ATCC9714 and UMC164, in which case, CPE were not
observed until 24 h following treatment.  Furthermore, cells treated with
supernatants from ATCC9714 and UMC164 showed morphological changes
similar to those observed in treatments with purified TcsL, wherein cells
demonstrated marked cell rounding without blebbing or detectable lysis (Fig. 6C).
Figure 6.  Supernatant cytotoxicity of C. sordellii isolates.  Culture supernatant
(48 h) from each of the C. sordellii strains was incubated with an ~ 75% confluent
HeLa cell monolayer in a 96-well plate in a total of 100 µl/well and observed for
72 h for CPE.  Pictures shown are representative of a routine cell treatment with
the indicated supernatant, and cells were observed at a magnification of 140 X.
All hemolytic strains induced similar effects as the PS4404 cell treatment shown








These observations indicated that cytolytic strains UMTB1, UMTB2, PS4401,
PS4404, and PS4475 caused cell death through a non-TcsL mechanism, which
differed from ATCC9714 and UMC164.
TcsL in isolates of C. sordellii.  Based on these observations, each of the
15 isolates was examined for the presence of the gene encoding TcsL.  In line
with the absence of TcsL-like CPE in the strains described above, only strains
ATCC9714 and UMC164 contained amplified DNA fragments corresponding to
regions of tcsl (Fig. 7A).  Furthermore, using Southern hybridization, tcsl was
detected only in ATCC9714 and UMC164 (Fig. 7B).
Following PCR and Southern blot analysis, the presence of TcsL was
confirmed by purifying and analyzing TcsL isolated from dialysis bag cultures of
C. sordellii ATCC9714 and UMC164.  As shown in Fig. 7C, TcsL produced by
C. sordellii UMC164 migrated at the correct size (~ 270 kDa) as a protein
doublet, as described in Chapter IV for TcsL produced by C. sordellii
ATCC9714, when examined via SDS-PAGE.  Additionally, both bands of the
TcsL protein doublet produced by this strain reacted with TcsL-specific antiserum
(Fig. 7D).  Immunoblot analysis of supernatant from the remaining C. sordellii
strains did not detect proteins corresponding to TcsL (data not shown).  To further
examine TcsL-UMC164, the protein was analyzed in a glucosylation assay for
TcsL-specific activity.  TcsL is known to modify Ras, Rac, and Cdc42, while it
does not glucosylate Rho, a C. difficile Toxin B-specific substrate (25).  As shown
Figure 7.  Analysis of tcsl and TcsL in C. sordellii isolates.  (A) Oligonucleotide
primers designed to amplify defined regions of the tcsl gene were included in
PCR reactions for each C. sordellii isolate.  Amplification products were
separated via 0.8% agarose gel electrophoresis and visualized via ethidium
bromide staining.  Shown are the reactions for ATCC9714 and UMC164.  Lane 1
= tcsl1-1668, Lane 2 = tcsl1669-3468, Lane 3 = tcsl3469-5271, and Lane 4 = tcsl5272-7095.  (B)
Chromosomal DNA from C. sordellii ATCC9714 and UMC164 was probed for
the presence of a ~ 1.7 kb region of tcsl via Southern blot analysis.  Lanes are
designated by the name of the respective C. sordellii strain.  (C) Purified TcsL
from C. sordellii UMC164 was visualized via 10% SDS-PAGE and Coomassie
Blue staining.  C. sordellii ATCC9714 was visualized for size comparison.  (D)
Purified TcsL from C. sordellii UMC164 was detected via Western blotting using
TcsL-specific antiserum.  Lanes are designated by the strain name of each C.
sordellii isolate.  (E) TcsL isolated from C. sordellii UMC164 was included in a
standard glucosylation assay with Rho, Ras, Rac, and Cdc42.  TcsL from C.
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in Fig. 7E, TcsL-UMC164 glucosylated Ras, Rac, and Cdc42 similar to TcsL-
9714, while no modification of Rho was observed in this assay.
Characterization of cytolytic activity in C. sordellii isolates.  The
cytolytic activity of TcsL-, cytolytic supernatants was similar to that reported in
studies of the cholesterol-dependent cytolysins (CDCs) (167).  These bacterial
toxins induce erythrocyte lysis and have been reported to cause tissue culture cell
lysis (167).  Thus, TcsL-, cytolytic strains were examined using a standard
hemolytic assay, which indicated that each of the TcsL-, cytolytic strains lysed
erythrocytes (data not shown).  To investigate the nature of this hemolytic factor,
these strains were further examined for the presence of a CDC by PCR analysis
using primers homologous to pfo, the gene encoding Clostridium perfringens
perfringolysin O (PFO).  As shown in Fig. 8A, each of the 15 C. sordellii strains
was found to contain an ~ 1 kbp region of pfo.  Since each strain contained a
homologous segment of DNA corresponding to pfo, each of the five hemolytic C.
sordellii strain supernatants was analyzed via Western blot analysis, using a PFO-
specific primary antibody, to determine protein homology with the CDC toxin
family.  As shown in Fig. 8B, each of the five hemolytic supernatants contained a
protein that reacted with, and was similar in molecular weight, to PFO.  These
results correlated directly with the ability of these strains to induce cytolysis in
tissue culture and erythrocyte lysis in vitro.
Figure 8.  Analysis of pfo and SDL in C. sordellii isolates.  (A) Oligonucleotide
primers designed to amplify cdc based on the reported sequence of pfo were
included in PCR reactions for each C. sordellii isolate.  Amplification products
were separated by 0.8% agarose gel electrophoresis and visualized via ethidium
bromide staining.  Lanes are designated by the strain names of each isolate in the
figure.  pRT20, a plasmid containing the pfo-encoding gene, was included as the
positive control.  (B) Ten µg of each supernatant was separated via 10% SDS-
PAGE and proteins were transferred to a PVDF membrane.  Following transfer,
the membrane was incubated with a PFO-specific primary antibody for
observation of reacting proteins.  Reacting proteins were visualized via enhanced






















































            Cell type specificity of TcsL and sordellilysin (SDL).  Based on the
initial characterization of the C. sordellii isolates, we reasoned that supernatants
from these strains might demonstrate differences in cell tropism and cytotoxicity.
To address this, a panel of cell lines was examined for sensitivity to supernatants
from cytotoxic TcsL- and TcsL+ strains.  HeLa (human epithelial), CHO (hamster
fibroblast), NIH/3T3 (mouse fibroblast), Raw 264.7 (mouse macrophage), and
HUV-EC-C (human endothelial) cells were examined for sensitivity to strain
supernatants.  As shown in Fig. 9A, each cell type was sensitive to TcsL-, SDL+
supernatants (PS4404) when exposed to 1 and 10 µg of supernatant for 24 h.
However, HUV-EC-C cells were substantially more resistant to cytolytic activity
at these concentrations, with ~ 40 – 50% reduction in cell viability at 24 h.
As shown in Fig. 9B, each cell type was sensitive to supernatant from the
TcsL+, SDL- C. sordellii isolate (UMC164).  However, Raw 264.7 cells were only
marginally sensitive to this supernatant, with an ~ 15 – 20% reduction in cell
viability at 24 h.  This resistance, however, did not correlate with CPE (Fig. 9C),
as Raw 264.7 cells displayed CPE when exposed to 1 and 10 µg of supernatant
protein.  In contrast to supernatant from a TcsL-, SDL+ strain, HUV-EC-C cells
showed increased sensitivity to supernatant from TcsL+, SDL- isolates, with 80-
100% CPE occurring at each concentration tested.  Additionally, the viability of
HUV-EC-C cells, in response to TcsL+, SDL- supernatant, decreased at each
concentration, with an ~ 25% decrease in survival when exposed to 0.01 µg of
Figure 9.  Cellular specificity of C. sordellii virulence factors.  Culture
supernatants from C. sordellii UMC164 (TcsL+, non-hemolytic) and C. sordellii
PS4404 (TcsL-, hemolytic) were incubated separately with HeLa, CHO, NIH/3T3,
Raw 264.7, and HUV-EC-C cells at the indicated concentrations in a total volume
of 100 µ l/well.  At 24 h post treatment, cells were examined for CPE by
visualization and for viability via CCK-8 staining as described in Materials and
Methods.  Treatments were performed in triplicate and error bars indicate the
standard deviation from the mean.  (A) Viability of cells incubated with PS4404
supernatant.  (B) Viability of cells incubated with UMC164 supernatant.  (C) CPE
of cells incubated with UMC164 supernatant.  % CPE was determined by
counting the number of rounded cells in a field of 100 cells in three separate wells
for each condition.          = HeLa,        = CHO,         =NIH/3T3,      =Raw 264.7,































































supernatant protein and an ~ 65% decrease when exposed to 10 µg of supernatant
protein.
LD50 analysis of TcsL+ and SDL+ supernatants in BALB/c mice.
Findings from the tissue culture analyses indicated supernatants from the two C.
sordellii strains might exhibit differing effects in vivo, since distinct differences
exist in tissue tropism for these isolates.  To examine the effect of TcsL and SDL
on virulence in vivo, C. sordellii supernatant - TcsL+, SDL- or TcsL+, SDL- - was
injected into the tail veins of female BALB/c mice and mice were observed for 24
h.  Mice injected with 25 – 50 µg of TcsL+, SDL- supernatant showed lethargy
leading to death by 24 h, while mice injected with a 10-fold excess (400 – 500 µg)
of TcsL-, SDL+ supernatant demonstrated lethargy leading to death by 24 h (data
not shown).  Indeed, further analysis revealed an LD50 between 30-40 µg for
TcsL+ supernatant.  These results indicate the importance of TcsL in C. sordellii
infection, with TcsL+ supernatant demonstrating much lower LD50 values than
SDL+ supernatants.
DISCUSSION
In the current study, virulence profiles were determined for 14 C. sordellii
cadaver-derived isolates, which had been collected from candidate tissue
transplant material.  Prior to this work, C. sordellii has been recognized as a
severe pathogen capable of causing disease in a variety of clinical settings; yet,
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very little is known about the phenotypic and genotypic variability of this
organism, especially in regard to virulence.
C. sordellii is a primary bacterial contaminant of tissue transplant material
and is detected at a relatively high frequency (104, 106).  Since the cadaver
donors died from causes other than C. sordellii, and transplant material is
harvested under sterile conditions, these isolates likely came from bowel flora that
entered the bloodstream soon after death.  C. sordellii residing in the normal
bowel flora may also be responsible for post-partum infection, as intestinal
contents come in contact with damaged tissue.  Yet, such observations present a
conundrum because isolates are identified more often than the actual frequency of
disease.  One possible explanation for this observation is that initiation of disease
requires a combination of events before serious illness can occur.  Alternatively, it
is plausible that most isolates of C. sordellii are avirulent, and, despite their
detection, these strains do not have the capacity to cause disease.  Finally, a
limited number of early reports suggest C. sordellii as a cause of myonecrotic
disease (14, 155, 157), while many recent studies have associated this organism
with a shock-like illness involving limited tissue damage (24, 143, 151).  Again,
these differences in C. sordellii disease could be due to the mechanism and site of
infection or due to the fact that some strains possess virulence factors that mediate
tissue destruction, while other strains produce toxins that induce shock.
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To address this issue, in the current study, we were able to take advantage
of the fact that C. sordellii is routinely isolated from cadaver-derived tissue
transplant material.  By using this single source of C. sordellii isolates, we were
able to assess differences in virulence among strains that exist in similar host
settings.  Prior to analysis of the virulence factor profiles, the strains were
characterized for basic genotypic and phenotypic differences.  These preliminary
analyses suggested a notable degree of diversity among the strains, with at least
10 unique strains based on ribotyping, antibiotic resistance profile, and virulence
factor variation (summarized in Table 3).  This is a relatively high level of
diversity, even for a member of the genus Clostridium.  For example, in a recent
study of C. difficile toxinotypes, ~ 80% of the 153 strains examined belonged to
the same toxinotype (65).  Additionally, C. perfringens strains are grouped into
one of five different toxinotypes, A – E, with no variation in the virulence factor
profiles in each toxinotype (153).
Although C. sordellii is considered a highly virulent, toxigenic pathogen,
only 6 of the 14 strains analyzed conferred cytotoxic effects in the panel of cell
lines tested.  While each of the strains produced neuraminidase, and all but one
was positive for phospholipase C activity, only the isolates producing TcsL or
SDL induced cytotoxic effects.  Yet, even the TcsL+ and SDL+ strains
demonstrated differences in cell type specificity.  Most cell types were sensitive
to the SDL+ supernatants, and this was somewhat expected since CDCs are known
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Table 3. Phenotypic and Genotypic Characterization of C. sordellii Isolates
Ribotype & Strain Characterization
Ribotype I
ATCC9714 tcsl+, cdc+, TcsL+, Neu+, CDC-, Csp+, GENI, CLIR, CIPI
Ribotype II
UMTB2 tcsl-, cdc+, TcsL-, Neu+, CDC+, Csp+, CLIR, CIPI
UMC178 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CLII, CIPI
Ribotype III
UMTB1 tcsl-, cdc+, TcsL-, Neu+, CDC+, Csp+, CLII
Ribotype IV
UMC164 tcsl+, cdc+, TcsL+, Neu+, CDC-, Csp+, GENI, CLIR, CIPI, LVXI
UMC193 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CLIR
UMC212 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CIPI
PS4423 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp-
PS4475 tcsl-, cdc+, TcsL-, Neu+, CDC+, Csp+
Ribotype V
PS4401 tcsl-, cdc+, TcsL-, Neu+, CDC+, Csp+, CLIR, CIPI
PS4404 tcsl-, cdc+, TcsL-, Neu+, CDC+, Csp+, CLII, CIPI
PS4422 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CIPI
PS4451 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CLIR, CIPI
PS4477 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CLII, CIPI
PS4490 tcsl-, cdc+, TcsL-, Neu+, CDC-, Csp+, CLIR, CIPI, TETI
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to lyse a broad range of cell types (167).  In contrast, the TcsL+ supernatant was
cytotoxic but more specific in cell tropism, and the TCD50 varied depending on
the type of cell tested.  This is likely due to either limitations in cell surface
receptor number or the dependence of different cells on small GTPase-targeted
signaling pathways.  The extensive sensitivity of endothelial cells to TcsL+
supernatants was of particular interest, since C. sordellii is known to cause severe
shock-like illness in post-partum women and sudden death in livestock.  In future
studies, it will be of particular interest to characterize strains involved with shock
from C. sordellii infections to determine if these are TcsL+ isolates.
Based on our LD50 analyses, SDL demonstrated an ~ 10-fold higher LD50
in mice compared to TcsL.  The absence of a pronounced in vivo effect of SDL is
not unusual given what has been found in studies involving other CDCs.  Indeed,
in the case of PFO, mutants lacking this CDC show only minor alterations in
virulence (12).  Finally, it is worth noting that the SDL-encoding gene was
detected in all of the C. sordellii strains examined in this study; however, the
toxin was only expressed in five of the isolates.  This suggests that many strains
may have attenuated the expression of SDL as the organism resides as part of the
normal bowel flora.
While the current study focused on characterizing the virulence profile of
C. sordellii in the context of tissue transplant material, these findings can be
extrapolated to other types of disease caused by this organism.  With the
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exception of intravenous drug users, C. sordellii disease is initiated from
endogenous sources, likely through the relocalization of bowel flora to the site of
tissue damage.  Thus, the variations in strains, detected in tissue transplantation
material, also represents the possible differences in isolates that could contribute
to other types of C. sordellii disease.  This may also explain why C. sordellii
disease is sporadic, yet, invariably severe.  One would predict that post-partum
contamination of damaged tissue with bowel flora is not particularly uncommon;
yet, C. sordellii causes disease infrequently in this clinical setting (24, 110, 143,
151).  However, Clostridium species have been reported to be isolated from the
vaginal flora of ~ 4% of non-pregnant women and ~ 29% of women following
abortion, making this a favorable niche for anaerobic growth (21, 84).
Furthermore, a shock-like disease caused by C. sordellii has been reported in 3
women taking RU486 (34).  While still speculative, based on our findings, these
cases may involve an unfortunate combination of post-partum or post-abortion
tissue damage and women colonized with a virulent strain of C. sordellii.
MATERIALS AND METHODS
Mammalian cell culture, bacterial strains, and TcsL purification.
Human epitheloid carcinoma (HeLa) cells, Chinese Hamster Ovary (CHO) cells,
NIH/3T3 mouse fibroblasts, human umbilical vein endothelial cells (HUV-EC-C),
and Raw 264.7 mouse macrophage-like cells were obtained from the American
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Type Culture Collection (ATCC).  HeLa, CHO, and NIH/3T3 cells were
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum
(Gibco) at 37°C in the presence of 6% CO2.  HUV-EC-C cells were maintained in
CS-C medium (Sigma) containing 0.1 mg/ml heparin (Sigma) and 0.05 mg/ml
endothelial cell growth supplement (Sigma).  Raw 264.7 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (Gibco) containing 10% fetal bovine
serum.  All cells were used between passages 10 and 20.  C. sordellii ATCC9714
was obtained from the ATCC, and all other C. sordellii strains were isolated in the
microbiology laboratory of the University of Miami Tissue Bank during routine
screening of cadaver-derived tissues from clinically non-septic donors.  All C.
sordellii strains were cultured anaerobically in Brain Heart Infusion (BHI) broth
(Difco) at 37°C prior to analysis.  For anaerobic growth, strains were cultured in
10 ml of BHI broth in anaerobic Balch tubes.  TcsL was purified from C. sordellii
strains ATCC9714 and UMC164 as previously described (137).  Unless otherwise
indicated, all chemical reagents used in this study were obtained from Sigma.
Isolation and initial characterization of cadaver-derived C. sordellii
isolates.  All isolates were recovered from anaerobic cultures of the blood, bone
marrow aspirates, or excised bones of donors previously screened by medical
history and physical examination to exclude the presence of clinically evident
sepsis.  All samples of blood, bone marrow, and tissues were collected under
aseptic conditions in designated sterile facilities.  The organisms isolated were
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identified to the species level by means of biochemical tests using the Microscan
Rapid Anaerobic ID Panel (Dade Behring).  Organisms with a biochemical profile
consistent with C. sordellii were further tested for confirmation of key reactions
by conventional methods.  These included tests for indole production by a spot
indole test (Remel), tests for urease production in urea agar slants (BBL) and/or
urea broth (Remel), and assays for phospholipase production.  Phospholipase
activity was determined by the presence of a visible precipitate around colonies of
the organism after growth on egg yolk agar (McClung-Toabe Agar, Modified)
(Remel).
PCR analysis of the 16S rRNA-encoding gene, tcsl, and cdc in C .
sordellii isolates.  Oligonucleotides (Integrated DNA Technologies, Inc.) were
included in PCR reactions with bacterial cells from each C. sordellii isolate for
amplification of the indicated genes.  Amplifications were performed in a 50 µl
reaction that included PCR reaction buffer containing 1.5 mM MgCl2 (Roche
Diagnostics), 300 nM of each primer indicated below, 200 µM dNTPs (Roche
Diagnostics), 1 µl of bacterial culture, and 2.6 units of Expand High Fidelity
polymerase (Roche Diagnostics).  Products were amplified using the following
temperature cycling conditions:  1 min at 95°C for initial denaturation followed
by 35 cycles consisting of 1) 95°C 1 min, 2) indicated annealing temperature 1
min, 3) 72°C 90 sec, followed by a final extension at 72°C for 15 min.  PCR
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amplification products were subsequently visualized via 0.8% agarose gel
electrophoresis and ethidium bromide staining.
i)  Amplification of the 16S rRNA-encoding gene.  Oligonucleotides
were designed to amplify the gene encoding 16S rRNA based on conserved
sequence among members of the domain Bacteria (97) and are designated 27F
and 1492R.  Primer sequences were as follows:  27F = 5’-
AGAGTTTGATCMTGG-3’ and 1492R = 5’-TACCTTGTTACGACTT-3’.  An
annealing temperature of 55°C was used in each reaction.  PCR amplification
products were subsequently purified using the Qiaquick PCR purification kit
(Qiagen) and were cloned into the pGEM/T-Easy vector (Promega) according to
the manufacturer’s instructions.  Plasmid from candidate clones was purified
using the Qiaquick MiniPrep system (Qiagen) and subsequently analyzed by
DNA sequencing for identification of the 16S rRNA species-specific sequences of
each strain.  Sequence alignments were performed and the entire 16S rRNA-
encoding gene sequences were examined for homology.  The resulting sequences
were compared to each other and also compared against the GenBank database.
ii)  Amplification of tcsl.  Primers were designed to amplify four separate
regions (nucleotides 1-1668, 1669-3468, 3469-5271, and 5272-7095) of the tcsl
gene and were as follows:  forward primer 1 = 5’-
GACTGACATATGATGAACTTAGTTAACAAAGCCCAA-3’, reverse primer 1
= 5’-GACTGAGGATCCTTATACTGTATTTTGAGCAAAATC-3’, forward
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primer 2 = 5’-GACTGACATATGCTTGATAAAGATTATGTTTCTAAA-3’,
r e v e r s e  p r i m e r  2  =  5 ’ -
GACTGAGGATCCTTAGTCTATTTCTGATAATACCAA-3’, forward primer 3
= 5’-GACTGACATATGTTTAATAATAATTCAATAACTTTA-3’, reverse
primer 3 = 5’-GACTGAGGATCCTTACTCACTATTTGCTATAAGAAT-3’,
f o r w a r d  p r i m e r  4  =  5 ’ -
GACTGACATATGGAAGATAATCAACGACAAGTTAAA-3’, reverse primer
4 = 5’-GACTGAGGATCCTTATTCACTAACTACTAATTCAGC-3’.  An
annealing temperature of 52°C was used in each PCR amplification.
iii)  Amplification of cdc.  PCR analysis was performed using primers to
a highly conserved genetic region of the gene known to encode for cholesterol-
dependent cytolysins (CDCs).  Oligonucleotides were designed to amplify a
specific ~1 kb segment of the pfo gene (nucleotides 380 - 1479) from C .
perfringens, and products obtained from these amplifications are referred to as
cdc.  Oligonucleotide sequences were as follows:  cdc forward primer = 5’-
GTACATATCCAGGAGCATTACAAC-3’ and cdc reverse primer = 5’-
CCACCATTCCCAAGCAAGACCTGT-3’.  pRT20 (a generous gift of Dr.
Rodney K. Tweten, University of Oklahoma Health Sciences Center), a plasmid
containing the pfo gene, was included in a separate PCR reaction as a control.  An
annealing temperature of 57°C was used in each of the PCR amplifications.
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PCR ribotyping of C. sordellii isolates.  Oligonucleotides (Integrated
DNA Technologies, Inc.) were designed to amplify the region between the 16S
and 23S rRNA-encoding genes (33) in each isolate.  Primer sequences were as
follows:  forward primer = 5’-GCTAACCTTTTAGGAGGCGGC-3’ and reverse
primer = 5’-GGCTACTTCCTGCACTATTCG-3’.  These oligonucleotide
sequences were designed based on the 3’ end of the 16S rRNA gene and the 5’
end of the 23S rRNA gene of C. sordellii.  Temperature cycling was performed as
described above with an annealing temperature of 55°C.  Following amplification,
the entire PCR reaction was separated via 2% agarose gel electrophoresis for 4 h
at 4°C and 100 V.  Following electrophoresis, DNA banding patterns were
visualized via ethidium bromide staining.  Isolates were assigned to ribotype
groups under the criteria of possessing at least one differing band when compared
to C. sordellii ATCC9714.
Transmission electron microscopy of C. sordellii isolates.
Approximately 10 µl of mid-log phase culture of each C. sordellii isolate was
applied to Formvar-coated grids for 5 min.  Grids were stained with 2%
phosphotungstic acid for 15 sec and subsequently observed via transmission
electron microscopy (TEM) using a Hitachi H-7600 microscope.  Samples were
observed at a magnification of 4000 – 6000 X and images were captured using a
Kodak 2K X 2K digital camera.
63
Antibiotic susceptibility of C. sordellii isolates.  A lawn of each C.
sordellii isolate was plated on Brucella Agar plates containing 5% sheep blood,
vitamin K, and hemin (Remel).  Following plating, antibiotic disks (Remel) were
dispensed onto plates with four antibiotics per plate.  Plates were subsequently
incubated anaerobically at 37°C for ~ 18 h, at which point, zones of clearing
around each antibiotic disk were measured and compared to the zones of clearing
observed in each of the isolates to determine relative susceptibility.  Antibiotics
tested were cefoxitin (30 µg), ceftriaxone (30 µg), gentamicin (10 µg),
erythromycin (15 µg), clindamycin (2 µg), ampicillin (10 µg), penicillin G (10 U),
amoxicillin/clavulanic acid (20/10 µg), ciprofloxacin (5 µg), levofloxacin (5 µg),
vancomycin (30 µg), and tetracycline (30 µg).  Results from these initial
antibiotic assays were compared only between C. sordellii strains to obtain
relative susceptibility.  Clindamycin resistance was further examined using the E-
test MIC determination strip method according to the manufacturer’s instructions
(AB Biodisk).  The results from the E-test were compared to the known standards
for anaerobes as specified by the manufacturer (AB Biodisk).  These standards
designate MIC values above 2 µg clindamycin/ml as resistant.
Neuraminidase activity assay.  Neuraminidase activity was examined
using the Amplex Red Neuraminidase Assay Kit (Molecular Probes).  Culture
supernatant (48 h) from each C. sordellii isolate was incubated with the Amplex
Red reaction mixture and incubated for 30 min at 37°C.  The reaction was
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monitored spectrophotometrically at A560 to detect released sialic acid, which
reacts with Amplex Red to increase absorbance at this wavelength.  Purified
neuraminidase from C. perfringens (Molecular Probes) and hydrogen peroxide
were included as positive controls.
Cytotoxicity assay.  Each C. sordellii isolate was grown anaerobically in
BHI broth (Difco) for 24 h and 48 h, at which point, 1 ml of culture supernatant
was harvested by centrifugation for 10 min at 9,000 X g.  Following
centrifugation and concentration of supernatants using 10 kDa molecular weight
cutoff Centricons (Millipore), 5 µg of total protein of the resulting supernatant
was added in triplicate to a 96-well plate containing 4 X 104 mammalian
cells/well in a confluent monolayer.  Cells were monitored for at least 72 h post-
treatment for signs of morphological changes indicative of cytopathic effects
(CPE).  Control cells were incubated with BHI.  Cells were observed at a
magnification of 140 X using a 1X-51 Olympus inverted microscope and images
were captured with a DP-70 Olympus digital camera.
In addition to visualization of cell viability, cytotoxicity was monitored
using the colorimetric CCK-8 Cell Viability Assay (Dojindo, Inc.).  This viability
assay uses WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulphophenyl)-2H-tetrazolium, monosodium salt], which is reduced to a
formazan derivative by dehydrogenases from viable cells.  This reaction is
monitored by reading the A450, which increases proportionally to the level of
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dehydrogenases.  Following addition of WST-8 to cells treated in a 96-well plate,
percent viability relative to the control was calculated using the formula (Atest –
Abackground)/(Acontrol - Abackground), where A = absorbance at A450, test = cells treated
with supernatant, background = media only, and control = cells treated with BHI
only.
Southern blot analysis of tcsl.  To analyze C. sordellii chromosomal
DNA for presence of the tcsl gene, a randomly digoxigenin (DIG)-labeled probe
was constructed via PCR amplification.  DNA was amplified from C. sordellii
ATCC9714 in a 50 µl reaction, as described above, using the following primers
( In tegra ted  DNA Technologies ,  Inc . ) :   3592F = 5’-
TTATCTATATATGATGTATTAAATATA-3’ for the forward primer and 5331R
= 5’-TATCGCTTTTAAAGACATTAACAA-3’ for the reverse primer.  The
resulting PCR product represented the ~ 1.7 kb DNA segment present between
the NcoI (bp 3592) and PstI (bp 5331) sites located on the tcsl gene.  Temperature
cycling was performed as described above with an annealing temperature of 55°C.
Following amplification, the product was denatured by boiling for 10 min and
was subsequently randomly labeled with DIG using the DIG High Prime DNA
Labeling Kit according to the manufacturer’s instructions (Roche Diagnostics).
Chromosomal DNA was isolated from mid-log phase cultures of C. sordellii
ATCC9714 and UMC164 using the DNeasy Tissue Kit (Qiagen) and was
subsequently restricted overnight at 37°C with NcoI and PstI (New England
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Biolabs).  Following restriction, chromosomal DNA was separated via 1%
agarose gel electrophoresis, denatured with buffer containing 0.5 M NaOH and
1.5 M NaCl, and subsequently neutralized with buffer containing 1.0 M Tris pH
8.0 and 1.5 M NaCl.  Following neutralization, DNA was transferred to a nylon
membrane via capillary transfer for 2 h in 10X SSC buffer (1.5 M NaCl, 150 mM
sodium citrate pH 7.0).  The membrane was subsequently UV-crosslinked for ~ 1
min, after which, it was incubated overnight at 60°C with ~ 600 ng of the
denatured, DIG-labeled probe for hybridization.  Following overnight
hybridization, the membrane was washed twice with 2X SSC buffer containing
0.1% SDS at room temperature and then washed twice with 0.5X SSC buffer
containing 0.1% SDS at 65°C.  The membrane was subsequently blocked for 30
min in milk buffer (Roche Diagnostics), incubated with an anti-DIG alkaline
phosphatase conjugate (Roche Diagnostics), and observed via
chemiluminescence, following exposure to film, for visualization of hybridized
DNA.
Immunoblot analysis of C. sordellii isolates.  Culture supernatants (10
µg) from C. sordellii ATCC9714 and UMC164 were separated via 10% SDS-
PAGE and subsequently electro-transferred to a poly(vinylidene difluoride)
membrane (Amersham Pharmacia).  For Western blotting, the membrane was
probed with anti-TcsL antiserum and reacting proteins were detected via
chemiluminescence using the ECL plus detection kit (Amersham Pharmacia).
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Anti-TcsL antiserum was isolated following immunization of New Zealand White
rabbits with a KLH-conjugated synthetic peptide (TcsL240-260) along with
Complete Freund’s adjuvant.  This 15-residue peptide, IRNLEKFADEDLVRC,
represents a putatively exposed hydrophilic region (residues 240-253) located at
the N-terminus of TcsL.  Following initial immunization, the immune response
was boosted once a month for three months with Incomplete Freund’s adjuvant
plus TcsL240-260 prior to serum collection.  Immunization and serum collection
were performed by Sigma Genosys.
Glucosylation assay.  TcsL-9714 or TcsL-UMC164 were incubated in a
standard glucosylation assay for 2 h at 37°C as previously described (159).
Following incubation, samples were separated via 15% SDS-PAGE and the gel
was dried and exposed to film for visualization of 14C-labeled proteins.
Hemolytic activity assay.  Total protein from the supernatant of each C.
sordellii strain was quantified via the Bradford protein assay (BioRad).
Following quantification, 7 µg of total protein in a final volume of 50 µl PBS
(Gibco) containing 1 mM dithiothreitol was used as the undiluted sample in a
standard hemolysis assay performed in a U-bottomed 96-well plate.  Eight 1:2
dilutions were performed for each isolate supernatant and 50 µl of a human
erythrocyte solution (3 X 107 cells/ml) in PBS was added to each well and mixed.
The plate was subsequently incubated at 37°C for 4 h.  Following incubation, the
plate was centrifuged at 1000 X g for 5 min to pellet non-lysed erythrocytes.
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Resulting supernatants were assayed spectrophotometrically analyzed at A540 to
detect hemolytic activity.
LD50 determination using BALB/c mice.  For LD50 measurements, 8 wk
old female BALB/c mice were injected i.v. with specific concentrations of
supernatant from either C. sordellii UMC164 (TcsL+, SDL-) or C. sordellii
PS4404 (TcsL-, SDL+).  Mice were injected via the tail vein using a 26.5 gauge
needle.  Six mice were injected with each test concentration to determine the




CLOSTRIDIUM SORDELLII LETHAL TOXIN IS MAINTAINED IN A
MULTIMERIC PROTEIN COMPLEX
Clostridium sordellii Lethal Toxin is Maintained in a Multimeric Protein
Complex.  (Daniel E. Voth, Maen Qa’dan, Elaine E. Hamm, Joy M. Pelfrey,
and Jimmy D. Ballard.  Infection and Immunity. 72:3366-3372)
Clostridium sordellii is a Gram-positive, spore-forming, anaerobic
pathogen, which causes a variety of diseases including postpartum toxic shock
syndrome, septic arthritis, neonatal omphalitis, and sudden death syndrome (2, 68,
100, 101, 143, 151, 169, 170).  This list of diseases has recently been expanded
with the implication of C. sordellii in the deaths of intravenous drug users
following injection of contaminated heroin (111).  In addition, C. sordellii has
been identified as a possible cause of death in recent cases of patients receiving
musculoskeletal allografts (99). Indeed, C. sordellii appears to have the capacity
to cause a diverse number of diseases.  For example, 16 different types of disease
have been reported in the approximately 30 publications regarding C. sordellii
infections. Unfortunately, very little is known about C. sordellii’s mechanism of
pathogenesis, making it difficult to provide tenable explanations for this
organism’s multi-faceted role in disease.
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Prior to the results described in Chapter III of this dissertation, only three
putative virulence factors from C. sordellii had been studied. C. sordellii produces
a lecithinase (phospholipase-C), which is similar to alpha-toxin, a major virulence
factor from Clostridium perfringens (93).  Two C. sordellii virulence factors,
TcsL and TcsH, have also been studied in some detail.  Toxoids of TcsL and
TcsH are effective vaccines against C. sordellii spore challenge in a guinea pig
model (10), indicating these toxins may play a pivotal role in disease progression.
TcsL and TcsH are members of the family of LCTs, which is composed of
at least five toxins possessing glycosyltransferase activity (25).  Members of the
LCT family of toxins, in addition to TcsL and TcsH, include TcdA and TcdB
from Clostridium difficile and Tcnα from Clostridium novyi.  Each LCT induces
pronounced cytopathic effects (CPE) in cultured mammalian cells, and these
effects are apparently a prelude to cell death.  For induction of CPE, LCTs
glycosylate, and thereby inactivate, members of the Ras family of small GTPases.
TcdA, TcdB, TcsH, and Tcnα preferentially inactivate Rho, Rac, and Cdc42 (4)
by transfer of sugar moieties derived from UDP-glucose or n-acetylglucosamine
to reactive threonines in the effector-binding loop of target GTPases.  TcsL also
glycosylates small GTPases, but differs from other LCTs by targeting Ras, Rac,
Rap, and Ral (4).
The enzymatic domain of LCTs has been narrowed to the amino-terminal
546 residues.  The difference in substrate specificity between TcsL and TcdB is
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due to sequence variation in the region of residues 364 to 516 within the
enzymatic fragment (79).  Residues important for binding UDP-glucose are found
at D286 and D288, while glucosyltransferase activity requires D270 and R273
(32).  Further studies have also implicated W102 in interaction with UDP-glucose
by TcdB and TcsL (31).  Despite these similarities, TcsL induces delayed CPE
relative to TcdB (39, 137) and it has been suggested that the slower cytotoxicity
could be due to delays in TcsL cell entry (39).  In addition, we recently reported
on the enhanced cytotoxicity of TcsL following exposure to pH 4.0 conditions
(137).  This finding indicated that TcsL might be substantially more active at pH
4.0, and this could be due to enhanced interactions with the cell following acid-
induced conformational changes.
To better understand the connection between cell entry and activation of
TcsL at pH 4.0, we analyzed the cytotoxic effects of TcsL’s enzymatic domain
using a surrogate cell entry system and found that alternative mechanisms of cell
entry markedly increased the rate of intoxication.  In addition, direct analysis of
TcsL at pH 4.0 revealed dissociation of a high-molecular weight complex
containing polypeptides of the toxin.  Findings from the current study indicate
that intoxication by TcsL is limited by the need for dissociation of a multimeric
complex, which occurs optimally under acid pH conditions.
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RESULTS
Normalized cell entry confers similar rates of CPE for TcdB and
TcsL.  Under normal cell culture conditions, TcsL induces cytopathic effects at a
rate substantially slower than TcdB (107). In earlier work, it was reported that
providing an extracellular pH 4.0 pulse quickened TcsL’s otherwise slow time-
course of intoxication (137).  pH 4.0-activated TcsL induced CPE at a rate similar
to that of TcdB, changing the time-point of 50% CPE from approximately 7 h to
90 min.  At pH 8.0, cells could be protected from TcsL by the extracellular
addition of anti-serum up to 2 h following treatment with the toxin.  These data
further indicated that TcsL intoxication is limited at the stage of cell entry, but
this is overcome by an extracellular acid pH.  Thus, in an effort to show directly
that TcsL’s slow rate of cytotoxicity was due to events at the point of cell entry,
we designed constructs of the enzymatic domains of TcsL and TcdB, which
allowed these fragments to enter cells in an identical manner.
To normalize cell entry for the enzymatic domains of TcdB (TcdB1-556) and
TcsL (TcsL1-556), we utilized a nontoxic derivative of anthrax lethal toxin, which
consists of protective antigen (PA) plus lethal factor (LF).  In past studies
involving cytosolic delivery of TcdB1-556, we used a derivative of anthrax lethal
toxin consisting of PA and a truncated form of LF (LFn), which is inactive but
can interact with PA and be translocated to the cytosol (159).  Genetic fusions
were constructed and used as a source of LFnTcdB1-556 in the earlier work, and a
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similar approach was used for constructing LFnTcsL1-556 in the current study.
Similar to our report on acid pH-pulsed entry of TcsL (137), glucosylation
profiles from extracts of cells treated with LFnTcsL1-556 plus PA showed that all
TcsL substrates were modified by the fusion (data not shown).   Thus the fusion
appeared suitable for making comparisons between the enzymatic domains of
TcsL and TcdB.
As shown in Fig. 10, LFnTcdB1-556 and LFnTcsL1-556 delivered to the
cytosol with PA demonstrated similar time-courses of CPE in HeLa cells. Wild-
type TcdB induced 100% CPE by 3 h as compared to 9 h required by TcsL for
full induction of CPE.  Both LFnTcdB1-556 and LFnTcsL1-556 induced 100% CPE
by 4.5 h.  These data further suggests that TcsL’s major barrier to intoxication
occurred at steps in cell entry.
TcsL forms an acid pH-dissociable complex. Under the described
conditions, TcsL from C. sordellii ATCC 9714 purified as a protein doublet even
after three rounds of anion exchange chromatography.  This observation is in
agreement with Martinez and Wilkins, who reported a doublet in their preparation
of TcsL from C. sordellii VPI 9048 (107).  In addition to the doublet, we also
observed the presence of ~5 smaller proteins co-purifying with TcsL.  These
smaller proteins, ranging in size from 45-55 kDa, cross-reacted with antiserum
that recognizes TcsL and became more prominent following long-term storage of
the toxin (data not shown), suggesting these were products of TcsL.
Figure. 10.  Time course of CPE in TcsL and LFnTcsL1-556 treated cells.  HeLa
cells were grown to confluence in a 96-well plate to ~ 5 x 104 cells/well.   Cells
were treated with either TcdB (100 fmol), TcsL (100 fmol), LFnTcsL1-556 (1 pmol)
or LFnTcdB1-556 (1 pmol) in a volume of 100 µl.  PA (30 pmol) was included with
the fusion proteins.  Control cells were treated with media, 20 mM Tris, heat-
inactivated toxin, or PA + LFn alone.  Following treatment, CPE were observed
for 10 h and calculated by visualizing the number of rounded cells from a field of
at least 100 cells.  The corresponding lines for each sample are labeled within the
figure. Samples were analyzed in triplicate and error bars represent the standard























Given the observations of TcsL dissociation, we investigated whether this
dissociation event might be related to TcsL’s unique requirement of acid pH for
activation.  As shown in Fig. 11, following incubation of TcsL at pH 4.0, the toxin
dissociates into a group of 45-55 kDa proteins. Inclusion of protease inhibitors,
reducing agents, and buffers across a range of ionic strengths did not alter the
dissociation profile (data not shown).
Interestingly, TcsL was able to reassemble when the sample was raised
back to pH 8.0, indicating that dissociation was reversible (Fig. 12).  To confirm
the close association required for a complex of this kind, we cross-linked TcsL at
pH 8.0 with Sulfo-EGS, a homobifunctional cross-linking reagent that cross-links
proteins with lysine residues within a 16 Å proximity.  As shown in Fig. 12, when
TcsL/Sulfo-EGS was placed under pH 4.0 conditions, no dissociation was
observed, indicating the close proximity of the complex components to each
other.  As shown in Fig. 13, TcsL/Sulfo-EGS, was no longer cytotoxic when
incubated with HeLa cells up to 72 h and was no longer able to glucosylate Ras in
vitro, while TcdB, cross-linked under the same conditions, retained full
cytotoxicity.  Additionally, as shown in Fig. 13B, TcsL/Sulfo-EGS did not
compete with TcsL for binding in a HeLa cell cytotoxicity assay.  These results
further suggest dissociation of this complex is required for interaction at the cell
surface and complete cytotoxic activity.
Figure. 11.  Acid pH-induced dissociation of TcsL.  Samples of purified TcsL
(10 µg) were incubated for 30 min with varying amounts of 100 mM ammonium
acetate buffer pH 3.8 to attain the indicated pH.  Indicated samples were then
supplemented with 250 mM Tris pH 9.0 to regain pH 8.0.  Proteins were
separated via 10% SDS-PAGE and observed using Coomassie Blue staining.  pH
range is indicated above gel.
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Figure. 12.  Impact of pH shifts and cross-linking on TcsL stability.  TcsL
samples (10 µg) were analyzed via 10% SDS-PAGE and observed using
Coomassie Blue staining following incubation under various pH conditions.
Lane 1 = TcsL pH 8.0, Lane 2 = TcsL pH 4.0, Lane 3 = pH 4.0 TcsL shifted back
to pH 8.0, Lane 4 = TcsL/Sulfo-EGS pH 8.0, Lane 5 = TcsL/Sulfo-EGS pH 4.0,
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Figure 13.  Toxicity, cell binding, and enzymatic activity of cross-linked
TcsL.  HeLa cells were incubated with TcsL, TcsL/Sulfo-EGS, or TcsL +
TcsL/Sulfo-EGS (2µg/ml) for up to 72 h and observed for morphological changes
associated with TcsL-induced cytotoxicity.  As a comparison, HeLa cells were
also incubated with TcdB or TcdB/Sulfo-EGS (2µg/ml) and observed for
morphological changes.  TcsL or TcsL/Sulfo-EGS were also incubated in a Ras
glucosylation assay as described in Materials and Methods.  (A) Control untreated
cells, (B) % Viability of TcsL, TcsL/Sulfo-EGS, and TcsL + TcsL/Sulfo-EGS-
treated HeLa Cells.  Inset compares glucosyltransferase activity of TcsL and
TcsL/Sulfo-EGS, Lane 1 = TcsL and Lane 2 = TcsL/Sulfo-EGS, (C) TcsL-treated
cells, (D) TcsL/Sulfo-EGS-treated cells, (E) TcdB-treated cells, (F) TcdB/Sulfo-
EGS-treated cells.  Samples were analyzed in triplicate and error bars indicate the
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           Protease resistance at pH 8.0.  To determine if TcsL dissociation was
specific for pH 4.0 conditions, the protein was submitted to a series of protease
digestions and high temperature incubation.  As shown in Fig. 14, proteases
including trypsin, α-chymotrypsin, V8 protease, and proteinase K, added in
excess, were unable to induce TcsL dissociation similar to that observed at pH
4.0.  However, the smaller polypeptides were sensitive to the various proteases, as
these fell below the level of detection following protease treatment.  As reported
by Popoff (131), we confirmed that only α-chymotrypsin had any effect on TcsL
activity, with CPE occurring ~50% slower than untreated TcsL (data not shown).
TcsL was also subjected to incubation at 100°C to determine if dissociation
occurs under elevated temperatures. Boiling TcsL for 15 min resulted in complete
degradation of the protein, distinct from the dissociation observed in pH 4.0
samples (data not shown).
TcsL forms high molecular weight oligomeric structures at pH 8.0.
Interestingly, the intensity of the 45-55 kDa proteins present in the pH 4.0-
dissociated TcsL was higher than that expected if these proteins were derived
from dissociation of TcsL alone.  Among the possible explanations for the
incongruent association between intensity of the smaller bands and levels of TcsL
was that some of the 45-55 kDa proteins were derived from a larger complex not
detected by standard 10% SDS-PAGE.  For this reason, we analyzed samples of
TcsL for high molecular weight complexes (>750 kDa) using SDS-agarose gel
Figure. 14.  Protease treatment of TcsL.  TcsL (10 µg) was incubated with an
excess of each indicated protease (15 µg) overnight prior to SDS-PAGE analysis.
pH is indicated above the gel and each pH section follows this order of protease
treatment:  Lanes 2 and 7 = TcsL, Lanes 3 and 8 = TcsL + trypsin, Lanes 4 and 9
= TcsL + α-chymotrypsin, Lanes 5 and 10 = TcsL + V8 protease, and Lanes 6 and
11 = TcsL + proteinase K.  Lane 1 indicates the molecular weight marker.
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electrophoresis (SDS-AGE).  As shown in Fig. 15A, a high molecular weight
protein was observed in TcsL samples at pH 8.0 which also dissociated under pH
4.0 conditions similar to TcsL.  Although TcsL reassembled when the sample was
brought back to pH 8.0, this larger protein was not detected following the pH
shift.
As shown in Fig. 15, high molecular weight proteins were not observed
when two related LCTs, TcdB (Fig. 15B) and Tcnα (Fig. 15C), were subjected to
the same pH conditions. Because high molecular weight proteins often represent
the presence of oligomeric structures, TcsL was observed via TEM at pH 8.0 and
pH 4.0.  As shown in Fig. 15D, protein aggregates were observed in TcsL samples
at pH 8.0, suggesting the formation of oligomers under these conditions.  These
oligomers, however, were not observed under pH 4.0 conditions (Fig. 15E), which
supports the previous observations of the protein sample on SDS-PAGE.
These findings suggested that the larger protein complex might account
for the protease resistance and protection to TcsL, and is dissociated at pH 4.0.
Based on this possibility, we predicted that TcsL not maintained in the complex
would be unstable.  Thus, the protein mixture was resolved via SDS-PAGE and
the protein resolving at ~ 280 kDa was electroeluted from the gel.  In addition, the
large protein complex was electroeluted following resolution by SDS-AGE.  Both
samples were then subsequently examined by SDS-PAGE.  As shown in Fig. 16,
following electroelution, TcsL spontaneously dissociated into the smaller 45-55
Figure. 15. SDS-AGE analysis of TcsL, TcdB, and Tcnα and TEM analysis of
TcsL.  Each respective toxin was separated using 1.5% SDS-AGE following
incubation under the indicated pH conditions.  Each lane represents 15 µg of
protein.  Each respective toxin is labeled in the figure.  TcsL at pH 8.0 was
stained with PTA and subsequently analyzed by TEM at 1X105 X magnification.
Arrows indicate examples of oligomeric structures.  A) TcsL, B) TcdB, C) Tcnα,
D) TEM analysis of TcsL at pH 8.0, E) TEM analysis of TcsL at pH 4.0.
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Figure. 16. Electroelution of TcsL and TcsL complex proteins.  Protein bands
representing TcsL and the TcsL complex were subjected to electroelution in the
presence of SDS for 2 h at room temperature.  Following electroelution, proteins
were separated via 10% SDS-PAGE and observed using Coomassie Blue staining.
Lane 1 = molecular weight marker, Lane 2 = protein electroeluted from TcsL,
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kDa proteins, similar to those observed following incubation at pH 4.0.
Electroelution of the larger complex from SDS-AGE resulted in slight
dissociation and the appearance of trace amounts of a protein resolving at the size
of TcsL.  Findings from the electroelution experiment indicate that TcsL outside
of the larger complex is unstable and subject to degradation even under mild
conditions.  Furthermore, this analysis suggests that TcsL is part of the larger
protein complex.
DISCUSSION
TcsL shares several common characteristics with other members of the
LCT family of virulence factors.  Among these attributes is the fact that TcsL is a
notably large, single polypeptide relative to other bacterial toxins, acts as an
intracellular toxin, and glycosylates small GTPases in order to alter target cell
physiology.  Yet, based on results from the current study, it appears that TcsL
may be unique among the LCTs, as this toxin is maintained in a dissociable high
molecular weight complex.   Dissociation of this complex may be the major rate-
limiting step in TcsL activity, and this barrier is overcome most effectively at acid
pH.  The need for dissociation of this complex prior to intoxication may explain
our earlier observations (137) and the predictions of Chaves-Olarte (39).  Both
studies suggested TcsL’s slow rate of inducing CPE was due to limitations at the
point of cell entry.
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Acid-induced activation is not uncommon to bacterial toxins; however, we
believe the mechanism by which TcsL is activated at low pH is distinct from other
reports.  For example, the cholesterol-dependent cytolysin, listeriolysin-O,
produced by Listeria monocytogenes, is optimally active within the acidified
endosome (133).  Unlike TcsL, listeriolysin-O is activated at low pH by direct
conformational changes in the protein, which leads to more efficient membrane
insertion, pore-formation, and, possibly, protein stability.  Yet, unlike TcsL,
activation of listeriolysin-O does not involve the dissociation of a multi-protein
complex. Vacuolating cytotoxin from Helicobacter pylori is also reportedly
activated by acid pH (109), but differs in several ways from activation of TcsL.
Although vacuolating activity is enhanced at low pH, this does not apparently
involve dissociation of a multimeric complex.  Furthermore, unlike TcsL,
activation of vacuolating cytotoxin is not reversible, as shifting the protein sample
back to pH 8.0 does not reduce activity.
In our experiments and in previous reports (131), TcsL was resistant to a
wide variety of active proteases including trypsin, V8 protease, and α-
chymotrypsin.  Each of these proteases had little effect on TcsL activity with only
α-chymotrypsin reducing the rate of CPE.  Proteinase-K cleaved and inactivated
TcsL, but this only occurred following extended incubations.  TcsL and the 45-55
kDa proteins were susceptible to these proteases when not associated with the
complex, further indicating that the high molecular weight complex provides
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protease resistance.  In this way, TcsL is similar to botulinum toxin, which also
resides in a multimeric complex.  Similar to the TcsL-complex, botulinum toxin
exists in a high molecular weight aggregate which is highly resistant to multiple
proteases (40).  However, unlike the TcsL complex, the botulinum toxin complex
does not dissociate under acidic conditions.
Recent studies by Pfeifer et al. indicate that TcdB is proteolytically
processed while entering the cytosol of target cells in early endocytic vesicles
(130).  This was also shown to be directly related to acidification within early
endosomes.  Thus, TcdB processing and disassembly of the monomer is
intimately linked to cell entry.  Likewise, our model for TcsL indicates that
processing of the toxin may be necessary for intoxication.  Yet, dissociation of
TcsL proceeds differently and, perhaps, at earlier stages than that found for TcdB.
The current model suggests TcsL dissociation requires extracellular low pH to
enhance cytotoxicity through breakdown of the high molecular weight complex.
It is unclear whether this also leads to translocation of a fragment of the toxin into
the cytosol as was reported for TcdB.
Investigations are underway to determine the mechanism behind multimer
formation and acid pH-induced dissociation of the complex.  It will be important
to differentiate between physical dissociation of the complex, proteolysis and
autocatalysis.   As mentioned in the results, inclusion of protease inhibitors does
not alter the dissociation profile, suggesting this event may not result from
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activation of proteases at acid-pH.  Furthermore, spiking the sample with other
proteins, such as BSA, does not result in degradation of these added proteins
when the pH is lowered (data not shown).  Thus, the current data indicates
protease activation is not a tenable explanation for dissociation of the complex.
However, the sequence of the gene encoding TcsL indicates this protein is
expressed as a single polypeptide, suggesting the protein must be proteolyzed at
some point.  Collectively, these data suggest two possibilities.  First, the toxin co-
purifies with a protease, which is highly specific for TcsL and is not blocked by
protease inhibitors that are currently available.  Alternatively, dissociation of the
multimer is due to a yet undefined mechanism of autocatalysis.  This would be in
line with the findings on the light chain of botulinum toxin, where studies
demonstrated this polypeptide showed autocatalysis over an extended period of
time at low pH (3).
The stability of the TcsL complex may influence C. sordellii disease.  As
one example, in a recent study of tissue from 795 donors, samples were analyzed
for the presence of C. sordellii (104).  Of these 795 donors, 8% were
contaminated with Clostridia and 37.7% of these were found to be C. sordellii.
Thus, contamination of allograft material by C. sordellii is a growing concern.
Furthermore, approaches to decontaminate tissue prior to transplantation may also
need to include methods to remove toxin.  Indeed, TcsL’s protease-resistant
multimer may allow this toxin to be effective in a variety of environments and
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explain in part how C. sordellii is capable of causing such a broad range of
diseases.
MATERIALS AND METHODS
Cell culture and toxin purification.  Human epitheloid carcinoma
(HeLa) cells were obtained from the American Type Culture Collection and
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum
(Gibco).  Cells were grown at 37°C in the presence of 6% CO2 and were used
between passages 10 and 20.  C. sordellii ATCC 9714, C. difficile ATCC 10463,
and C. novyi ATCC 19402 strains were used in this study for purification of TcsL,
TcdB, and Tcnα, respectively.  TcsL, TcdB, Tcnα, PA, and LFnTcdB1-556 were
isolated as previously described (137, 159).
Construction, expression, and isolation of LFnTcsL1-556.  The region
encoding the enzymatic domain of TcsL was amplified from C. sordellii ATCC
9714 genomic DNA by PCR using the forward primer
5’-GCGCGCGGATCCATGAACTTAGTTAACAAAGCCCAA-3’ and the
r e v e r s e  p r i m e r  5 ’ -
GCGCGCGGATCCTTATTATAATATTTTTTTAGAAACATAATC-3’ to
generate tcsL1-1668 with a 5’ and 3’ BamHI site. tcsL1-1668 was then restricted with
BamHI, and lfn was genetically fused to tcsL1-1668 by ligation overnight at 16°C
with BamHI restricted pABII, a derivative of pET15b containing lfn.  This
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construct generated an in-frame fusion of lfn and tcsL1-1668 and the resulting
plasmid was labeled pMQ101. The correct genetic fusion resulted in joining the
3’ end of lfn at the codon TCC encoding S254, followed by sequences within the
multiple cloning site that encoded the linker region and a string of residues
(PGGGGGS), with the 5’ end of tcsL1-1668 at the ATG codon encoding M1.
pMQ101 was then transformed into Escherichia coli DH5α (CLONTECH), and
candidate clones were screened by mini-prep analysis. In-frame, correctly
oriented clones were identified by restriction analysis and DNA sequencing and
were subsequently transformed into E. coli BL-21 (DE3) (Stratagene).  For
protein expression, cells were grown at 37°C until an OD600 of 1.0 was reached, at
which point expression was induced with 0.1 mM Isopropyl-B-D-
Thiolgalactopyranoside (Denville Scientific, Inc.) at 16°C for 16 h.  LFnTcsL1-556
was purified using Ni2+ affinity chromatography according to the manufacturer’s
instructions (Novagen).  The purified protein migrated within the predicted size
range (∼94 kD) as analyzed by SDS-PAGE and was reactive to both anti-LF and
TcdB polyclonal antisera.
Glucosylation, cell viability, and quantification of cytopathic effects.
Differential glucosylation assays were performed in a similar manner to those
previously described (137), except PA (300 pmol) plus LFnTcsL1-556 (300 pmol)
was substituted for acid-pulsed TcsL. Ras glucosylation assays were also
performed as previously described (137), with the substitution of Ras
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(Calbiochem) in place of cell extracts.  Cell viability assays were performed using
the WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt) colorimetric assay according to
the manufacturer’s instructions (Dojindo Laboratories).  The following formula
was used to determine % cell viability: {(Atest-Abackground)/(Acontrol-Abackground)*100},
where A = absorbance at OD450, background = media alone, and control = cells
treated with media alone.  Percent cytopathic effects (% CPE) were calculated by
counting a minimum of 100 cells in 3 fields for each sample.  Fully rounded cells
were scored positive for CPE and the final % CPE was calculated as % rounded
cellstest - % rounded cellscontrol, where control sample = cells treated with media
alone.  In a standard assay, cells were treated with 100 fmol of TcdB or TcsL in a
volume of 100 µl.  For assays with the fusion proteins, cells were treated with 30
pmol of PA and 1 pmol of either LFnTcsL1-556 or LFnTcdB1-556 in a volume of 100
µl.
Electrophoretic analysis of TcsL, TcdB, and Tcnα, and immunoblot
analysis of TcsL.  100 mM ammonium acetate buffer pH 3.8 was added to 10 µg
of TcsL, TcdB, or Tcnα in varying amounts to obtain the indicated pH in each
sample.  Samples were incubated with this buffer for 30 min at room temperature,
at which point the indicated samples were raised back to pH 8.0 using 250 mM
Tris pH 9.0 and incubated for 30 min at room temperature.  Samples were then
separated using either 10% SDS-PAGE or 1.5% SDS-agarose gel electrophoresis
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(SDS-AGE) as indicated and observed using Coomassie Blue staining.  Indicated
TcsL samples were subjected to western blot analysis using a C. difficile TcdB-
specific primary antibody (TechLab, Inc.).
Electroelution. Following separation via 10% SDS-PAGE or 1.5% SDS-
AGE, the band representing TcsL or the high molecular weight complex was
excised from the gel and subjected to electroelution in the presence of SDS using
the Centrilutor  Micro-electroeluter (Millipore).  Proteins were allowed to
electroelute for 2 h at room temperature.  Following elution and concentration, the
protein samples were again analyzed via 10% SDS-PAGE to determine content of
protein complexes.  Initial gels contained 15 µg of protein per lane and were
visualized using Coomassie Blue staining.
Transmission electron microscopy analysis of TcsL.  TcsL samples at
pH 8.0 were observed via transmission electron microscopy (TEM) using a
negative staining procedure.  Briefly, TcsL (300 ng/µl) was placed on a copper
support surface and allowed to adhere for 2 min.  Following adherence, 100 µl of
Phosphotungstic Acid (PTA) was applied to the grid for a 1 min incubation.
Subsequently, the PTA was removed and the support was allowed to dry.
Following drying, the protein was observed via TEM at 1X105 X magnification.
Additional samples were incubated at pH 4.0 for 30 min and subsequently
observed using TEM.
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TcsL cross-linking with Sulfo-EGS.  TcsL at pH 8.0 was cross-linked
using Sulfo-EGS, a homobifunctional cross-linking reagent, according to the
manufacturer’s instructions (Pierce Biotechnology, Inc.).  Briefly, TcsL (200 µg)
was buffer-exchanged into 50 mM HEPES pH 8.0 and subsequently incubated
with Sulfo-EGS in a volume of 100 µl at room temperature for 30 min.  Cross-
linking reactions were stopped by the addition of 50 mM Tris pH 8.0 for 15 min
at room temperature.  A decreasing range of Sulfo-EGS concentrations was used
from 2.5 mM to 250 pM to account for the effects of excess Sulfo-EGS.
Following cross-linking, samples were analyzed via 10% SDS-PAGE, and
observed using Coomassie Blue staining following incubation at the indicated pH.
Each sample cross-linked with a varied concentration of Sulfo-EGS was tested in
a routine HeLa cell cytotoxicity assay.  Briefly, HeLa cells at 75% confluence
were incubated with TcsL/Sulfo-EGS (2 µg/ml) and observed for 72 h.  Cell
viability was determined via the WST-8 assay as described above.  As a control,
TcdB was subjected to the same cross-linking conditions and Sulfo-EGS
concentrations described above.  HeLa cells were also incubated with
TcdB/Sulfo-EGS to determine effects of Sulfo-EGS on TcdB-induced
cytotoxicity.
Protease treatments and heat treatment of TcsL.  TcsL (10 µg) was
incubated with 15 µg of the following proteases in a final volume of 25 µl:
proteinase K (Geno Technology, Inc.), α-chymotrypsin (Sigma-Aldrich), V8
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protease (Sigma-Aldrich), and trypsin (Sigma-Aldrich).  Indicated samples were
placed under pH 4.0 conditions as described above, prior to protease treatment.
All incubations were performed at room temperature and 37°C for 16 h except
proteinase K, which was incubated at 55°C for 16 h.  Additionally, protease-
treated TcsL samples (2µg/ml) were incubated with HeLa cells up to 72 h and
observed visually for CPE.  Indicated TcsL samples were heated at 100°C for 15
min prior to electrophoretic analysis.
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CHAPTER V
MODULATION OF HOST CELL PHYSIOLOGY VIA INDUCTION OF
APOPTOSIS BY CLOSTRIDIUM SORDELLII LETHAL TOXIN
Clostridium sordellii lethal toxin (TcsL) is a member of the family of large
clostridial toxins (LCTs), which inactivate small GTPases in the cytoplasm of
mammalian cells.  LCTs share functional and sequence homology, but vary in
substrate specificity and co-substrate utilization (4).  In the case of TcsL, the toxin
hydrolyzes UDP-glucose and transfers the liberated sugar moiety to a reactive
threonine (Thr-35) found in the effector-binding loop 1 of Ras, Rac, Ral, and Rap
(82, 89, 132).  TcsL also differs from other LCTs in that TcsL produced by C.
sordellii reference strain ATCC9714 is maintained in a multi-protein complex,
and acid pH-induced dissociation from this multimer enhances cytotoxic activity
(shown and discussed in Chapter IV of this dissertation).
In earlier work, we demonstrated that cell rounding and death are
temporally distinct events that occur in TcsL-intoxicated cells (137).  While cell
rounding occurs relatively early in intoxication (< 6 h), loss of viability is delayed
for up to 24 h.  Indeed, there are several complex steps during TcsL intoxication
that precede both cell rounding and death of the targeted cell.  The most
immediate, post-translocation activities include localization of TcsL to the inner
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plasma membrane and substrate modification, followed by modulation of
mitochondrial membrane integrity (112, 129).  However, the individual
contribution of substrate modification, mitochondrial membrane disruption, and
cell rounding to the ultimate death of the cell are not known.
Changes in cellular ultrastructure, while important, do not completely
explain loss in cell viability.  Indeed, incubation of mammalian cells with actin
depolymerizing agents, such as cytochalasin D, does not result in a similar mode
of cell death as that observed upon treatment with the LCTs (129).  It also seems
unlikely that cell death is due to a direct modulation of the mitochondrial
membrane by TcsL, since recent work has shown localization of the toxin to the
inner plasma membrane (112).  This activity is accomplished through a sequence,
encoded within the N-terminal 18 residues of TcsL, which specifically binds to
phosphatidylserine.  It is thought that this localization sequence allows TcsL to
traffic to the inner plasma membrane of the cell, where active GTPases
accumulate.  Deletion of this 18-residue domain prevents TcsL from causing
cytopathic effects, suggesting this short amino acid sequence is essential for
cytotoxicity.
Petit et al. also reported that TcsL modulates the mitochondria of
intoxicated cells within 2 h following treatment of HL-60 cells (129).  By
disrupting mitochondrial membrane integrity, TcsL triggers the release of
cytochrome c and subsequent downstream events in apoptosis.  Thus, TcsL
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intoxication is bimodal, in that the toxin inactivates specific small GTPases
followed by modulation of the mitochondria.
Based on these observations, the current model of TcsL intoxication
suggests the toxin first localizes to the inner plasma membrane and glucosylates
substrates, leading to cell rounding, modulation of mitochondrial integrity,
activation of apoptosis, and finally death of the cell.  Yet, the signaling events, or
loss thereof, that lead to changes in mitochondrial integrity, and eventual cell
death, in TcsL-intoxicated cells are poorly defined.  However, based on published
studies of Ras-regulated signaling pathways, the protein kinase Akt should be one
of the signaling proteins impacted by TcsL immediately following inactivation of
small GTPase substrates.
Akt is a prominent cell survival protein found in mammalian cells that acts
downstream of, and in response to, Ras activation (49, 128).  Following activation
of Ras, via extracellular growth factors, phosphatidylinositol-3-kinase (PI3K)
triggers the phosphorylation of PDK1, which subsequently aids in the
phosphorylation of Akt at Thr-308 and Ser-473, resulting in the active form of the
protein (7).  Active Akt can then modulate downstream pro-survival pathway
proteins, including ERK, MDM2, Forkhead transcription factors (FKHRs), and
mTOR, and has been shown to phosphorylate, and inactivate, the pro-apoptotic
protein Bad (49, 128).  Active Akt is also responsible for phosphorylating
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glycogen synthase kinase 3-beta (GSK-3β) (45), which is involved in cell cycle
regulation and apoptosis.
Therefore, TcsL-mediated inactivation of Ras could have an immediate
effect on Akt signaling, leading to downstream changes in mitochondrial integrity
and, perhaps, activation of apoptosis.  For this reason, in the current study,
experiments examined the temporal effects of TcsL intoxication on Akt signaling.
The results from this study suggest that TcsL induces rapid declines in the levels
of phosphorylated Akt, followed by dephosphorylation and loss of GSK-3β,
without dramatically influencing mitochondrial apoptotic effectors, such as Bad.
In addition to determining early Akt-dependent events involved in TcsL
cytotoxicity, late-stage mitochondrial-associated apoptotic events were also
examined.  The results of these studies suggest that TcsL activity results in late-
stage changes in the mitochondrial-dependent apoptotic pathway, including Bid
and Bcl-xL cleavage.  In total, the current data suggest TcsL intoxication of
mammalian cells results in an apoptotic feedback mechanism that ensures death
of the affected cell.
RESULTS
TcsL intoxication results in late induction of apoptosis.  While late
stage apoptotic markers have been reported in TcsL-treated HL-60 cells (129), a
temporal analysis of apoptosis, in HeLa cells, was required for interpretation of
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results in the current study.  In particular, caspase-3 activation and poly-ADP-
ribose polymerase (PARP) inactivation, two proteins that are classical markers for
the late stages of death in cells undergoing apoptosis (127), were analyzed in
lysates collected from TcsL-treated HeLa cells.
As shown in Fig. 17A, caspase-3 was activated between 8-12 h post-
treatment in HeLa cells incubated with TcsL.  Cleaved, inactivated PARP was
subsequently apparent by 12-24 h (Fig. 17B).  These results also correlate with
those previously shown (129) and provide a timing of the late events in TcsL-
induced apoptosis.  These results also indicate that each of these apoptotic steps
occur downstream of GTPase inactivation, which is thought to occur shortly (< 1
h) following toxin entry into the target cell and subsequent escape from an
endosomal compartment.
TcsL intoxication results in a rapid decline in the levels of activated
Akt.  Since TcsL was found to induce classical apoptotic events at least 8 h
following glucosylation, and inactivation, of GTPases, components upstream of
the caspases and pro-apoptotic mitochondrial proteins were examined in order to
further understand the contribution of Ras inactivation to TcsL-induced cell death.
A strong candidate for involvement in the pathway between Ras and apoptosis is
Akt.  This signaling protein is a vital regulatory component central to multiple cell
survival networks in healthy cells (49).  Additionally, Akt activity can be
influenced by Ras activity via phosphorylation by PI3K.  For functional Akt
Figure 17.  Late stage apoptotic events occurring in TcsL-treated HeLa cells.
(A) HeLa cells (4 X 104 cells/ml) were cultured in a 96-well black plate prior to
analysis of caspase-3 activity.  Following incubation with TcsL-W (1 µg/ml) for
the indicated time points, cells were analyzed using the Apo-ONE
Homomgeneous Caspase-3/7 Assay as described in Materials and Methods.
Control samples were incubated with 20 mM Tris, pH 8.0, for the indicated time
points.  Samples were analyzed in triplicate and error bars represent the standard
deviation from the mean.        = TcsL-W-treated cells and       = control cells.  (B)
HeLa cells were cultured in 25-cm2 flasks and treated with TcsL-W (1 µg/ml) at ~
75% confluence.  Following treatments, cells were harvested, lysed, and total
protein was separated via 4-15% SDS-PAGE and analyzed via Western blotting
using a PARP-specific primary antibody.  Control cells were incubated with 20
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activity, the protein must be phosphorylated at Ser-473 by upstream factors, such
as PI3K or PDK1 (7).  Therefore, it was hypothesized that TcsL inactivation of
Ras would result in a decline in the levels of phosphorylated Akt, resulting in a
pro-apoptotic phenotype in TcsL-treated cells.
Using Western blot analysis, a rapid decline in the levels of
phosphorylated Akt was observed early in routine TcsL treatment of HeLa cells,
with an ~ 65% decrease in this form of the protein by 1 h post-treatment (Fig.
18A).  This decline was in contrast total levels of Akt in TcsL-treated cells, which
remained constant across the same time course (Fig. 18B).  To determine whether
this loss in phosphorylated Akt was dependent on TcsL-specific GTPase
inactivation, the activation status of Akt was analyzed in lysates collected from
HeLa cells treated with Clostridium difficile Toxin B (TcdB), a homologous
glucosyltransferase that inactivates Rho, Rac, and Cdc42, but not Ras (4).  As
shown in Fig. 18C, treatment of HeLa cells with TcdB, for the same time course
as TcsL, had no detectable negative effect on the levels of phosphorylated Akt,
suggesting this effect was dependent on the inactivation of TcsL-specific
substrates.
TcsL glucosyltransferase activity is required to induce rapid declines
in active Akt.  As mentioned above, some debate exists as to whether GTPase
modification is a required step in the initiation of apoptosis in TcsL-treated cells
(129).  To better understand GTPase involvement in this process, we took
Figure 18.  Levels of phosphorylated Akt in TcsL-treated HeLa cells.
Following incubation with either 1 µg/ml TcsL-W (A and B) or 1 µg/ml TcdB (C)
for the indicated time points, cells were harvested, lysed, and total protein was
separated via 4-15% SDS-PAGE and analyzed via Western blotting using a
phospho-Akt-specific primary antibody.  Times of treatment are indicated above
the gel.  (A) Levels of phosphorylated Akt in TcsL-W-treated cells.  (B) Levels of
















































































advantage of a fusion protein delivery system based on the cellular entry of
anthrax toxin that was described in Chapter IV of this dissertation.  Using this
fusion protein, LFnTcsL1-556, along with protective antigen (PA) from Bacillus
anthracis, we were able to analyze the effects of the enzymatic domain of TcsL
alone on the levels of phosphorylated Akt.  As shown in Fig. 19A, treatment of
cells with PA plus LFnTcsL1-556 resulted in a decline in phosphorylated Akt by ~ 4
h, suggesting the toxin’s glucosyltransferase activity is sufficient to influence the
levels of active Akt.
To further examine the requirement for glucosyltransferase activity in
TcsL-induced declines in active Akt, the toxin was inactivated by incubation with
the UDP derivative UDP-2’,3’-dialdehyde as previously reported (64).
Inactivation of the toxin in this manner results in a form of the protein that still
binds and enters the cell but is no longer able to modify GTPases due to its
inability to bind UDP-glucose and, thus, can no longer induce CPE (Fig. 19).  As
shown in Fig. 19B, HeLa cells incubated with derivatized TcsL exhibited no
decline in the levels of phosphorylated Akt, further indicating the
glucosyltransferase activity of the toxin is required for mediating these early
events.
Downstream effects of TcsL inactivation of Akt.  Downstream effectors
of active Akt were next examined following TcsL intoxication.  In this study, the
phosphorylation state of Bad and GSK-3β was examined in HeLa cells following
Figure 19.  Effects of TcsL glucosyltransferase activity on Akt activation.
Following incubation with either 1 µg/ml LFnTcsL1-556 + 1 µg/ml PA (A) or 1
µg/ml derivatized TcsL-W (B) for the indicated time points, cells were harvested,
lysed, and total protein was separated via 4-15% SDS-PAGE and analyzed via
Western blotting using a phospho-Akt-specific primary antibody.  Times of
treatment are indicated above the gel.  (A) Levels of phosphorylated Akt in cells
incubated with LFnTcsL1-556 + PA.  (B) Levels of phosphorylated Akt in cells
incubated with derivatized TcsL-W.  (C-E) HeLa cells were cultured in 96-well
plates and subsequently incubated with either 20 mM Tris, pH 8.0 (C), TcsL-W

























































incubation with TcsL.  As shown in Fig. 20, TcsL-intoxicated HeLa cells showed
decreases in the phosphorylated form of GSK-3β (Fig. 20A) at 8 – 12 h post-
intoxication and a corresponding decline in levels of total GSK-3β (Fig. 20B).
These declines did not, however, result from a global loss in cellular protein (Fig.
20C).  This condition represents a pro-apoptotic phenotype late in intoxication
due to activation of GSK-3β, which is known to influence cell cycle regulation
and apoptosis (45, 78).  Surprisingly, no detectable loss in phosphorylated Bad
was observed under these conditions (data not shown).  While Bad has been
shown to be involved in apoptotic responses in specific cells following Akt
inactivation (148), it is possible that other, unidentified factors function at the
mitochondrial surface following Akt inactivation in TcsL-intoxicated cells.
Since TcsL inactivation of Akt affected specific downstream effectors of
this pro-survival pathway, Wortmannin, an inhibitor of PI3K and, consequently,
Akt (Fig. 21A), was employed to examine the global response in cells lacking
active Akt.  As shown in Fig. 21B, treatment of cells with Wortmannin resulted in
a rapid decline in phosphorylated GSK-3β; however, no corresponding loss in
GSK-3β was observed, with total levels of this protein remaining constant
through 24 h (Fig. 21B).  These results further suggested TcsL-specific and
glucosylation-specific effects were occurring in the cells treated with this LCT.
Late apoptotic events occurring in cells intoxicated by TcsL.  To
further understand the apoptotic events occurring in cells treated with TcsL,
Figure 20.  Downstream effects of Akt inactivation by TcsL.  Following
incubation with TcsL-W (1 µg/ml) for the indicated time points, cells were
harvested, lysed, and total protein was separated via 4-15% SDS-PAGE and
stained with Coomassie Blue or analyzed via Western blotting using a phospho-
GSK-3β-specific primary antibody.  Times of treatment are indicated above the
gel.  (A) Levels of phosphorylated GSK-3β in TcsL-W-treated cells.  (B) Levels
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Figure 21.  Levels of phosphorylated Akt and phosphorylated GSK-3β in
Wortmannin-treated HeLa cells. Following incubation with Wortmannin (1
µM) for the indicated time points, cells were harvested, lysed, and total protein
was separated via 4-15% SDS-PAGE and analyzed via Western blotting using a
phospho-Akt-specific, Akt-specific, phospho-GSK-3β-specific, or GSK-3β-
specific primary antibody.  Times of treatment are indicated above the gel.  (A)
Levels of phosphorylated Akt and total Akt in Wortmannin-treated cells.  (B)
Levels of phosphorylated GSK-3β and total GSK-3β in Wortmannin-treated cells.
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specific mitochondrial effectors were examined to determine their potential role in
TcsL cytotoxicity.  In particular, Bid, Bcl-2, and Bcl-xL were examined in this
study, as these are three well-known mitochondrial proteins involved in apoptotic
responses (94, 164).  As shown in Fig. 22, total levels of Bcl-2, an anti-apoptotic
protein, were unaffected following intoxication of NIH/3T3 cells by TcsL.  In
contrast, both Bid and Bcl-xL underwent cleavage by 8 – 12 h, indicative of pro-
apoptotic conditions (94).  Interestingly, this cleavage event was not observed in
lysates taken from cells incubated in the presence of TcsL and a pan-caspase
inhibitor (Fig. 22).  Active caspase-3 has been previously shown to cleave other
proteins, including Bid and Bcl-xL, resulting in an amplification/feedback
apoptotic response that ensures the death of the affected cell (94, 152).  This
evidence, in combination with the current results, suggests that TcsL intoxication
of NIH/3T3 cells results in specific caspase-dependent, late stage apoptotic events
that create an amplification response involving specific mitochondrial apoptotic
effector proteins (summarized in Fig. 23).
DISCUSSION
In the current study, we examined the pre-mitochondrial events leading to
apoptosis in cells intoxicated by the bacterial glucosyltransferase TcsL.  These
results indicate that TcsL activity causes the rapid inactivation of a major cell
survival regulator, Akt.  Akt is a serine/threonine kinase that functions
Figure 22.  Effects of TcsL intoxication on mitochondrial apoptotic effector
proteins.  Following incubation with TcsL-W (1 µg/ml) for the indicated time
points, cells were harvested, lysed, and total protein was separated via 4-15%
SDS-PAGE and analyzed via Western blotting using either Bcl-2-, Bcl-xL-, or
Bid-specific primary antibody.  Times of treatment are indicated above the gel.
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Figure 23.  Model of TcsL-induced apoptosis involving early glucosylation-
specific events and an amplification/feedback response.  Following cell entry,
TcsL glucosylates Ras at the inner cell membrane, resulting in an inactive form of
the protein.  Inactivated Ras results in the inactivation of Akt, a major cell
survival regulator that controls multiple signaling pathways.  The absence of
active Akt triggers a cell death response via downstream effectors, such as GSK-
3β and the mitochondrial effector Bad.  Once the mitochondrial membrane
potential has been perturbed, cytochrome c is released into the cytosol, where it
forms a complex with caspase-9 termed the apoptosome.  This complex is then
responsible for downstream processing of caspases, such as caspase-3.  Caspase-3
then functions as an executioner caspase that cleaves additional proteins,
including Bid and Bcl-xL.  Processing of these mitochondrial effectors enhances
the apoptotic response via a feedback/amplification loop.  These processes



































downstream of Ras, a TcsL substrate, to enhance cell survival (49, 128, 146) via
multiple phosphorylation cascades.  Akt itself is activated via phosphorylation at
Ser-473, following which, the protein participates in multiple signaling pathways
including, but not limited to, ERK, GSK-3β , and p53, and regulates
transcriptional activators, such as the FKHR family, in order to prevent apoptosis
(49, 128).  The current results indicate that TcsL inactivation of Akt, via GTPase
glucosylation, leads to mitochondrial- and caspase-dependent events that ensure
death of the target cell.
While unique among the LCTs, exploitation of Akt signaling, through
inactivation, by at least three bacterial pathogens, including Pseudomonas
aeruginosa (74), Serratia marcescens (52), and Yersinia enterocolitica (147), has
been previously demonstrated.  Most notably, Exoenzyme S, a Type III effector
protein produced by Pseudomonas aeruginosa, is an ADP-ribosyltransferase that
inactivates Ras in target cells (74).  The ADP-ribosyltransferase activity of this
bacterial toxin leads to declines in active Akt, disruption of the actin cytoskeleton
(58), and ultimately to death of the affected cell.  Additionally, as with the current
derivatized TcsL results, ExoS mutants lacking enzymatic activity are no longer
able to modulate Akt activation and are rendered non-toxic (74).  These studies,
along with the current TcsL results, suggest Akt may be a common signaling
protein targeted by bacterial toxins that impact small GTPase activation.
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Although ExoS inactivation of Akt has been demonstrated in serum-
starved cells subsequently exposed to growth factors (74), the current TcsL data
indicate that this bacterial toxin induces the inactivation of Akt in cells growing in
the presence of serum containing growth factors.  Following incubation of HeLa
cells, in the presence of serum, with TcsL, rapid (< 1 h) declines in the levels of
phosphorylated Akt were observed.  These declines were observed prior to the
reported time of mitochondrial- and caspase-dependent events that eventually
ensue due to TcsL activity.  In studies examining mitochondrial protein- and
caspase-related activity, cytochrome c release and caspase-9 activation were not
observed until 2 h post-treatment with TcsL (129), suggesting that the toxin’s
effects on Akt may be a prerequisite for mitochondrial-dependent apoptosis.
Additionally, studies of the TcsL enzymatic domain and derivatized TcsL indicate
that these Akt-specific effects are dependent on catalytically active toxin.  In total,
these results suggest that glucosylation, and inactivation, of small GTPases is an
essential step in TcsL cytotoxicity.
Due to the observed effects of TcsL on Akt activation, we also examined
the activation status of downstream Akt effectors as a consequence of Akt
inactivation.  These results indicated that TcsL intoxication has specific effects on
the downstream protein GSK-3β .  In the current study, GSK-3β  was
dephosphorylated by 8 - 12 h post-intoxication, with a corresponding loss in total
GSK-3β, further supporting an apoptotic phenotype late in intoxication.  In
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contrast, no detectable change in the activation state of Bad was observed in the
current study.  Subsequent experiments, using Wortmannin as a general Akt
inhibitor, showed no effect on total GSK-3β, suggesting this is a TcsL-specific
response.
Following examination of TcsL-specific early effects on Akt inactivation,
specific mitochondrial effectors were also examined to determine their role in
TcsL-induced cell death.  In particular, the mitochondrial effectors Bcl-2, Bcl-xL,
and Bid were examined for their potential roles in TcsL-induced apoptosis.  In
healthy cells, both Bcl-2 and Bcl-xL serve as anti-apoptotic factors that function to
inhibit cytochrome c release from the mitochondria (164).  The current results
showed no detectable Bcl-2 involvement in TcsL cytotoxicity; however, TcsL-
intoxicated cells demonstrated processing of Bcl-xL, shown by cleavage of this
mitochondrial-associated protein.  This cleavage event has been reported to be
caspase-3-dependent, resulting in a pro-apoptotic form of Bcl-xL (22, 59).  At the
same time point of Bcl-xL processing, cleaved Bid was also detected in TcsL-
intoxicated cells.  This cleavage has also been shown to be a pro-apoptotic
response that results in a feedback response via caspase-3 activity (152).  In line
with these observations, the current results showed prevention of both Bcl-xL and
Bid processing when cells were incubated in the presence of TcsL and a
pancaspase inhibitor, further suggesting the requirement of caspases to elicit a
complete apoptotic response to the LCTs.
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In total, the current data suggests TcsL induces an apoptotic program in
target cells that involves early pre-mitochondrial, mitochondrial, and late stage
caspase-mediated events that result in a feedback/amplification response to ensure
cell death (Fig. 23).  In studies of the LCT-producing clostridia, major emphasis is
placed on the toxins, and their ability to cause cell death, as a major determinant
in the severity of disease.  While it has been established that mitochondrial
proteins and caspases are important for apoptosis in LCT-intoxicated cells, the
current study stresses the need to dissect the upstream components involved in
these toxins’ mechanisms of action.  In particular, the link between GTPase
glycosylation and the proteins responsible for cell death must be defined in order
to halt toxin activity before apoptosis proceeds to a point of no return.  The
current results indicate that TcsL modulates a vital cell survival protein, Akt, prior
to observation of cell rounding and mitochondrial-dependent apoptotic events.
While TcdB, a related LCT, was not found to elicit similar effects, these results
suggest that each of the LCTs could impact diverse cell survival signaling
pathways prior to the induction of apoptosis.
MATERIALS AND METHODS
Mammalian cell culture, bacterial strains, and toxin purification.
Human epitheloid carcinoma (HeLa) and NIH/3T3 mouse fibroblast cells were
obtained from the American Type Culture Collection and maintained in RPMI
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1640 medium (Gibco) containing 10% fetal calf serum (Gibco) at 37°C in the
presence of 6% CO2.  All cells were used between passages 10 and 20.  C.
sordellii strain W (Dr. Dennis Stevens, VA Hospital, Boise, Idaho) was used for
isolation of TcsL in this study and C. difficile ATCC 10463 was used for isolation
of TcdB.  For toxin purification, C. sordellii or C. difficile were cultured in 1 L
dialysis bag cultures, and TcsL and TcdB were purified as previously described
(138).  LfnTcsL1-556 and PA were expressed in Escherichia coli and isolated as
described in Chapter IV of this dissertation.  Unless otherwise indicated, all other
chemical reagents were from Sigma.
Inactivation of TcsL.  TcsL was inactivated via incubation with UDP-
2’,3’-dialdehyde using a modified version of the protocol described by Genth et
al. for C. difficile TcdB (64).  TcsL (0.5 µg/ml) was incubated in a 100 µl solution
containing 1 mM UDP-2’,3’-dialdehyde (Sigma) solubilized in 20 mM Tris, 150
mM NaCl, pH 7.5.  The sample was incubated at 37°C for 3 h to inactivate the
toxin.  Following inactivation, the sample was passed over a 50 kDa MWCO filter
using the Microcon system (Amicon).  Using this system, the toxin was washed
three times with 20 mM Tris, pH 8.0 for removal of excess UDP-2’,3’-
dialdehyde.  Inactivated TcsL was subsequently incubated with HeLa cells in a
96-well plate overnight to determine loss of cytotoxic activity.
Western blot analysis.  HeLa cells, grown to confluence in 6-well tissue
culture plates, were incubated with TcsL (1 µg/ml), LfnTcsL1-556 (1 µg/ml) +
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protective antigen (1 µg/ml), TcdB (1 µg/ml), or Wortmannin (1 µM) for the
indicated periods of time.  In indicated samples, cells were pretreated for 1 h with
a pancaspase inhibitor (50 µM) (Calbiochem) prior to toxin treatment.  Following
toxin treatment, cells were harvested via incubation on ice for 20 min in buffer
containing 50 mM Tris-HCl (pH 5.7), 5 mM EDTA, 1% SDS, 100 mM NEM, and
protease inhibitor cocktail.  Cell lysates were subsequently passed through a 20
gauge needle 10 times.  Total cell lysate protein was quantified using the DC
Protein Assay method according to the manufacturer’s instructions (BioRad).
Cell lysates (10 µg) were separated via 4-20% SDS-PAGE and transferred to a
poly(vinylidene) membrane.  Following transfer, membranes were probed with
the indicated primary antibodies (Cell Signaling Technologies).  After overnight
incubation in primary antibody, membranes were incubated with an HRP-
conjugated secondary antibody (Cell Signaling Technologies) and reacting
proteins were visualized via enhanced chemiluminescence using the ECL-plus kit
(Amersham).
Caspase-3 activation assays.  To analyze the activation state of caspase-3
in TcsL-treated cells, the Apo-ONE Homogeneous Caspase-3/7 Assay
(Promega) was utilized.  HeLa cells were grown to ~ 75% confluence in a 96-well
plate and subsequently incubated with TcsL (1 µg/ml) for the indicated time
points.  Following toxin treatment, the Apo-ONE Caspase-3/7 Reagent was
added to each well, including control cells and blank wells.  Following incubation
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at room temperature for 1 h, fluorescence intensity of each well was determined
using a Fluostar Optima fluorimeter (BMG Labtechnologies).  An excitation
wavelength of 485 nm and an emission wavelength of 530 nm were used.  Each





The studies described in this dissertation were designed in order to gain a
better understanding of the virulence mechanisms of C. sordellii, with particular
emphasis on the soluble virulence factors produced by this organism.  While C.
sordellii-associated disease has been reported, in humans, for many years now,
and appears to be on the rise, little is known regarding the virulence determinants
responsible for this disease.  As with many of the pathogenic clostridia, C.
sordellii produces a number of soluble virulence proteins that are thought to be
responsible for establishing infection and causing disease.  To this end, the current
studies involved analyzing a panel of C. sordellii isolates for virulence factor
production and activity.  Following this characterization, the primary C. sordellii
virulence factor, TcsL, was studied at the biochemical and cell biology level to
further understand the role of this toxin in C. sordellii pathogenesis.
In Chapter III of this dissertation, an extensive study of cadaver-derived C.
sordellii strains was undertaken in order to determine the frequency at which this
pathogen produces one, two, or more of its reported virulence factors.
Surprisingly, only one of the examined strains produced TcsL, which is thought to
be the major virulence determinant in C. sordellii-associated disease.  Aside from
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TcsL, five of the cadaver-derived strains produced an active hemolysin, termed
sordellilysin (SDL).  SDL lysed erythrocytes in vitro and was also cytolytic to a
panel of cultured mammalian cells.  Additionally, using Western blot analysis, we
determined that SDL shares some homology with perfringolysin O produced by
C. perfringens.
In order to better understand the importance of TcsL and SDL in C.
sordellii pathogenesis, the mouse model of intravenous injection was employed.
Using this model, supernatants from TcsL+, SDL- and TcsL-, SDL+ strains were
compared via LD50 analysis.  From these experiments, we found that supernatants
containing TcsL demonstrated an ~ 10-fold lower LD50 than supernatants
containing active SDL.  Additionally, supernatants lacking these toxins, but
containing other virulence factors, were not lethal in the mouse model.  In total,
these results suggest that a high percentage of strains of C. sordellii produce an
active hemolytic protein that may aid in causing specific forms of disease;
however, studies using the mouse model suggest that TcsL may be more
important for the shock-like death observed in patients with C. sordellii-
associated disease.  These results also show a high degree of variability in
virulence factor profiles among C. sordellii strains, which may be a key
component of this organism’s ability to cause many different types of disease.
In Chapter IV of this dissertation, a closer examination of the biochemical
aspects of TcsL was performed, with an emphasis on the pH-specific effects on
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the toxin.  In these studies, we found that TcsL dissociates at acid pH (< pH 5.0),
the same pH at which the toxin demonstrates enhanced cytopathic effects (CPE)
when incubated with cultured mammalian cells.  This acid pH triggers TcsL to
dissociate into a group of 40 – 50 kDa proteins.  The close association of these
smaller proteins in the TcsL protein complex was confirmed using a chemical
crosslinking reagent.  In the presence of this reagent, TcsL no longer dissociated
into the smaller protein group when placed in an acid pH environment, and
crosslinked TcsL was no longer cytotoxic to cultured cells.  In addition to toxin
dissociation, we also found that TcsL samples contained a high molecular weight
complex that was also subject to pH-induced dissociation.  Using an
electroelution technique, it was determined that TcsL was indeed a component of
this multimeric complex.  Suspecting that this complex may be a protective
environment for TcsL, protease treatments of the toxin were also performed.  The
results of these studies indicated that TcsL is a highly stable protein that is not
subject to common protease digestion unless elevated to high temperature.
Collectively, the results from these studies suggest that TcsL is a stable toxin that
is maintained in a protective complex and dissociates at acid pH to enhance
cytotoxicity.  These characteristics would likely offer a beneficial environment to
the toxin in the context of the host disease setting.
In Chapter V of this dissertation, the impact of TcsL on cell physiology
was examined, with a particular emphasis on signaling pathways affected by this
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toxin.  These studies were designed to gain a better understanding of the
immediate downstream effects of glucosylation of small GTPases by TcsL.  Due
to its role in multiple cell survival pathways, and its activation via Ras, Akt was
examined as a possible effector of GTPase glucosylation by TcsL.  Results from
these experiments indicate that TcsL’s activity results in rapid declines in the
levels of phosphorylated (activated) Akt in intoxicated cells.  Following Akt
inactivation a notable decrease in phosphorylated GSK-3β and total GSK-3β was
observed.  These results suggest that TcsL affects one of the cell’s major survival
response proteins, Akt, and elicits subsequent effects on downstream survival
response pathways in order to ensure cell death.  Additionally, these data provide
a direct link between GTPase glucosylation and cell death induced by TcsL.
After examining the early events occurring in TcsL-intoxicated cells, we
also studied some of the later apoptotic events in these cells, focusing on
mitochondrial-dependent apoptotic effector proteins.  The results from these
studies suggest TcsL induces a late stage apoptotic feedback mechanism via Bid
and Bcl-xL.  In TcsL-intoxicated cells, both Bid and Bcl-xL were cleaved by 12 h
post-intoxication.  Cleavage of these two proteins represents a pro-apoptotic
condition in these cells.  This cleavage event, however, was not observed in the
presence of a caspase inhibitor, suggesting caspase activation is required prior to
activation of these mitochondrial proteins.  Thus, the late stage phenotype of
TcsL-intoxicated cells indicates that these cells are undergoing caspase-dependent
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apoptosis that involves a feedback mechanism proceeding through the
mitochondrial effector proteins, Bid and Bcl-xL.
In total, the work described in this dissertation presents some important
advances in the field of C. sordellii pathogenesis.  In regard to the organism, the
current results provide a better understanding of the versatility of this pathogen
due to its ability to produce a variety of virulence factors.  The virulence factor
characterization also identified a potentially important virulence determinant in
SDL, a hemolytic factor produced by a high percentage of the strains examined.
In regard to TcsL, the current results have further defined the pH-dependent
effects of this toxin on the cell and, additionally, show that TcsL exerts its effects
on the Akt cell survival pathway prior to mitochondrial apoptotic events.  It is my
hope that the findings presented in the current dissertation would contribute to a
better understanding of C. sordellii pathogenesis and provide a basic knowledge
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In addition to the LCT studies described in this dissertation, a period of
my graduate career involved studies designed to better understand the mechanism
of action of two of the components of anthrax toxin, the bacterial toxin produced
by Bacillus anthracis.  B. anthracis produces a tripartite toxin composed of lethal
factor (LF), edema factor (EF), and protective antigen (PA).  The combination of
LF and PA yields lethal toxin (LT), and EF plus PA yields edema toxin (ET).
While anthrax toxin has been studied for many years, the majority of research has
focused on understanding LT activity and its effects on host cells.  Thus, the two
chapters of this appendix include two studies detailing previously undescribed
functions of PA and EF.  The results of each of these studies suggest a larger,
cytotoxic role for these two components of anthrax toxin in the disease and will
be discussed in the discussion sections of each chapter.  These two studies are
presented in their peer-reviewed form in this appendix.
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BACILLUS ANTHRACIS OEDEMA TOXIN AS A CAUSE OF CELL
TYPE-SPECIFIC CYTOTOXICITY
Bacillus anthracis Oedema Toxin as a Cause of Tissue Necrosis and Cell-
Type Specific Cytotoxicity.  (Daniel E. Voth*, Elaine E. Hamm*, Lan G.
Nguyen, Amy E. Tucker, Isabelle I. Salles, William Ortiz-Leduc, and Jimmy
D. Ballard.  Cellular Microbiology. 7:1139-1149.  *D.E.V. and E.E.H.
contributed equally to this work.)
Bacillus anthracis produces three proteins that work in binary
combination to induce edema and lethality.  During intoxication, protective
antigen (PA) mediates the cellular entry of edema factor (EF) and lethal factor
(LF), yielding edema toxin (ET) and lethal toxin (LT), respectively (13).  Once in
the cytosol, LF, a zinc-dependent metalloprotease, cleaves mitogen-activated
protein kinase kinases, consequently disrupting signaling pathways modulated by
extracellular signal regulated kinases 1 and 2, c-jun N-terminal kinase, and p38
(14).  EF is a Ca2+- and calmodulin-dependent adenylate cyclase that generates
high levels of cAMP in the cell (29, 30).  This rapid rise in cAMP levels has been
implicated in the inhibition of phagocytosis in neutrophils and may provide an
initial defense from the host immune system during infection (43).  Furthermore,
isogenic strains of B. anthracis lacking LF or EF are reduced in virulence (44),
indicating both ET and LT play an important role during the disease process.
EF is a member of the class of adenylate cyclase toxins, which modify cell
physiology by the rapid conversion of cellular ATP to cAMP.  First described by
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Leppla as an adenylate cyclase (29), EF shares sequence homology with the
adenylate cyclase toxin (CyaA) from Bordetella pertussis (15) and ExoY from
Pseudomonas aeruginosa (65).  These virulence factors alter cell physiology
through the supraphysiological accumulation of cAMP.  Additionally, CyaA has
been reported to contribute to apoptosis in macrophages during B. pertussis
infection in vivo (21).  While ET has been shown to disrupt neutrophil function
and alter cytokine production (23), the full impact of this toxin on the host, or on
specific cell physiology, is not understood.  In fact, Moayeri and colleagues
recently reported on the ability of LT to cause tissue damage and hypoxia (37) in
a murine model, but whether or not ET also contributes to cell death and tissue
necrosis is unclear.
In order to examine potential ET-induced tissue damage, we have taken
advantage of the developing zebrafish embryo as a model system to study this
toxin.  The zebrafish embryo model proved useful in earlier studies on LT,
wherein we confirmed the ability of LF to disrupt glycogen synthase kinase-3β
activity (59).  The developing zebrafish model presents several distinct
advantages for the study of intracellular bacterial toxins.  In addition to their
ability to develop during a short time-period, zebrafish embryos are optically
transparent for a week past fertilization, allowing for convenient visualization of
multi-organ systems (25).  Unlike other models, whole animal histopathological
analysis of zebrafish is simple, as longitudinal cross-sections of the entire fish can
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be prepared and visualized.  Furthermore, a complete immune system is absent
during initial stages of development, and this allows assessment of tissue damage
without major inflammatory responses (58).  Thus, one can assess the direct
impact of a bacterial toxin on specific organs and tissue using this model.  For
these reasons, we utilized the developing zebrafish embryo as a model to improve
our understanding of ET and determine if this toxin demonstrates organ-specific
activity and causes tissue necrosis.  Results from these treatments indicate ET
effectively caused tissue necrosis and cell death, as well as, lethality in the
zebrafish model.  Based on these observations further experiments were
performed to determine if ET is cytotoxic to a variety of mammalian cell types,
the results of which indicate the impact of this toxin is cell-type specific and
cAMP levels do not correlate with death in all cells.
RESULTS
ET induces cytotoxic effects in zebrafish Pac2 embryonic fibroblasts.
Prior to treatment of live embryos, we sought to determine if ET was capable of
intoxicating zebrafish-derived cells.  Based on the reported sequences from the
partially completed zebrafish genome, we were able to identify homologs of the
EF cofactor calmodulin (NP_892012) and zebrafish cDNA clones homologous to
the two known PA receptors, ANTXR1 (BI866712.1) and ANTXR2 (CA471164).
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As shown in Fig. A-1A, treatment of Pac2 cells resulted in an increase in
cAMP levels compared to cells treated with buffer alone or the enzymatically
inactive EF-K346R mutant plus PA.  Furthermore, ET treatments resulted in a
decrease in cell viability, with a ~50% reduction in the number of live cells at 48
h following treatment (Fig. A-1A).  Finally, when compared to control Pac2 cells
(Fig. A-1B), Pac2 cells treated with ET demonstrated distinct morphological
changes, including cell elongation and eventual rounding (Fig. A-1C).
  Treatment of zebrafish embryos with ET results in widespread
tissue damage.  With the preliminary results indicating ET could intoxicate
zebrafish cells, experiments were performed to determine the effect of ET on
intact zebrafish embryos. Exposure to ET caused notable pleiotropic effects in the
developing embryos, including tissue damage, and swimbladder defects.  Notable
discoloration of the head and trunk regions and degeneration of the cranial
epithelium, both phenotypes that are likely indicative of tissue damage and decay,
were observed in a majority of the embryos.  A small population of affected fish
experienced moderate retention of the yolk sac (Fig. A-2).  Additionally, most of
the larvae were unable to inflate their swim bladder.  Although the ET-treated
embryos survived through all seven stages of development, most of the embryos
succumbed to the toxin 7 days post-treatment.  Interestingly, among all of the
diverse defects, we were unable to detect any pronounced edema among the
Figure A-1.  Impact of ET on cAMP levels and cell survival in zebrafish Pac2
embryonic fibroblasts.  Pac2 fibroblasts were incubated with ET for the
indicated periods of time.  Cells were subsequently analyzed for morphological
changes, cell viability via WST-8 staining, or changes in the levels of intracellular
cAMP via the BioTrak EIA.  cAMP levels are reported in pmol/mg of total
protein.  Samples were analyzed in triplicate and error bars indicate the standard
deviation from the mean.  (A) cAMP levels and cell viability in ET-treated Pac2
cells.  (B and C) Representative morphological changes demonstrated by (C) ET-
treated Pac2 cells as compared to (B) control Pac2 cells.
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Figure A-1.
Figure A-2.  Impact of ET on developing zebrafish embryos.  Following
treatment of zebrafish during blastula stage with EF alone (left panel) or with ET
(right panel), changes in development were observed.  (A) Arrows indicate
regions of defects: uninflated swimbladder (arrow 1), discoloration (arrow 2), and
internal bleeding (arrow 3).  (B) Arrows demark regions of abnormalities:
discoloration (arrow 1) and uninflated swimbladder (arrow 2).  (C) Arrows
indicate regions of abnormalities: discoloration (arrow 1), uninflated swimbladder
(arrow 2), and degeneration of cranial epithelium (arrow 3).  Photographs were




several hundred ET-treated embryos examined throughout the course of these
studies.
ET-treated embryos were further examined by histopathology to determine
the degree of cell death and tissue necrosis.  The histological examination
revealed regions of acute tissue damage of the gill epithelia (Fig. A-3A) and gill
chamber, gastrointestinal tract (Fig. A-3B), and moderate, acute damage of the
liver (Fig. A-3C).  The entire gut appeared necrotic with substantial cell death and
sloughing of cells within this region (see boxed area Fig. A-3B).
It is important to note that sensitivity to ET was not stage-dependent, as
the aforementioned defects could be detected in all treatments regardless of stage
of exposure.  Additionally, each concentration of toxin caused the same types of
defects (tissue and organ damage, yolk sac retention, swimbladder defects, and
animal death); however, tissue damage was more extensive in zebrafish exposed
to the highest dose of toxin.
  ET induces cell death in murine macrophage-like cells.  Results from
the zebrafish embryo analysis suggested ET could induce cytotoxic effects and
tissue necrosis in this model.  Yet, it was unclear whether ET could also cause cell
death in mammalian cells.  For this reason, we first examined the impact of ET on
RAW 264.7 and IC-21 murine macrophage-like cells.  Prior studies on LT have
shown RAW 264.7 and IC-21 cells to be highly susceptible to PA-mediated
intoxication (although only RAW 264.7 cells are killed by LT), allowing us to
Figure A-3.  Marked tissue necrosis following ET treatment of zebrafish
embryos.  Cross-sections of zebrafish treated with ET at the blastula stage were
stained with hematoxylin and eosin.  (A) Section of the gill epithelia.  Arrows
denote cells of necrotic tissue.  (B) Section of the gastrointestinal tract.  Black box
demarks regions of tissue necrosis.  (C) Cross-section of liver.  Arrows indicate




predict these cells would be effectively targeted by ET.  As shown in Fig. A-4A,
in RAW 264.7 cells, levels of cAMP approached 1000 pmol per mg of cell lysate
by 24 h and showed a decline to basal level by 48 h.  As shown in Fig. A-4B, the
increased cAMP levels correlated with the time of death observed in this cell line,
with ~ 80% death occurring by 48 h.  RAW 264.7 cells also demonstrated
rounding and eventual lysis at the later times of intoxication (Fig. A-4C and A-
4D).
  IC-21 cells also exhibited an increase in cAMP surpassing that observed in
RAW 264.7 cells when incubated in the presence of ET (Fig. A-4A).  cAMP
levels approached 7000 pmol per mg of cell lysate by 24 h and, in contrast to the
RAW 264.7 cells, exhibited a steady decline in total cAMP up to 48 h.  As shown
in Fig. A-4B, these increases in cAMP also correlated with cytotoxicity, resulting
in ~ 70% cell death by 72 h.  IC-21 cells also showed rounding and eventual lysis
at the late time points of intoxication (Fig. A-4E and A-4F).
Analysis of apoptosis profiles in ET-treated macrophages.  We next
examined the type of cell death occurring in ET-treated macrophages.  Although
ET-treated macrophages did not demonstrate visual apoptotic hallmarks, such as
membrane blebbing and apoptotic body formation, cAMP regulation has been
reported in several cases to have differential effects on apoptotic cell death (19,
48); therefore, apoptosis was examined as a possible mechanism of death in these
ET-sensitive cells. Both RAW 264.7 and IC-21 cells were pretreated for 1 h with
Figure A-4.  Levels of cAMP and cell survival in cells treated with ET.   RAW
264.7 macrophages, IC-21 macrophages, and NIH/3T3 fibroblasts were incubated
with ET and, at the indicated time points, examined to determine cAMP levels
and cell viability.  cAMP was measured via the Biotrak EIA and reported as
pmol/mg of total protein.  Cell viability was determined via WST-8 staining and
reported as % viability compared to the control.  Samples were analyzed in
triplicate and error bars indicate the standard deviation from the mean.  (A) cAMP
levels following incubation with ET.  (B) Cell viability following incubation with
ET.  (C – H) Morphological changes in RAW 264.7, IC-21, and NIH/3T3 cells
treated with Tris control and ET.  Each picture is representative of a routine ET
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a pan-caspase inhibitor, ZVAD-FMK, prior to treatment with ET.  As shown in
Fig. 5, RAW 264.7 (Fig. A-5A) and IC-21 (Fig. A-5B) cells were not protected
from ET-induced death in the presence of ZVAD-FMK.  Corresponding to
apoptosis inhibitor results, there was no discernible increase in cleaved caspase-3
(Fig. A-5C) or poly-ADP-ribose polymerase (PARP) (Fig. A-5D).  In contrast,
control cells treated with LFn/TcsL1-556, a fusion protein that consists of LFn (the
PA-binding domain of LF) fused to the enzymatic domain of Clostridium sordellii
lethal toxin and a potent inducer of apoptosis (60), revealed activation of both
caspase-3 and PARP.  Finally, in line with these results, TUNEL staining for 3’
nicked DNA did not reveal any notable chromosomal fragmentation in ET-treated
macrophages (Fig. A-5F and A-5G).
The time-course of cell death in ET-treated macrophages was indicative of
apoptosis, yet we were unable to detect any of the standard hallmarks of this
pathway.  For this reason, oncosis was also investigated as a possible mechanism
of ET-induced cell death.  Toxin-induced oncosis generally occurs within a short
time-period (< 4 h) and can be blocked by the addition of extracellular glycine (9,
12).  Thus, we reasoned that ET-induced cell death should be blocked by the
addition of glycine if these cells were dying by oncosis.  Addition of up to 10 mM
glycine to ET-treated cells did not protect either IC-21 or RAW 264.7
macrophages from cell death (data not shown), further suggesting these toxin-
Figure A-5.  Effect of ET on apoptosis in RAW 264.7 macrophages.  (A and
B) Influence of caspase inhibitors on ET-induced cytotoxicity.  RAW 264.7 and
IC-21 cells were pre-treated with ZVAD-FMK (30 µM for RAW 264.7 and 50
µM for IC-21 cells) for 1 h prior to treatment with ET.  At the indicated time
points, cell viability was determined via WST-8 staining.  Samples were analyzed
in triplicate and error bars indicate the standard deviation from the mean.  (A)
RAW 264.7 cell viability. (B) IC-21 cell viability.  (C – G)  RAW 264.7 cells
were treated with ET (2µg/ml), harvested, and evaluated via western blotting and
TUNEL staining.  For western blotting, cells lysates were collected, separated via
10 % SDS-PAGE, and analyzed using the indicated primary antibody.  (C) Anti-
caspase-3 western blot of RAW 264.7 cell lysates.  (D) Anti-PARP western blot
of RAW 264.7 cell lysates.  In each western blot, times and treatment conditions
are indicated above the panel.  In each panel, C = Tris control and L = PA +
LfnTcsL1-556.  At 24 h post-treatment, cells were collected and processed via
TUNEL staining as described in Experimental Procedures.  (E) 20 mM Tris.  (F)
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treated cells did not die by either of the classically defined apoptosis or oncosis
pathways.
Non-macrophage cells are differentially sensitive to ET intoxication.
In light of the above results regarding macrophage sensitivity to ET, we
investigated the cytotoxic effects of this toxin on NIH/3T3 murine fibroblast cells,
a non-macrophage murine fibroblast cell line, to determine whether the effects of
ET were macrophage-specific. NIH/3T3 cells were incubated in the presence of
ET, as in the macrophage experiments described above, and observed for
intracellular cAMP accumulation, changes in cell viability, and morphological
changes.  As shown in Fig. A-4A, in contrast to the macrophage cell lines,
NIH/3T3 cells showed no increase in cAMP above basal level in the presence of
ET.  As shown in Fig. A-4B, these cells also did not exhibit any loss in viability
up to 48 h.  Additionally, these cells showed no change in morphology over the
time course of treatment (Fig. A-4G and A-4H).   Treatment with 10-fold more
ET also had no detectable impact on NIH/3T3 cell physiology, viability, or levels
of cAMP (data not shown).
In order to determine if defects in cell entry might account for the
resistance of NIH/3T3 cells to ET, we again utilized LFn/TcsL1-556 to examine the
susceptibility of NIH/3T3 cells intoxicated through a PA-dependent mechanism.
As shown in Fig. A-6, following treatment with PA and LFn/TcsL1-556, NIH/3T3
Figure A-6.  Cytopathic effects and cell death caused by LFnTcsL1-556 in both
IC-21 and NIH/3T3 cells.  Each cell type indicated was incubated with
LFnTcsL1-556 (2µg/ml) plus PA (2µg/ml) for the indicated time points, at which
point cell viability was determined via WST-8 staining.  Samples were analyzed



























cells appeared more sensitive to the fusion than IC-21 macrophages, indicating
reduced cell entry was an unlikely explanation for NIH/3T3 resistance to ET.
We next sought to determine if EF was capable of modifying NIH/3T3
cells when provided access to the cytosol in a PA-independent manner.  To
address this issue, we generated a transfected NIH/3T3 cell line containing the
EF-encoding gene (cya) under the control of a mifepristone-inducible promoter.
Following addition of mifepristone, the cya-transfected NIH/3T3 cells showed a
rapid rise in cAMP levels.  As shown in Fig. A-7A, the amount of cAMP in
NIH/3T3-cya cells reached a high level (~ 740 pmol per mg of cell lysate at 24 h)
comparable to that observed in the RAW 264.7 cell line.  As shown in Fig. A-7B,
this rise in cAMP was also accompanied by a decrease in cell viability, indicating
that EF, under these conditions, was able to induce cell death in a non-
macrophage cell line when steps in cell entry were by-passed.  As shown in Fig.
A-7D, induction with mifepristone also resulted in marked morphological
changes, including cell elongation and bladdering.  Plasmid and mock controls of
NIH/3T3 cells demonstrated no noticeable changes in morphology (Fig. A-7C).
Having observed three different cell type-specific effects of ET, CHO
cells, which were first used to define the activity of EF (29), were examined to
determine correlations between cAMP levels and cell viability.  As shown in Fig.
A-8A, when CHO cells are incubated with ET there is a rapid rise in cAMP, with
peak levels of ~ 2600 pmol per mg of cell lysate between 2 and 12 hours.  While
Figure A-7.  Morphological changes, cAMP accumulation, and cell viability
following induction of NIH/3T3 fibroblasts, transfected with the cya gene
(NIH/3T3-cya), with mifepristone. NIH/3T3-cya fibroblasts were plated at
50,000 cells/well and, following overnight incubation, were incubated in the
presence of the indicated concentrations of mifepristone and observed for 24 h for
observation of morphological changes, cAMP accumulation, and changes in cell
viability. At this point, cells were either lysed and supernatants processed using
the cAMP EIA or viability was determined via WST-8 staining. Samples were
analyzed in triplicate and error bars indicate the standard deviation from the
mean.  (A) cAMP levels of mifepristone-induced NIH/3T3-cya cells.  (B) Cell
viability of mifepristone-induced NIH/3T3-cya cells.  (C and D) The pictures
shown are representative of a routine assay in which cells were induced with 1 X
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Figure A-8.  cAMP accumulation and cell viability in ET-treated CHO cells.
CHO cells were incubated with ET and at the indicated time points were
examined to determine cAMP levels and cell viability.  cAMP was measured via
the Biotrak EIA and reported as pmol/mg of total protein.  Cell viability was
determined via WST-8 staining and reported as % viability compared to the
control.  Samples were analyzed in triplicate and error bars indicate the standard
deviation from the mean.  (A) cAMP levels and cell viability following incubation
with ET.  (B) Morphological changes observed in ET-treated CHO cells.  (C)






























B               C
159
these levels are higher than those observed for the RAW 264.7 cells, which
experience a loss in viability, CHO cells showed no significant loss in cell
viability over a 72 h period (Fig. A-8A). Distinct morphological changes are seen
between ~ 2 – 6 h, with cell elongation being the major feature (Fig. A-8B and A-
8C); however, following this morphological change, CHO cells exhibited no
further effects due to ET treatment, even following repeated additions of ET over
an extended time period (data not shown).
The survival of ET-treated CHO cells was unexpected based on the levels
of cAMP observed and what had been found from the macrophage and NIH/3T3-
cya experiments.  Despite the sustained levels of cAMP, CHO cells adapt and
appear to grow normally following exposure to ET.  This survival event could be
due to cAMP’s reported ability to promote the expression of anti-apoptotic factors
in certain cell types (19, 24).  To address this experimentally, CHO cells were
pretreated for 45 min with ET and then exposed to staurosporine, a potent inducer
of apoptosis.  As shown in Fig. A-9, ET did not protect CHO cells from
staurosporine, but in fact made these cells even more sensitive to this factor.
This effect was dependent on the enzymatic activity of EF, as the EF-K346R
mutant did not increase the sensitivity of CHO cells to staurosporine.  These
results indicate that it is unlikely that ET is triggering an anti-apoptotic effect, and
the more plausible explanation is that these cells have adapted to this
supraphysiological level of cAMP.
Figure A-9.  ET effects on CHO cell sensitivity to staurosporine.  CHO cells
were pretreated with ET (2 µg/ml) or EF-K346R (2 µg/ml) + PA (2 µg/ml) for 45
min, at which point staurosporine (500 mM) was added to the cells.  Cell viability
was determined via WST-8 staining and reported as % viability compared to the
control.  Samples were analyzed in triplicate and error bars indicate the standard





























Results from the current study reveal ET’s capacity for inducing tissue
damage and cell-type specific cytotoxicity.  While the majority of work has
focused on LT as the primary B. anthracis virulence factor, there is no reason why
this should be so.  Isogenic strains with disruptions in cya demonstrate an
increased LD50 (44) and are less effective attenuated vaccines than strains
expressing EF and PA (45).  Thus, it is reasonable to assume that ET plays an
integral part in anthrax disease.  In addition, adenylate cyclases from several
pathogens, including B. pertussis (21), P. aeruginosa (65), and Yersinia pestis
(34) are also thought to be involved in their respective diseases.  Therefore,
dissecting the influence of ET on cell, tissue, and organ physiology should
provide new insights into anthrax disease.
   The developing zebrafish embryo provided an ideal vertebrate model for
assessing the impact of ET on tissues and major organs.  For these studies, the
developing zebrafish embryo model was selected over more traditional animal
models for several reasons.  First, several hundred embryos can be collected from
a single fertilization and these can be exposed to toxin in a single treatment.
Second, laboratory zebrafish, including our Oklahoma strain, remain a relatively
outbred population, and previous work on LT and B. anthracis found mouse
sensitivities varied by several orders of magnitude depending on the strain of mice
examined (17, 38).  Thus, it was difficult to predict which mouse line would be
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most appropriate for the study of ET.  Third, zebrafish embryos are translucent for
up to seven days following fertilization, making initial analysis possible by simple
visualization (25).  Fourth, whole sagittal plane slices can be prepared from the
treated embryos, which allows for rapid, yet thorough analysis of multiple
systems in a single pathology preparation.  Finally, the immune system remains
immature at points when major organ systems are in place (58).  This was
especially important to our studies because we wanted to implicate ET directly in
the observed tissue damage and eliminate the possibility that damage was a result
of inflammatory responses.
Given the broad impact of cAMP in cell physiology, and in light of the
distinct pathologies observed in ET treated zebrafish, we expected cells of various
lineages might respond differently to intoxication by ET.  Indeed, the differential
influence of cAMP on various cell types is extensively reported in the literature.
For example, cAMP has been implicated in protection against apoptotic agents in
hepatocytes (48), T84 colon cancer cells (42), neutrophils (26), and cardiac
muscle cells (11).  Conversely, cAMP has been implicated in the induction of
apoptosis in endothelial cells (24), human glioma cells (19), rat leukemia cells
(51), and lymphoma cells (66).  Our findings reinforce this point, since various
cell types responded to ET-induced changes in cAMP with distinct differences.
ET induced cell death in two cell lines, RAW 264.7 and IC-21, while remaining
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seemingly harmless to NIH/3T3 fibroblasts and causing only morphological
changes in CHO cells, which survived ET intoxication.
The explanation for the absence of cAMP accumulation in ET-treated
NIH/3T3 cells remains unclear, since our results indicate these cells support PA-
mediated entry and show high levels of cAMP when EF is expressed from within
the cell.  It is formally possible that NIH/3T3 cells are defective in a previously
undescribed step in cell entry, which is specific to ET.  It is also possible that
expression of EF from within the cell far exceeds levels that could be obtained by
the normal modes of entry, and EF, in such excess, can overcome the resistance.
Multiple attempts were made to quantify expression levels of EF within the cell,
but were not successful.  Despite this caveat, the data from the cya-transfected
NIH3T3 cells does indicate that cofactors (e.g. accessible calmodulin and Ca2+)
are available in amounts sufficient to permit EF adenylate cyclase activity.
In contrast to NIH/3T3 cells, CHO cells clearly show a large increase in
cAMP levels, yet survive intoxication.  Since the levels of cAMP remain high in
ET-treated CHO cells, the explanation for resistance is not the rapid turnover of
this second-messenger, but more likely is due to cAMP effects, which are
substantially different than those occurring in sensitive cells.
There are several possible explanations for ET’s cell-specific cytotoxicity.
First, EF may possess a yet undiscovered activity that contributes to cell death.
Thus, changes in cAMP levels are of little consequence in the presence of other
164
activities.  Arguing against this possibility is the fact that EF mutants defective in
adenylate cyclase activity do not induce cytotoxic effects in our treatments.  The
second, and more likely, explanation is that some cells adapt to changes in levels
of cAMP, even when these amounts become unusually high.  In fact, an adaptive
response seems a likely explanation in CHO cells, since we observe a dramatic
change in cell morphology during the early stages of treatment with ET, yet these
cells survive intoxication while the levels of cAMP remain high up to 48 h
following treatment.  However, other cell types, such as RAW 264.7 and IC-21
macrophages, which eventually die following ET treatment, are not capable of
adapting to high levels of cAMP.
The mechanism of ET-induced cell death appears to be somewhat unique
and does not fit the classic profile of apoptosis or oncosis.  In previous work from
our group on large clostridial toxins, we were able to use pancaspase inhibitors to
partially protect cells against toxin-induced apoptosis. However, in the case of
ET-treated macrophages, addition of a pancaspase inhibitor did not reduce
toxicity. In line with this, we did not detect activated caspase-3 in the ET-treated
cells.  Other hallmarks of apoptosis, such as nuclear fragmentation and cleavage
of PARP are also not detected in macrophages treated with ET.  Additionally,
microscopic examination of the cells treated with ET did not reveal characteristic
blebbing or formation of apoptotic bodies, both of which occur in apoptotic cells.
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Indeed, with the exception of the long time-course to death, these cells did not
show any of the classic signs of apoptosis.
Collectively these findings indicate ET may contribute to B. anthracis
pathogenesis through cytolysis of host cells.  Clearly, this does not preclude the
possibility that ET also disrupts important aspects of physiology in cells that do
not eventually die from intoxication, but does suggest necrosis and cell death
observed in anthrax disease could be attributed in part to ET.
MATERIALS AND METHODS
Cell culture.  NIH/3T3 murine fibroblast cells (NIH/Swiss mice), IC-21
murine macrophages (C57BL/6 mice), RAW 264.7 murine macrophages
(BALB/c mice), and Chinese Hamster Ovary (CHO-K1) cells were obtained from
the American Type Culture Collection.  NIH/3T3, IC-21, RAW 264.7, and CHO
cells were maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum (Gibco).  NIH/3T3-cya cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum, zeocin (300 µg/ml), and
hygromcin (100 µg/ml) (Invitrogen).  Cells were grown in the presence of 6%
CO2 at 37°C and used between passages 10 and 20.  Zebrafish Pac2 embryonic
fibroblast cells were kindly provided by W. Chen (Oregon Health and Science
University) and maintained in supplemented Leibovitz Medium (Gibco)
containing 15% fetal calf serum and grown at 30ºC at 0.5% CO2 (32).
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Expression and isolation of recombinant PA, EF, and LfnTcsL1-556.
PA-pET15b and EF-pET15b plasmids were generous gifts from Dr. R. John
Collier (Harvard Medical School).  Each plasmid was transformed into
BL21(DE3) E. coli cells (Novagen) for protein expression.  E. coli cultures were
incubated at 37°C until an OD600 of 1.0 was reached, at which point protein
expression was induced with 0.1 mM isopropyl-β-D-thiolgalactopyranoside
(Denville Scientific) overnight at 16°C.  Following overnight induction, the
proteins were purified using nickel affinity chromatography according to the
manufacturer’s instructions (Novagen).  As previously described (60), LFnTcsL1-
556 was expressed from pMQ1 and also isolated by nickel affinity
chromatography.
Construction of the EF mutant, EF-K346R.  EF-K346R was previously
described by Xia et al. (64) and is a mutant form of EF lacking adenylate cyclase
activity due to a base substitution (K to R) in the ATP-binding site.  EF-K346R
was constructed using the Stratagene Quikchange Kit to introduce a point
mutation, according to the manufacturer’s protocol, into functional EF using the
EF-pET15b plasmid.  The primers used were as follows: 5’-
GGTGTGGCTACAAGGGGATTGAATGTTCATGG-3’ for the forward primer
and 5’-CCATGAACATTCAATCCCCTTGTAGCCACACC-3’ for the reverse.
Following DNA sequencing and transformation of pET15b/EF-K346R into E. coli
167
BL21 (DE3) cells, EF-K346R was expressed and purified as described above for
the other proteins used in this study.
Zebrafish maintenance and care.  Zebrafish were maintained at 28.5º C
on a 14 h light/10 h dark cycle in 10-gallon tanks in a Z-plex stand-alone unit
(Aquatic Habitats).  Embryos used for toxin treatment were obtained by placing
two females and one male (which had been separated the night before) in a 1.0
liter mating chamber for up to one hour.  The embryos were subsequently
collected, bleached, sorted according to morphology, and maintained in sterile
embryo water (10% Hank’s solution with full strength calcium and magnesium,
pH 7.0) at 28.5º C (61).
  Treatment of zebrafish embryos with ET.  Within 15 min following
fertilization, zebrafish embryos were separated into a 24-well plate containing 10
embryos/well, in a final volume of 1 ml.  The stage of development was
determined by morphology (25).  ET-treated embryos were incubated with a
range of concentrations (10 µg PA + 10 µg EF, 20 µg PA + 20 µg EF, or 40 µg
PA + 40 µg EF), with each concentration inducing representative defects.  Control
treatments included 40 µg/ml PA alone, 40 µg/ml EF alone, 40 µg/ml PA + 40
µg/ml EF-K346R, or 20 mM Tris, pH 8.0 alone.  Each treatment was performed
in replicates of five (for a total of 50 embryos/treatment).  The embryos were
observed for seven days post-treatment for morphological changes.  Whole
bisected fish were processed into paraffin, sectioned on a sagittal plane, stained
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with hematoxylin and eosin, and histopathology of ET-treated embryos was
performed at the University of Oregon Zebrafish International Resource Center.
Cell viability assays.  Cell viability was assessed at the indicated time
points using the CCK-8 viability assay according to the manufacturer’s protocol
(Dojindo Laboratories).  This colorimetric assay was performed using WST-8 [2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt], which is reduced to a formazan derivative by
cellular dehydrogenases.  The level of WST-8 formazan was determined by
reading A450, which yields an increased absorbance proportional to the level of
cellular dehydrogenases.  Briefly, following addition of the WST-8 dye to each
well of a 96-well plate, the A450 was recorded for each well and percent viability
was calculated using the formula (Atest-Abackground)/(Acontrol-Abackground)*100, where
A=absorbance at A450, background = media alone, and control = cells treated with
20 mM Tris, pH 8.0.  In the indicated experiments, Caspase Inhibitor VI (ZVAD-
FMK) and staurosporine were obtained from Calbiochem, Inc.
Determination of cAMP levels.  Cells were plated in a 96-well plate at a
density of 2 X 105 cells/ml and incubated overnight (14-16 h) at 37°C.  Following
ET treatment or induction, cells were lysed, supernatants collected, and cAMP
levels determined.  cAMP levels were determined using the cAMP BioTrak
Enzyme-immunoassay (EIA) according to the manufacturer’s protocol
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(Amersham Pharmacia Biotech).  Levels of cAMP are reported in pmol/mg of
total cellular protein.
Western blotting.  For all western blotting experiments, cells were grown
in T-25 flasks until ~ 75% confluency was attained.  Following treatment with the
indicated reagent, cells were incubated in 2 ml of lysis buffer (1% SDS, 50 mM
Tris pH 7.4, 5 mM EDTA) on ice for 15 min.  Following incubation on ice, cells
were passed through a 22-gauge needle 10 times and subsequently pelleted via
centrifugation at 10,000 RPM for 10 min to obtain supernatants containing
cellular protein.  Samples (10 µg/well) were separated via 10% SDS-PAGE, after
which protein was transferred to PVDF for blotting.  Western blotting was
performed using either anti-Caspase-3 or anti-PARP primary antibodies according
to the manufacturer’s protocol (Cell Signaling Technology).
Transfection of NIH/3T3 cells with cya.  PCR was used to amplify cya
from pXO1, the toxin-encoding plasmid of B. anthracis.  For PCR amplification
and subsequent cloning, two oligonucleotides were designed.  As a forward
primer the f irs t  ol igonucleotide with the sequence 5’-
GACTGAGGTACCGCCATGGATGAACATTACACTGAGAGTGAT-3’ was
designed to hybridize to the 5’ region of cya starting at the sequence encoding for
mature EF.  This primer was also designed to encode a Kozak sequence
(GCCATGG) and a KpnI restriction site upstream of the homologous region.  As
a reverse primer a second oligonucleotide with the sequence 5’-
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GACTGAGAATTCAGTTTTTCATCAATAATTTTTTGGAA-3’, was designed
to hybridize to the 3’ end of cya and included sequences which encoded for a
downstream EcoRI restriction site.     The PCR amplification product was
subsequently restricted with KpnI and EcoRI and directionally cloned into
compatible sites of pGene/V5-His plasmid version B (Invitrogen).  The ligation
mixture was transformed into E. coli XL1-blue and candidate clones were
identified by plasmid mini-prep and subsequent restriction analysis.
For transfection, the EF-encoding plasmid was linearized with SapI, and
transfected into GeneSwitch-NIH/3T3 fibroblast cells (Invitrogen) via lipofection
according to the manufacturer’s protocol using the LipofectAMINE PLUS
Reagent Kit (Gibco).  Cells that were transfected following lipofection were
identified by growth on F-12 (HAM) selective medium (Gibco) containing zeocin
(300 µg/ml) and hygromycin (100 µg/ml).  Cells resistant to both zeocin and
hygromycin were selected as transfectants and maintained under drug pressure for
the experiments in this study.  For EF expression, the cells were exposed to
concentrations of mifepristone (Invitrogen) prior to cAMP and cell viability
determinations.
TUNEL assay of apoptosis.  Cells were grown in T-25 flasks until ~ 75%
confluence was attained, at which point cells were harvested and fixed in 1%
paraformaldehyde for 30 min.  Following fixing, cells were allowed to
permeabilize overnight at -20°C in 70% ethanol.  Following permeabilization,
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cells were incubated with BrdUTP (Molecular Probes) for 2 h at 37°C for labeling
of nicked DNA indicative of apoptosis.  Cells were subsequently incubated in the
presence of anti-BrdU alexa fluor 488-labeled antibody (Molecular Probes) for 30
min at room temperature.  Following TUNEL staining, cells were analyzed using
a FACSCalibur flow cytometer and data was analyzed using CELLQUEST
software (Becton Dickinson).
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CYTOTOXIC ACTIVITY OF BACILLUS ANTHRACIS PROTECTIVE
ANTIGEN OBSERVED IN A MACROPHAGE CELL LINE
OVEREXPRESSING ANTXR1
Cytotoxic Activity of Bacillus anthracis Protective Antigen Observed in a
Macrophage Cell Line Overexpressing ANTXR1. (Isabelle I. Salles*, Daniel
E. Voth*, Sabrina C. Ward, Kathleen M. Averette, Rodney K. Tweten,
Kenneth A. Bradley, and Jimmy D. Ballard.  Cellular Microbiology.  In press.
*I.I.S. and D.E.V. contributed equally to this work.)
Bacillus anthracis, the causative agent of anthrax, produces two major
virulence factors, a poly-D-glutamic acid capsule and anthrax toxin (AT).  AT is
composed of three polypeptides, protective antigen (PA, 83 kDa) and two
catalytic moieties, edema factor (EF, 89 kDa) and lethal factor (LF, 90 kDa).
Binary combination of PA plus LF yields lethal toxin (LT), while PA plus EF
produces edema toxin (ET) (14, 29, 31).  There is a notable attenuation in
virulence for isogenic strains of B. anthracis containing disruptions in genes
encoding for PA, LF, or EF, suggesting these toxin subunits play an important
part in anthrax disease (44).  Thus, delineation of AT’s mechanism of action -
including defining aspects of cell entry, substrate modification, and protein
structure - provides relevant insights into how B. anthracis causes disease.
PA, the focus of the current study, has historically been considered to be
non-toxic, serving only as a mediator of cell entry for LF and EF.  Thus, studies to
date have focused on defining the mechanisms by which PA localizes to the cell
surface, oligomerizes, and translocates LF and EF into the cytoplasm.  Two PA
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receptors have been identified and are encoded by the TEM8/ANTXR1 and
CMG2/ANTXR2 genes (8, 53), and PA binds directly to integrin-like inserted
domains (I domains) on these receptors.  The crystal structure of the ANTXR2 I
domain has recently been solved in isolation and in complex with both
monomeric and heptameric forms of PA (27, 28, 52).  While no structure for
ANTXR1 has been reported, the interaction of PA with ANTXR1 I domain
exhibits characteristics similar to that of CMG2 (7, 8), although PA binds
ANTRX1 with a lower affinity (27, 62) (S.C.W. and K.A.B., unpublished
observations and (54)) and PA bound to ANTXR1 forms pores at a more neutral
pH than PA bound to ANTXR2 (47).
Following receptor binding, PA is cleaved by a furin-like protease at the
sequence RKKR167, causing the release of the amino-terminal PA20 (20 kDa)
peptide and leaving a receptor-bound 63 kDa form of PA (PA63).  PA63 forms a
heptameric prepore structure to which EF and LF bind (39, 40, 49).  PA
oligomerization and binding of LF and EF accelerates the clearance of heptameric
PA63 from the cell surface by promoting uptake of the complex via receptor-
mediated endocytosis in a lipid-raft-dependent manner (1, 4).  Acidic pH triggers
conformational changes and membrane insertion of the heptameric PA63 β-barrel
into the vesicle membrane and the translocation of LF and EF into the cytosol of
mammalian cells (5, 36).  Within the cytosol, LF functions as a metalloprotease
cleaving mitogen-activated protein kinase kinases, and EF, as a calmodulin-
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dependent adenylate cyclase, generates high levels of cAMP (14, 29).  Thus, the
current model of anthrax intoxication indicates that EF and LF are solely
responsible for alterations in cell physiology, with PA serving only as a conduit
for cell entry via interaction with ANTXR1 and ANTXR2.
Despite these important advances in understanding the activity of PA,
little is known about the influence of receptor levels on the activities of this
protein within the cell, and it is conceivable that the formation of heptamers could
be limited at several steps of cellular intoxication.  The amount of furin-like
protease, the availability of lipid-rafts, the rate of endocytosis, and levels of
available PA receptor could each contribute to the extent of heptamer formation
and sensitivity to LT.  Thus, in the current study, experiments were performed to
determine if expression levels of ANTXRs influence PA-related processes during
intoxication.  Herein, we show that heightened expression of ANTXR1 results in
increased levels of cell-associated heptameric PA and report that under these
conditions PA alone induces cytotoxicity.   These findings suggest, for the first
time, that under certain conditions, exposure to PA can lead to cell death in the
absence of LF or EF.
RESULTS
Stability of SDS-resistant PA oligomers in RAW 264.7ANTXR1 cells.
Using a transduced cell line designed to overexpress ANTXR1, we were able to
initially assess the impact of increased receptor levels on PA oligomer formation
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and stability during intoxication. In these experiments, normal RAW 264.7
macrophages or RAW 264.7ANTXR1 cells were treated with PA, incubated 1 h, and
then washed extensively to remove any extracellular PA remaining in the media.
Lysates were then collected from these cells over a 10 h time period and
characterized for levels of the heptameric pore-form of PA.  PA heptamers that
have undergone acidic pH-mediated conformational transitions are resistant to
dissociation by SDS and, therefore, can be detected by SDS-PAGE (33, 36).  To
assess oligomer levels, extracts from PA-treated RAW 264.7 and RAW
264.7ANTXR1 cells were examined by immunoblot.  As shown in Fig. A-10, distinct
differences in the stability of the PA oligomer in RAW 264.7ANTXR1 cells and
RAW 264.7 cells were observed.  While oligomer formation was transient in
RAW 264.7 macrophages, PA heptamer was detected in RAW 264.7ANTXR1 cells
over a 10 h period.  Additionally, the level of PA heptamer detected was up to
2.5-fold higher in RAW 264.7ANTXR1 as compared with RAW 264.7 cells.
Densitometry analysis was used to determine the rate of turnover for the PA
oligomer.  Interestingly, as summarized in Table A-1, in addition to the increased
accumulation of PA heptamer in RAW 264.7ANTXR1 cells, heptamer levels in these
cells appeared to decline at a rate slower than that observed in cells expressing
basal levels of receptor.  Collectively, these experimental findings suggest PA
heptamers accumulate to higher levels and are degraded at a slower rate in RAW
264.7ANTXR1 cells compared to RAW 264.7 cells.
Figure A-10.  Analysis of PA oligomers in RAW 264.7ANTXR1 cells.  RAW 264.7
or RAW 264.7ANTXR1 cells were treated with PA (1 µg/ml) for 1 h at 4˚C and
subsequently washed to remove any unbound protein. Cell lysates were collected
at the indicated times (h), and equivalent amounts of cytosolic protein were
analyzed by SDS-PAGE and immunoblot using anti-PA or anti-tubulin antiserum
and corresponding secondary antibodies conjugated to HRP.  Negative control =
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Table A-1.  Relative  PA heptamer levels and rates of degradation in RAW
264.7 and RAW 264.7ANTXR1 cells




   Normalc       ANTXR1d
Fold
Difference
  Normalc           ANTXR1d
0 5,741 6,325    NA 1468 units/h 1164 units/h
0.5 15,567 19,443 1.25
P=0.0253 P=0.0208
1 18,975 27,256 1.43
2 15,488 23,525 1.51
R=0.87 R=0.85
4 12,745 27,709 2.17
6 7,424 19,742 2.65
8 5,340 10,919 2.04
10 6,720 13,398 2.0
a: Band intensity determined by densitometry analysis, arbitrary units
b: Degradation rate adjusted to reflect 1.45 fold overall higher band intensity of
PA oligomer in RAW 264.7ANTXR1 versus normal RAW 264.7 cells
c: Normal RAW 264.7 cells
d: RAW 264.7ANTXr1 normalized to control based on relative tubulin levels
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PA-mediated cytotoxicity in RAW 264.7ANTXR1 cells.  Given the
inordinate stability of PA heptamers within RAW 264.7ANTXR1 cells, we next
sought to determine how sustained formation, and increased levels, of this pore
complex might influence cell viability.  Previous studies have shown that mixing
of lysosomal contents with the cytoplasm can lead to activation of death pathways
(57), and we suspected such an event could be plausible if PA exhibited sustained
heptamer formation.
For these reasons, RAW 264.7ANTXR1 cells were examined for cytotoxicity
following exposure to PA.  When exposed to PA, RAW 264.7ANTXR1 cells
exhibited significant rounding and condensation indicative of a cytopathic effect
(Fig. A-11).  Normal RAW 264.7 macrophages did not exhibit changes in cell
morphology following treatment with PA, which is consistent with what has been
previously reported for PA (41).
As shown in Fig. A-11A, approximately 70% of RAW 264.7ANTXR1 cells
were killed by treatment with PA (≥ 1 µg/ml), whereas PA had no effect on RAW
264.7 cells.  The loss in cell viability began 6 h after the addition of PA and was
more significant at 12 and 24 h.  By 72 h, cell numbers began to recover,
apparently as a result of outgrowth of the cells that survived treatment with PA
(Fig. A-11B).  Further analysis of PA-treated RAW 264.7ANTXR1 cells using trypan
blue exclusion staining indicated that the decrease in cell number was a direct
result of cytotoxicity and not a cytostatic effect (Fig. A-11H).
Figure A-11.  Cytotoxic effects of PA on RAW 264.7ANTXR1 cells.  (A) Dose
curve demonstrating PA cytotoxicity in RAW 264.7ANTXR1 cells.  RAW 264.7 cells
(closed circles) or RAW 264.7 ANTXR1 cells (open squares) were treated with PA
and assayed for viability after 24 h.  (B) Time-course of PA cytotoxicity.  RAW
264.7ANTXR1 cells were treated with either 1 µg (closed circles) or 5 µg (open
squares) of PA and monitored over time for viability.  (C) RAW 264.7 cells or
RAW 264.7ANTXR1 cells were incubated with various amounts of PA in
combination with a range of concentrations of LF for 24 h and assayed for
viability.  Solid lines = RAW 264.7 macrophages, dashed lines = RAW
264.7ANTXR1 cells, closed circles = 0.1 µg/ml PA, open squares = 1.0 µg/ml PA,
open triangles = 5.0 µg/ml PA.  (D – H) Photomicrographs of RAW 264.7 or
RAW 264.7ANTXR1 cells treated with 5 µg/ml PA or corresponding buffer control
for 24 h.  (D) RAW 264.7 cells plus buffer control, (E) RAW 264.7 cells plus PA,
(F) RAW 264.7ANTXR1 cells plus buffer control, (G) RAW 264.7ANTXR1 cells plus
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We next examined how the overexpression of ANTXR1 influenced
sensitivity to LT.  Previous work found that Chinese hamster ovary cells
overexpressing ANTXR1 display increased sensitivity to challenge with PA +
LFNDTA (7, 8).  Consistent with this finding, RAW 264.7ANTXR1 cells display an
increased sensitivity to LT compared to wild type RAW 264.7 cells (Fig. A-11C).
Thus, higher receptor levels not only correlated with sensitivity to PA, but also
reduced the minimal cytotoxic dose of LT.
Analysis of ANTXR1 derivatives in PA-mediated cytotoxicity.  Given
the finding of PA cytotoxicity, we next sought to determine if cell killing required
a fully intact receptor and/or functional PA-ANTXR1 interactions.  Cells
expressing ANTXR1 that lacks a cytoplasmic tail (ANTXR11-345) or a mutant
form of ANTXR1 unable to bind PA (ANTXR1D50A) were treated with PA for 24
h (Fig. A-12A).  RAW 264.7ANTXR1(1-345) cells displayed the same sensitivity to PA
as RAW 264.7ANTXR1 cells, whereas RAW 264.7ANTXR1(D50A) cells were significantly
less sensitive to PA.  Collectively, these results suggested effective PA-mediated
toxicity required ANTXR1 with a functional PA-binding site, but did not depend
on the receptor’s cytoplasmic tail.
Analysis of PA mutants.  Given the results using mutants of ANTXR1,
reciprocal experiments were next performed to confirm the necessity of functional
PA for cytoxicity.  To accomplish this, RAW 264.7ANTXR1 cells were challenged
with PA mutants defective for important activities.  The first mutant, PA(SSSR),
Figure A-12.  Influence of ANTXR1 derivatives and PA mutants on PA-
induced cytotoxicity.  (A) RAW 264.7 cells (open squares) and RAW 264.7
cellls expressing ANTXR1 (closed squares), ANTXR1(D50A) (open circles) or
ANTXR1(1-345) (closed diamonds) were treated for 24 h with a range of PA
concentrations and subsequently assayed for cell viability.  (B) RAW 264.7 or
RAW 264.7ANTXR1 cells were treated with 1 µg/ml PA (black bars), the furin-
insensitive form of PA: PASSSR (white bars), or the pore formation deficient














































binds receptor but is not proteolytically cleaved at the cell surface (2, 18).  A
second derivative of PA (PAK397D, D425K) binds to the receptor, oligomerizes, and
interacts with LF, but is defective in LF translocation (55).  As shown in Fig. A-
12B, neither PA mutant was cytotoxic to RAW 264.7ANTXR1 or RAW 264.7ANTXR1(1-
345) cells suggesting that PA binding, oligomerization, and effective channel
formation are required for cytotoxic effects on RAW 264.7ANTXR1 macrophages.
PA-mediated cytotoxicity requires endosomal acidification.  Previous
results have shown that the acidic pH of the endosome triggers formation of SDS-
resistant oligomers and membrane insertion of PA (16, 35, 46).  To determine if
endosomal acidification is necessary for PA-induced cytotoxicity, RAW
264.7ANTXR1 cells were incubated with various concentrations of the vacuolar H+
ATPase inhibitor bafilomycin A1, then treated with PA and assayed for survival.
Pretreatment with bafilomycin protected RAW 264.7ANTXR1 cells from LT or PA
alone (Fig. A-13A), showing that PA cytotoxicity depends on endosomal
acidification.  These results, along with the PA mutant analysis, demonstrate the
necessity for functional channel formation by PA in order to cause cell death.
Yet, it was possible that channels might be inordinately formed at the cell surface
due to increased levels of PA localizing to the plasma membrane of RAW
264.7ANTXR1 cells.  We excluded this possibility by using a 86Rb+ release assay to
show that the degree of cell-surface channel formation did not differ in RAW
264.7ANTXR1 and normal RAW 264.7 cells (Fig. A-13B).  Furthermore, channel
Figure A-13.  The role of acid pH during PA-mediated cytotoxicity in RAW
264.7ANTXR1 cells.  (A) RAW 264.7ANTXR1 cells were treated with 5 µg/ml PA or
1µg/ml LT (1 µg/ml of each PA and LF), and with bafilomycin or MeOH when
indicated, 30 min prior to PA or LT treatments.  Cell viability was assayed by
WST-8 reactivity at 24 h following treatment compared to cells treated with 20
mM Tris pH 8.0.  (B) Channel formation by PA in cells expressing normal and
high levels of ANTXR1.  RAW 264.7ANTXR1 cells were loaded with 86Rb+ and
incubated for 2 h at 4°C with PA, PASSSR, PAK397D, D425K or with 20 mM Tris pH
8.0.  Unbound toxin was removed by washing, fresh medium (20 mM Tris-MES,
145 mM NaCl, pH 5.0) was added, and the incubation was continued for 30 min.
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formation strictly required an acidic pH and could not be detected at neutral pH
(data not shown).
Mechanism of PA cytotoxicity in RAW 264.7ANTXR1 macrophages.  The
relatively slow time-course of cell death in RAW 264.7ANTXR1 macrophages
corresponded with a rate expected for apoptosis.  Furthermore, this is the expected
type of cell death, which would occur following sustained mixing of lysosomal
and cytoplasmic contents.  Thus, PA-treated cells were assayed for several
common hallmarks of apoptosis.  As shown in Fig. A-14, treatment of RAW
264.7ANTXR1 macrophages resulted in chromosomal fragmentation, activation of
caspase-3, and cleavage of PARP, all of which are consistent with a caspase-3-
dependent, apoptotic mechanism of cell death.   In addition, caspase-3, but not
caspase-8, was activated in PA-treated cells, suggesting activation of apoptosis
occurred through an intrinsic pathway.  Finally, we assessed activation of Bid
since this is a known intermediary between caspase-3 activation and release of
lysosomal contents (57).  Corresponding to caspase-3 activation, cleaved Bid was
also detected in PA-treated RAW 264.7ANTXR1 cells, further supporting the
possibility that sustained formation of PA heptamers could lead to induction of
apoptosis by release of vesicular proteins.  Finally, analysis of lysates from RAW
264.7ANTXR1 cells treated with PAK397D, D425K did not reveal activation of caspase-3
or Bid (Fig. A-14D), which is in line with the observations that this mutant of PA
is unable to cause cell death
Figure A-14.  Induction of apoptosis in PA-treated RAW 264.7ANTXR1
macrophages.  (A and B) RAW 264.7ANTXR1 cells were incubated with 20 mM
Tris (A) or PA (B) for 15 h and subsequently analyzed via TUNEL staining and
flow cytometry.  Brackets indicate area of apoptotic cells.  (C) RAW 264.7 or
RAW 264.7ANTXR1 cells were incubated with 20 mM Tris or PA for 15 h, and cell
lysates were isolated and analyzed by immunoblot.  Cell lysates were separated
using 4-20% SDS-PAGE, and proteins were transferred to a PVDF membrane and
analyzed for activation of apoptosis-related proteins, including caspase-3, PARP,
Bid and caspase-8, using corresponding primary antibodies and matched HRP
conjugated secondary.  (D) RAW 264.7 or RAW 264.7ANTXR1 cells were incubated
with PA(K397D, D425K) for 15 h and subsequently subjected to immunoblot
analysis as described above to detect caspase-3 and Bid.
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Figure A-14.
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PA is essential for AT intoxication of mammalian cells and is known to
make at least three defined contributions to the activity of this toxin.  First, PA
binds to the cell surface, which is critical for localizing the proteins of AT to
target cells.  Second, following proteolytic processing, PA interacts with EF and
LF to form toxic complexes.  Third, PA mediates the translocation of EF and LF
into the cytoplasm of targeted cells where these enzymes alter cell function.
Although there are several points of interaction with the cell, including cell
surface receptors and membranes, prior to the current work, PA has not been
reported to influence cell physiology on its own.  In contrast to this longstanding
paradigm, results from the current studies indicate PA, in the absence of EF or
LF, is cytotoxic to macrophages that overexpress ANTXR1.
The initial purpose of these experiments was to assess the possible rate-
limiting steps in formation of PA heptamers.  Based on previous studies, there
were several points at which formation of membrane-inserted, SDS-resistant PA
heptamers could be limited.   Indeed, since AT entry has been found to be limited
to lipid-rafts (1, 4), it was conceivable that only marginal amounts of PA could
enter the cell despite heightened levels of receptor.  Our findings argue against
this possibility and suggest that a major limitation in cell entry by PA may be the
level of PA receptors.  Increasing the levels of PA receptors correlated with
heightened amounts of oligomer formation, as well as, an increased sensitivity to
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PA.  Furthermore, the receptor levels also appear to contribute to the rate at which
PA heptamers are degraded within the cell.  To date, little is known about the host
factors that contribute to toxin stability and function within the cell, but the
current data suggest the receptor may be one of the determinants in this process,
as higher levels of ANTXR1 correlates with increased heptamer stability.  The
data also suggest that without appropriate PA degradation, cytotoxicity can occur
even in the absence of EF or LF.  It is appealing to speculate that degradation of
PA represents an important host mechanism of resistance to this protein, and
identification of cellular factors involved in this process could add to our
understanding of AT intoxication.
Results from experiments examining the effects of ANTXR1 mutants and
PA mutants provided insight into the molecular requirements for PA-cytotoxicity.
The data suggests functional PA and ANTXR1, with an intact PA binding
domain, are necessary for cytotoxicity.  Bradley et al. previously showed that
CHO cells overexpressing ANTXR1 with a D50A mutation in the MIDAS
domain were resistant to treatment with PA and LFnDTA (7).  As expected, RAW
264.7ANTXR1(D50A) cells displayed reduced sensitivity to PA, demonstrating the
importance of a functional receptor for PA-mediated toxicity.  Furthermore, PA
mutants resistant to protease cleavage, and thus production of PA63 and the
heptamer, were not cytotoxic.  The double mutant of PA (K397D, D425K), which
is defective for translocation of LF, also was not cytotoxic to RAW 264.7ANTXR1
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cells, further suggesting PA-mediated cytotoxicity requires a functional PA.
RAW 264.7ANTXR1(1-345) cells lacking the cytoplasmic domain of ANTXR1 and
RAW 264.7ANTXR1 cells were equally sensitive to PA making it unlikely that
cytotoxicity was conferred through an intracellular signaling event activated by
PA-ANTXR1 interactions.  In line with this observation, a previous report by Liu
and Leppla found that ANTXR1, lacking a cytoplasmic tail, could mediate
binding, uptake, and oligomerization of PA (33), all of which we found to be
required for PA-mediated cytotoxicity.  Yet, it is worth noting that although the
cytoplasmic tail of ANTXR1 was not required for PA-mediated cytotoxicity, this
does not dismiss the possibility that other proteins interact with this complex and
promote intracellular signaling events, which contribute to cell death.  It is unclear
how such a process would require functional channel formation by PA, or would
need endosomal acidification, but our findings do not completely dismiss this
possibility.  Overall, the data indicates PA-mediated cytotoxicity requires receptor
binding, endosomal acidification, and sustained oligomer formation.
ANTXR1’s role in PA cytotoxicity may primarily involve localizing
increased amounts of this protein to the cell surface, rather than sustaining
oligomer formation. Recent work by Rainey and colleagues described the
dissociation of ANTXRs from the PA oligomer at acidic pH, indicating that PA
may dissociate from receptor during pore formation (47).  Based on these
observations, sustained oligomer and pore formation, which we found to be
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essential for PA cytotoxicity, do not require ANTXR1 receptor per se.  Our
findings cannot be completely reconciled with this work, since we are able to
correlate oligomer stability with levels of ANTXR1.  It is possible that the cellular
processes leading to degradation of heptameric PA become saturated when high
levels of PA interact with the cell, and this leads to a slower rate of degradation.
In this case, ANTXR1 would not have a direct influence on degradation, but
could serve only to localize PA to the cell.
Whether increased levels of ANTXR2 also confer sensitivity to PA
remains unclear, since we were unable to obtain high expression of this second
PA receptor in RAW 264.7 macrophages.  Interestingly, Banks and colleagues
recently demonstrated that ANTXR2 was the predominant PA receptor in RAW
264.7 macrophages (3).  Careful examination of the results shown in Fig. 5
reveals a small amount of caspase-3 and PARP cleavage in wild-type RAW 264.7
macrophages, suggesting ANTXR2 might also trigger apoptosis if present at
higher levels.  Alternatively, the two ANTXRs may behave differently with
respect to PA-mediated toxicity.  Indeed, two recent reports identify significant
differences in the pH threshold at which PA forms pores depending on the
receptor to which it is bound (47, 63).  PA bound to ANTXR1 forms pores at a
less acidic pH and, therefore, likely forms pores earlier in the endocytic pathway
than ANTXR2-bound PA.  Differences in the subcellular location at which PA
forms pores and uncouples from receptor may lead to differences in pore stability
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and cytotoxicity.  Clearly, further experimentation will be necessary before any
definitive links can be made between ANTXR2 levels and PA-mediated
cytotoxicity.
Taken together, the current findings suggest the following preliminary
model for PA-mediated cytotoxicity.  Due to the increased levels of ANTXR1,
PA oligomers are more stable and accumulate to such levels that an inordinate
number of pores are generated in acidified vesicles.  As a result, apoptosis is
triggered in the intoxicated cells, and this leads to caspase-3 cleavage and
eventual cell death.  While the precise inciting event leading to caspase-3
activation is unclear, there is at least one scenario worth consideration.  Due to
increased pore formation by PA, proteases, such as cathepsins, may be released
from the acidified vesicle, and these proteases trigger the activation of apoptosis.
In line with this possibility, cathepsins have been shown in other studies to
proteolyze and activate Bid, which leads to caspase-3 activation via modulation of
the mitochondria (57).  In this case, cleavage of Bid may occur prior to caspase-3
activation and play a more prominent role in activation, rather than amplifying the
apoptosis pathway.  Alternatively, lysosomal proteases may activate caspase-3, in
a system similar to the mechanism described for cytochrome-c-independent
apoptosis (22).  While still speculative, future studies will closely examine the
possibility that release of lysosomal contents initiates apoptosis during PA
cytotoxicity.
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Studies to date have not determined the relative distribution of ANTXR1
and ANTXR2 on various cell types, but it is now reasonable to suggest that cells
with higher ANTXR1 levels could be susceptible to PA treatment and need to be
investigated.  Interestingly, ANTXR1 was first identified as tumor endothelial
marker 8 (TEM8), a gene with increased expression in endothelial cells associated
with tumor neovasculature (10, 56).  Recently, Bonuccelli et al. reported high
levels of TEM8 expression in epithelial cells lining the lungs, as well as, skin and
intestines (6).  The lungs have been shown to be a primary site of damage during
anthrax disease (20), raising the possibility that PA could directly impact this
organ due to high levels of ANTXR1.
The current findings also raise concerns about the efficacy of anthrax
vaccines consisting of recombinant, functional PA.  There is currently no
information regarding the variations in receptor levels throughout an outbred
population.  While further work is needed, the data suggests individuals
expressing higher levels of ANTXR1 could suffer side effects from such a
vaccine due to PA toxicity.  Thus, recombinant, functionally inactive mutants of
PA may hold greater promise as vaccine candidates.
MATERIALS AND METHODS
Cell lines.  RAW 264.7 cells were purchased from the American Type
Culture Collection (TIB-71).  Cells were cultured in RPMI 1640 medium
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supplemented with 10% fetal calf serum and maintained in a humidified
atmosphere of 6% CO2 at 37°C.
Wild type or mutant forms of ANTXR1 fused to green fluorescent protein
(GFP) were stably expressed in RAW 264.7 cells following retroviral
transduction as previously described (7).  Briefly, pseudotyped murine leukemia
virus vectors were generated by transient transfection of ~107 HEK 293 cells with
15 µg pMD.gagpol, 5 µg pMD.G (VSV-G envelope protein), and 20 µg of
pLEGFP-N1 (Clontech) encoding wild-type or mutant versions of ANTXR1-
EGFP fusions.  Forty-eight hours after transfection, virus-containing supernatants
were harvested, filtered through 0.22 µm syringe filters, and used to infect RAW
264.7 cells.  Infections were performed at a multiplicity of infection (MOI) of ~ 5
by adding virus-containing media in the presence of 8 µg/mL polybrene (Sigma)
to sub-confluent cultures of RAW 264.7 cells.  Forty-eight hours later, 800 µg/mL
G418 (Invitrogen) was added to the culture medium of infected cells to select
against uninfected cells.  For these studies, ANTXR1 splice variant 2 was defined
as wild type receptor (8, 53).  ANTXR11-345 represents a C-terminal deletion
lacking amino acids 346-368 that results in loss of the cytosolic domain of
ANTXR1, and ANTXR1D50A represents an aspartate to alanine mutation at residue
50 that disrupts the MIDAS motif resulting in loss of PA binding.
Purification of recombinant PA, PA mutants, and LF.  Recombinant
forms of PA and LF expressed in pET15b were purified from E. coli BL-21(DE3)
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using His-tagged affinity chromatography according to the manufacturer’s
protocol (Novagen).  LPS was removed from the purified protein samples using a
polymyxin B column according to manufacturers instructions (Sigma), and
endotoxin levels were determined using the limulus amebocyte lysate assay
(BioWhittaker) with detection limits at 0.06 endotoxin units per ml.  PASSSR, a
furin-insensitive PA, was expressed in pET22b and purified from periplasmic
extracts of E. coli BL21 and further purified by anion-exchange chromatography.
A purified dominant negative (DN) mutant of PA (K397D, D425K) was kindly
provided by Dr. R. John Collier and has been previously described (55).
Detection of PA63 SDS-resistant oligomers by immunoblotting.  RAW
264.7 or RAW 264.7ANTXR1 cells were treated for 1 h at 4˚C with 1 µg/ml PA,
washed with PBS, and then pre-warmed growth media was added to the cells.
After different incubation times at 37°C, cells were washed three times in PBS
and lysed in NP40 buffer (50 mM Tris-Cl pH 8.0, 1 % Nonidet P-40, 150 mM
NaCl) supplemented with protease inhibitors (Complete Mini, Roche).  Cell
lysates (150 µg total protein/sample) were subjected to SDS-PAGE using 4-15%
gradient gels (Biorad).  Alternatively, 15 µg total protein/sample of the same cell
lysates were separated by 10% SDS-PAGE for analysis of tubulin. Samples were
transferred to PVDF membranes, which were then blocked overnight with 5%
powdered milk proteins (BioRad) in TBST (50mM Tris, 150 mM NaCl, 0.1%
Tween-20, pH 8.0).  Western blotting was then performed as previously described
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(50) using affinity purified anti-PA polyclonal sera (provided by Dr. G. Jonah
Rainey, Salk Institute).
Analysis of PA heptamer stability in RAW 264.7 and RAW
264.7ANTXR1 cells.  Following detection by immunoblot, band intensities were
determined by densitometry using a Fluorchem 8900 imager (Alpha Innotech) and
corresponding AlphaEase FC software.   Arbitrary units generated from the
densitometry analysis were then used to graph the changes in heptamer levels
over time using Prism 4 software (GraphPad).  Degradation rates were determined
using the linear regression function of Prism 4 software.  Since PA heptamers
accumulated to higher levels in RAW 264.7ANTXR1 cells compared to RAW 264.7
cells, the rates of degradation were adjusted accordingly in order to directly
compare the two conditions.  Adjustments were made by extrapolating to the Y
intersect of the lines generated from the results of each treatment, and a ratio (1.6)
was determined based on this analysis.
Cell viability and lysosomotropic inhibitor assays.  Cells were
harvested by scraping and plated at a density of 2x104 cells/well, unless otherwise
indicated, in 96-well culture plates.  Cells were then treated with PA (5µg/ml to
10 ng/ml), or PA (SSSR) and DN mutants, for 24 h or other indicated times, at
which point, they were assayed for cell viability using WST-8 (2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,
monosodium salt (Dojindo Molecular Technologies), which detects levels of
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soluble formazan dye reduced from WST-8.  Data is presented relative to the
proliferation of control samples incubated with 20 mM Tris pH 8.0 and represent
an average of at least four measurements from two separate experiments (±SD).
For determining the requirement of endosomal acidification for PA-mediated
cytotoxicity, bafilomycin (Sigma) was added to cells at different concentrations (5
nM to 20 nM) 30 min prior to PA addition, and cell viability was assayed as
described above.
86Rb+ efflux measurements.  To determine the level of membrane
permeabilization during PA-induced cytotoxity, cells were plated at a density of 2
x 105 in 24-well culture plates. Approximately 8-10 h after plating, fresh medium
containing 10 µCi 86Rb+ (1Ci=37.0Gbq/g) was added, and cells were incubated
overnight under normal growth conditions.  Cells were washed with medium, and
were then incubated for 2 h at 4°C with fresh medium containing 5 µg/ml PA or
PA mutants.  Cells were washed twice to remove unbound PA, and isotonic buffer
(20 mM MES-Tris, 145 mM NaCl, pH 5.0) was added for 30 min at 4°C.  At the
end of the incubation period, an aliquot of medium was removed, and released
86Rb+ was measured using a scintillation counter.  Cells were lysed with 1.0 %
SDS to determine the amount of retained 86Rb+.  The percentage of released 86Rb+
was calculated by dividing the 86Rb+ released by the total amount of 86Rb+
(retained + released) * 100.
196
Detection of caspase and Bid activation, PARP cleavage, and TUNEL
assays.  Lysates from treated RAW 264.7 and RAW 264.7ANTXR1 cells were
collected 15 h following treatment with 5 µg/ml PA.  Lysates were examined by
standard immunoblotting using primary antibody (Cell Signaling Technologies) to
caspase-3, Bid, poly-ADP-ribose polymerase (PARP), and caspase-8 (BD
Pharmingen), followed by the appropriate secondary antibody conjugated to
horseradish peroxidase.  Bands recognized by the antibody were visualized by
addition of the ECL Plus chemilumenescent substrate and autoradiography of the
blots (Amersham Pharmacia).  For terminal-uridyl nicked end labeling (TUNEL)
staining, fragmented DNA was labeled with BrdUTP and detected using an Alexa
Fluor 488-labeled anti-BrdU antibody (Molecular Probes).  Samples were
subsequently analyzed using a FACSscan flow cytometer (Becton Dickinson).
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